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RÉSUMÉ 
 
L’accident vasculaire cérébral (AVC) est une cause principale de décès et de 
morbidité dans le monde; une bonne partie des AVC est causée par la plaque 
d’athérosclérose carotidienne. La prévention de l’AVC chez les patients ayant 
une plaque carotidienne demeure controversée, vu les risques et bénéfices 
ambigus associés au traitement chirurgical ou médical. Plusieurs méthodes 
d’imagerie ont été développées afin d’étudier la plaque vulnérable (dont le 
risque est élevé), mais aucune n’est suffisamment validée ou accessible pour 
permettre une utilisation comme outil de dépistage. L’élastographie non-
invasive vasculaire (NIVE) est une technique nouvelle qui cartographie les 
déformations (élasticité) de la plaque afin de détecter les plaque vulnérables; 
cette technique n’est pas encore validée cliniquement. Le but de ce projet est 
d’évaluer la capacité de NIVE de caractériser la composition de la plaque et sa 
vulnérabilité in vivo chez des patients ayant des plaques sévères carotidiennes, 
en utilisant comme étalon de référence, l’imagerie par résonance magnétique 
(IRM) à haute-résolution. Afin de poursuivre cette étude, une connaissance 
accrue de l’AVC, l’athérosclérose, la plaque vulnérable, ainsi que des 
techniques actuelles d’imagerie de la plaque carotidienne, est requise. 
 
Trente-et-un sujets ont été examinés par NIVE par ultrasonographie et IRM à 
haute-résolution. Sur 31 plaques, 9 étaient symptomatiques, 17 contenaient des 
lipides, et 7 étaient vulnérables selon l’IRM. Les déformations étaient 
significativement plus petites chez les plaques contenant des lipides, avec une 
sensibilité élevée et une spécificité modérée. Une association quadratique entre 
la déformation et la quantité de lipide a été trouvée. Les déformations ne 
pouvaient pas distinguer les plaques vulnérables ou symptomatiques. 
 
En conclusion, NIVE par ultrasonographie est faisable chez des patients ayant 
des sténoses carotidiennes significatives et peut détecter la présence d’un cœur 
vii 
 
lipidique. Des études supplémentaires de progression de la plaque avec NIVE 
sont requises afin d’identifier les plaques vulnérables. 
 
 
Mots-clés : Accident vasculaire cérébral (AVC), Plaque de l’artère 
carotidienne, Plaque d’athérosclérose, Élastographie, Ultrasonographie, 
Élastographie Non-invasive Vasculaire (NIVE), Imagerie par résonance 
magnétique (IRM), cœur lipidique. 
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ABSTRACT 
 
Stroke is a leading cause of death and morbidity worldwide, and a significant 
proportion of strokes are caused by carotid atherosclerotic plaque rupture. 
Prevention of stroke in patients with carotid plaque poses a significant 
challenge to physicians, as risks and benefits of surgical or medical treatments 
remain equivocal. Many imaging techniques have been developed to identify 
and study vulnerable (high-risk) atherosclerotic plaques, but none is 
sufficiently validated or accessible for population screening. Non-invasive 
vascular elastography (NIVE) is a novel ultrasonic technique that maps carotid 
plaque strain (elasticity) characteristics to detect its vulnerability; it has not 
been clinically validated yet. The goal of this project is to evaluate the ability 
of ultrasound NIVE strain analysis to characterize carotid plaque composition 
and vulnerability in vivo in patients with significant plaque burden, as 
determined by the reference standard, high resolution MRI. To undertake this 
study, a thorough understanding of stroke, atherosclerosis, vulnerable plaque, 
and current non-invasive carotid plaque imaging techniques is required. 
 
Thirty-one subjects underwent NIVE and high-resolution MRI of internal 
carotid arteries. Of 31 plaques, 9 were symptomatic, 17 contained lipid and 7 
were vulnerable on MRI. Strains were significantly lower in plaques 
containing a lipid core compared to those without lipid, with high sensitivity 
and moderate specificity. A quadratic fit was found between strain and lipid 
content. Strains did not discriminate symptomatic patients or vulnerable 
plaques. 
 
In conclusion, ultrasound NIVE is feasible in patients with significant carotid 
stenosis and can detect the presence of a lipid core. Further studies of plaque 
progression with NIVE are required to identify vulnerable plaques. 
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Keywords: Stroke, Carotid Artery Plaque, Atherosclerotic Plaque, 
Elastography, Ultrasound, Non-Invasive Vascular Elastography (NIVE), 
Magnetic Resonance Imaging (MRI), lipid core. 
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Figure 1.1: Left lateral view of the brain. Each part of the brain identified 
serves a specific function. Adapted and modified from: Morton 
DA, Foreman KB, Albertine KH. The Big Picture: Gross 
Anatomy, 1
st
 edition: www.accessmedicine.com. 
Figure 1.2: A. Lateral and B. coronal views of extracranial and intracranial 
arteries. A: The common carotid artery bifurcates into the 
external and internal carotid artery. The external carotid supplies 
blood to the face. The internal carotid supplies the anterior part of 
the brain. The vertebral artery arises from the subclavian artery, 
and supplies the posterior part of the brain. B: The anterior and 
posterior circulations are linked through the posterior 
communicating artery (Post. Comm.), forming the Circle of 
Willis (highlighted in dark red). This architecture provides 
collateral circulation of blood in case of obstruction in one of the 
major intracranial arteries. The pink arrow demonstrates the 
direction of blood flow arising from the heart. ACA = Anterior 
cerebral artery; Ant. Comm.= Anterior communicating artery; 
MCA = Middle cerebral artery; PCA = Posterior cerebral artery; 
ICA = Internal carotid artery; ECA = External carotid artery; 
CCA = Common carotid artery; SCA = Superior cerebellar artery; 
AICA = Anterior Inferior cerebellar artery; PICA = Posterior 
inferior cerebellar artery; a.= artery. Figure 1.2A adapted and 
modified from Longo DL, Fauci AS, Kasper DL, Hauser SL, 
Jameson JL, Loscalzo J. Harrison’s Principles of Internal 
Medicine, 18
th
 edition: www.accessmedicine.com. Figure 1.2B 
adapted and modified from: Andreoli TE, Carpenter CCJ, Griggs 
RC, Loscalzo J.  Cecil Essentials of Internal Medicine, 6
th
 edition: 
consulted on CD-ROM.  
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Figure 1.3: Blood supply to the brain by arterial territory. Adapted and 
modified from Longo DL, Fauci AS, Kasper DL, Hauser SL, 
Jameson JL, Loscalzo J. Harrison’s Principles of Internal 
Medicine, 18
th
 edition: www.accessmedicine.com. 
Figure 1.4: Coronal view of the brain showing the motor homunculus and 
blood supply areas of the precentral gyrus of the frontal lobe. 
Image modified and adapted from: Waxman SG. Clinical 
Neuroanatomy, 26
th
 edition: www.accessmedicine.com. 
Figure 1.5: Ischemic brain tissue downstream of arterial occlusion. Adapted 
from: www.neurologiaroma.it 
Figure 1.6: Mechanisms of ischemic stroke. Adapted and modified from (9).  
Figure 1.7: Anatomy of cerebral arteries and sites of predilection of 
atheromatous plaque. Blue arrows show direction of blood flow. 
Plaque has a tendency to form in areas of flow turbulence, such as 
bifurcations. Adapted and modified from: Andreoli TE, Carpenter 
CCJ, Griggs RC, Loscalzo J.  Cecil Essentials of Internal 
Medicine, 6
th
 edition: consulted on CD-ROM. 
Figure 1.8: Signs of left middle cerebral artery (MCA) stroke. Right facial 
and upper limb weakness. Adapted and modified from (20). 
Figure 1.9: Normal brain images. A. Axial CT scan of the brain. Adapted 
from: Moeller TB, Reif E. Normal Findings in CT and MRI, 1
st
 
edition, page 7. B. Axial T2-weighted MRI of the brain. MRI 
provides a good assessment of brain structures with differences in 
signal intensity. C. CT angiogram of intracerebral arteries with 3-
dimensional volume rendering (axial and slightly oblique view). 
Gray matter (large white arrows), white matter (curved white 
arrow), lateral ventricles (black arrowheads), fat (small white 
arrows), and cortical bone (large arrowheads) on different pulse 
sequences. Structures identified are the genu (g) and splenium (s), 
caudate head (c), putamen (pt), and thalamus (T). For B and C, 
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images adapted from: Chen, Pope and Ott. Basic Radiology, 2
nd
 
edition, Chapter 12. 
Figure 1.10: CT scan of a cerebral infarction in a 56 year old hypertensive and 
diabetic male who presented with left hemiparesis in the 
emergency department. A and B. Axial CT at 2 different levels 
without contrast injection showing a well-defined hypodense area 
in the right MCA territory (between white arrows) and a mass 
effect on the surrounding brain tissue (compression of right 
ventricle). The right MCA is brighter than the left (large white 
arrow head on B) and corresponds to an occluding thrombus. C. 
A 3-D volume rendering CT angiogram shows the occlusion in 
the superior branch of the right MCA. D. Axial CT with contrast 
injection shows decreased filling of blood vessels in the right 
MCA territory (between white arrows) compared to the left (black 
arrows). Images adapted from: Chen, Pope and Ott. Basic 
Radiology, 2nd edition, Chapter 12. 
Figure 1.11: Axial CT scan without contrast of a 68 year old hypertensive 
female who was found unresponsive. There is a large bright 
(hyperdense) area consistent with hemorrhage in the right basal 
ganglia (black arrow), mass effect (small white arrows), bleeding 
into the ventricles (arrowheads), and entrapment of the left 
ventricle (large white arrow). This bleed is probably due to a 
vascular defect induced by chronic hypertension. Thrombolysis is 
contra-indicated, and immediate neurosurgical consultation is 
required for surgical decompression. Image adapted from: Chen, 
Pope and Ott. Basic Radiology, 2nd edition, Chapter 12. 
Figure 1.12: Axial MR images of the patient with right MCA territory 
infarction shown in Figure 1.10. Images are at the same anatomic 
level. A. DWI demonstrating restricted movement of water in the 
infarcted area (increased signal intensity between white arrows). 
B. T2-weighted image demonstrating area of hyperintensity and 
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mass effect on surrounding structures. C. T1-weighted image with 
contrast injection showing enhancement of vasculature in the 
territory of infarction, corresponding to slow flow of intravascular 
contrast. Images adapted from: Chen, Pope and Ott. Basic 
Radiology, 2nd edition, Chapter 12. 
Figure 1.13: Site of carotid plaque formation. It can cause significant 
obstruction of blood flow or rupture and embolize to a smaller 
vessel in the brain. Adapted from:  
 http://chicago.medicine.uic.edu/departments___programs/depart
ments/neurosurgery/clinical_services/neurovascular_surgery/caro
tid_disease/ 
Figure 1.14: Two different criteria can be used to measure degree of carotid 
stenosis on angiography: NASCET and European Carotid 
Surgery Trial (ECST) criteria. Adapted and modified from (22).  
Figure 1.15: A. Carotid Endarterectomy (CEA) procedure. Adapted and 
modified from: 
http://stanfordhospital.org/clinicsmedServices/COE/surgicalServi
ces/vascularSurgery/patientEducation/carotid.html  
 B. Endovascular carotid angioplasty (stenting) procedure. 
Adapted and modified from: 
http://www.sfveincenter.com/images/stories/med_images/carotid
_stent.jpg  
Figure 2.1: Normal vascular architecture (A) and anatomy (B). A. General 
organization of vascular system. Arrows show the direction of 
flow. Modified and adapted from Kumar: Robbins&Cotran 
Pathologic Basis of Disease, Professional Edition, 8
th
 ed. (2009). 
B. Structure of the arterial wall. Modified and adapted from: 
artery: transverse section of an artery. [Art]. Encyclopædia 
Britannica Online. Retrieved 17 April 2012, from  
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 http://www.britannica.com/EBchecked/media/121565/Transverse
-section-of-an-artery 
Figure 2.2: Cellular interactions in atherosclerosis plaque progression. SMC, 
smooth muscle cell; MCP-1, monocyte chemoattractant protein 1; 
LDL, low-density lipoprotein; ox-, oxidized; PDGF, platelet-
derived growth factor; M-CSF, macrophage colony-stimulating 
factor; MMP, matrix metalloproteinase. Adapted and modified 
from (39). 
Figure 2.3: Different Types of Vulnerable Plaque. Adapted from (33). 
Figure 2.4. Typical thin fibrous cap atheroma with a large lipid core, 
neovascularisation, intraplaque hemorrhage, and inflammatory 
macrophages in the shoulder of the cap. This plaque is considered 
a “rupture-prone” vulnerable plaque. 
Figure 2.5: A stable plaque with a thick fibrous cap. This plaque is unlikely 
to rupture. 
Figure 2.6: Expansive (outward) vessel remodeling with minimal change in 
lumen diameter. 
Figure 2.7: How primary prevention could be effective in high-risk patients 
with no warning symptoms. If atherosclerosis is not detected at 
the subclinical phase, and a sudden rupture of a VP develops, for 
example at 60 years of age, a potentially fatal clinical ischemic 
event will occur. On the other hand, if screening for VP and 
effective preventative therapy are offered early (during the “blue” 
subclinical phase), the atheroma will be less likely to evolve into 
a thrombotic plaque, the risk of having a clinical ischemic event 
at the same age will be lower, and the patient will have a 
prolonged and better quality of life. 
Figure 3.1: Scheme explaining relation between stress, strain and elastic 
modulus in an isotropic elastic material. A corresponding stress-
xx 
 
strain curve is plotted. Beyond a certain compression force (dot 
“2” on the graph), the material loses its elastic behaviour, i.e. it 
does not return to its original length. 1 = true elastic limit; 2 = 
elastic limit. 
Figure 3.2: How a CT machine works. Adapted and modified from: 
http://www.bchsys.org/bchserv/Imaging/CT 
Figure 3.2.1: Different Types of Vulnerable Plaque. (A) Rupture-prone plaque 
with a large lipid core, a thin fibrous cap and macrophages. (B) 
Ruptured plaque with a sub-occlusive thrombus and ruptured cap. 
(C) Erosion-prone smooth muscle cell-rich plaque with a 
proteoglycan matrix. (D) Eroded plaque with a sub-occlusive 
thrombus. (E) Intra-plaque haemorrhage from the vasa vasorum. 
(F) Calcified nodule protruding into the vessel lumen. (G) 
Chronic critically stenotic plaque with extensive calcification and 
an old thrombus. Adapted from Naghavi et al with permission 
(33). 
Figure 3.2.2: Doppler ultrasound of carotid arteries of a 46-year-old woman 
with hypercholesterolemia and transient cerebral ischemia of the 
right middle cerebral territory. (a) Significant stenosis of the left 
internal carotid artery from an echogenic homogeneous plaque 
that narrows the vessel lumen. (b) 80% right internal carotid 
artery stenosis (in diameter reduction, according to criteria from 
(76)). The stenotic plaque is echolucent (soft plaque) likely 
because of its high lipid content, haemorrhage and low calcium 
content. 
Figure 3.2.3: Doppler ultrasound of the left carotid artery of a 75-year-old 
asymptomatic man. (a) Sagittal reconstruction of the carotid 
artery lumen on MDCTA of the left ICA with a small calcified 
nodule (an inset of this image zoomed in on the lesion will be 
provided for article submission). (b) Doppler ultrasound 
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longitudinal image of the region of interest (red rectangle in a) 
showing 70% stenosis. The plaque meets criteria of vulnerability 
with plaque heterogeneity and a calcified nodule protruding into 
the vessel lumen. (c) Axial image centered on the calcified 
nodule. (d) A schematic representation of this plaque showing a 
calcified nodule protruding into the vessel lumen. Image (d) 
adapted and modified from (33) with permission. 
Figure 3.2.4: Doppler ultrasound of the carotid artery of an 82-year-old male 
with amaurosis fugax and transient left MCA territory ischemia. 
(a) Ultrasound image showing 75% left internal carotid artery 
stenosis with ruptured plaque and a non-occlusive clot. (b) 
Enlargement of the region of interest (red rectangle in a) where 
heterogeneous plaque can be seen. The echo-lucent zone may 
reflect hemorrhage or a lipid core. (c) Axial Doppler image 
centered on the plaque where stenosis is maximal, showing 
plaque heterogeneity. (d) Schematic representation of plaque with 
a non-occlusive clot and ruptured cap may reflect the plaque 
features seen on ultrasound in this case. This patient has 
undergone CEA demonstrating a ruptured and thrombotic 
atheroma intraoperatively. (e) Doppler spectral analysis. Maximal 
systolic velocity is 295 cm/s. Image (d) adapted and modified 
from (33) with permission. 
Figure 3.2.5: Carotid artery contrast-enhanced ultrasound. Hyperechoic foci 
within the plaque represent neovessels. Sonovue® is an aqueous 
suspension of stabilized sulfur hexafluoride (SF6) microbubbles 
(precontrast image currently unavailable for pre and post-contrast 
comparison). Courtesy of Christian Greis, Bracco Diagnostics. 
The color image is a schematic representation of vulnerable 
plaque with a normal cap and neovessels. Schematic inset adapted 
and modified from (33) with permission. 
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Figure 3.2.6: (a) CT scanner of carotid bifurcation showing a stenosis on the 
left side surrounded by calcifications. (b) B-mode image of the 
same plaque from reconstructed raw radiofrequency (RF) signals, 
used for vascular elastography. (c) Strain profile of segmented 
areas in (b). Rigid structures, such as calcifications, have stable 
cumulative strain values whereas soft plaque areas have 
increasing cumulative strain values. (d) For the same B-mode 
image, strain values can be displayed by colour code 
(elastogram). Dark zones represent calcifications with low strain 
values. (e) In a similar manner, shear stress (mechanical 
behaviour at the interface of 2 different structures) can be 
displayed by color code and help locate areas of high mechanical 
stress (white and dark areas).  T=fibrous tissue; CA=calcification; 
L=lumen. Adapted from (113) with permission. 
Figure 3.2.7: Patient with left-sided amaurosis fugax. (a) Sagittal reconstruction 
of the carotid artery lumen on MDCTA. Severe left internal 
carotid artery stenosis and a small ulceration. (b) and (c) Cross-
sectional images from the regions of interest (red rectangle in a). 
(b) The plaque likely contains a lipid core with an ulcer because 
the contrast agent in the lumen has an irregular contour. (c) A 
large lipid core and a calcified nodule are found inferiorly to the 
image in (b). 
Figure 3.2.8: Cross-sectional high-resolution MRI of an asymptomatic patient’s 
right internal carotid artery plaque. This patient has a 50% 
stenosis. (a) T1-weighted image showing a thick fibrous cap and 
large lipid core, easier to depict on the corresponding post-
gadolinium injection T1-weighted image in (d). (b) A drop in 
relative signal intensity on this T2-weighted image (compared to 
other sequences) characterizes the presence of a lipid-rich 
necrotic core. (c) Proton density image shows an isointense core. 
(d) After gadolinium injection, plaque enhancement is observed in 
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the postero-medial aspect of the plaque, suggesting 
neovascularisation or inflammation. 
Figure 3.2.9: High-resolution cross-sectional MRI of the right carotid 
bifurcation of an asymptomatic patient. (a) On T1-weighted 
acquisition of right internal carotid artery stenosis, the plaque 
appears to be heterogeneous. The external carotid artery lumen is 
observed (white arrow), and both vessel walls consist of 
heterogeneous signals reflecting fibro-calcific tissue. (b) and (c) 
T2-weighted and Proton Density images show a hyperintense area 
not clearly apparent on T1 pre and post contrast images. This 
hyperintense area likely represents loose matrix fibrous tissue. (d) 
There is no significant plaque enhancement after gadolinium 
injection, suggesting that there is no neovascularisation or 
inflammation. 
Figure 4.1: Schematic depiction of ultrasound NIVE. Blood pressure from the 
systolic carotid pulse induces a compression (axial stress denoted 
by large red arrows) and a deformation (axial strain denoted by 
∆L/L X 100) of the atherosclerotic plaque. This is a simplified 
depiction, because axial strain is calculated for each individual 
window (1.54 X 2.99 mm), after which mean axial strain for the 
entire segmented plaque is calculated. 
Figure 4.2: Elastogram and strain curves of the left carotid plaque of a 70 
year old man who presented with left-sided amaurosis fugax. (a) 
A two-dimensional longitudinal view B-mode image 
reconstructed from raw RF data showing the segmented plaque 
(red contour) on the anterior vascular wall of the internal carotid 
artery (ICA), and the same image with a superimposed 
elastogram (color map) representing cumulated axial strain at 
maximal systolic compression. The colors range from -20% (dark 
blue) to +20% (dark red), denoting areas of dilation and 
compression respectively. (b) A graph of instantaneous mean 
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axial strain is obtained from the strain difference between two 
consecutive image frames, thus representing the variation of mean 
axial strain over time. Peak systolic compression is denoted by 
red circles. Mean Strain at Peak Systolic Compression (MSPSC) 
is the average of these peak values over the number of cardiac 
cycles. Dotted vertical lines represent end-diastole, estimated 
from B-mode videos and M-mode images. (c) Strain Rate is the 
slope of the instantaneous strain in (b). Maximum Strain Rate 
(MaxSR) is the mean of the greatest strain rate occurring at end-
diastole (green circles). Minimum Strain Rate (MinSR) is the 
mean of the lowest strain rate, occurring at the onset of diastole 
(purple circles). In other words, MaxSR represents greatest tissue 
compression over time, and MinSR represents greatest tissue 
dilation over time, which explains why MinSR is a negative 
value. (d) A graph of cumulated mean axial strains is derived 
from (b). Double-sided blue arrows represent strain amplitude for 
each cardiac cycle. Mean Strain Amplitude (MSA) is the average 
of these three amplitudes. The peak of the third cardiac cycle 
corresponds to the elastogram in (a). 
Figure 4.3: High-resolution MRI of the left internal carotid artery plaque of a 
65 year old man who presented with a left hemispheric stroke 
(axial view). This is a vulnerable-appearing lipid-rich 
hemorrhagic plaque. The external and internal carotid arteries are 
indicated with a white and black arrow, respectively. The 
segmentation using the QPlaque software is shown superimposed 
on the T1-weighted image (framed inset at the center). The green 
and red contours designate the outer and inner vascular wall 
contours of the internal carotid artery. Yellow represents lipid, 
pink represents hemorrhage, and purple represents inflammation. 
T1W = T1-weighted; T2W = T2-weighted; PDW = Proton 
Density-weighted; T1WC+ = T1-weighted post-contrast injection. 
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Figure 4.4: Flowchart of subject recruitment. 
Figure 4.5: ROC curves for NIVE strain parameters to detect the presence of 
a lipid core. 
Figure 4.6: Distribution of axial strain parameters by presence of symptoms. 
MSPSC = Mean Strain at Peak Systolic Compression; MSA = 
Mean Strain Amplitude; MaxSR and MinSR = Maximal and 
Minimal Strain Rates. 
Figure 4.7: Scatter plots with curve fitting functions of the natural logarithm 
of strain parameters with (a) % Lipid volume and (b) % Calcium 
volume (bivariate analyses). Note that only for the MinSR 
parameter, 2 outliers were removed to normalize the distribution. 
For all other parameters, a natural logarithm was applied for 
normalization. MSPSC = Mean Strain at Peak Systolic 
Compression; MSA = Mean Strain Amplitude; MaxSR and 
MinSR = Maximal and Minimal Strain Rates. Note: red stars = 
symptomatic group, blue circles = asymptomatic group 
Figure 4.8: Common issue of slice acquisition overlap between image 
sequences. 
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CHAPTER 1 
Stroke, a Cerebrovascular Disease 
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1. Stroke, a Cerebrovascular Disease 
1.1.  Background 
 
Cerebrovascular disease is a term that designates a wide spectrum of disorders 
of the arterial and venous circulations of the central nervous system, including 
ischemic stroke, hemorrhagic stroke, and other cerebrovascular anomalies. A 
stroke, also called cerebrovascular accident (CVA), is a clinical syndrome
1
 
characterized by the abrupt onset of a focal neurological deficit due to either 
inadequate blood flow (i.e. ischemia) or hemorrhage in the brain. Stroke is a 
major cause of mortality and morbidity worldwide, and it is frequently 
devastating for both the patient and family. Generally, there are two types of 
stroke: ischemic and hemorrhagic, accounting for 87% and 13% of all strokes, 
respectively [1].  
 
This chapter will focus on understanding the clinical and pathological aspects 
of ischemic stroke and will provide a brief overview of hemorrhagic stroke. 
Current issues associated with ischemic stroke will be described, and the 
premise and objectives of the present research project will be explained.  
 
1.2.  Anatomy and Physiology 
 
The human nervous system is divided into three specialized sub-systems. The 
central nervous system (CNS) consists of the brain and spinal cord; it functions 
to initiate decisions and coordinate actions. The peripheral nervous system 
(PNS) consists of neurons coming out from the CNS; it is responsible for 
                                                          
1
 Syndrome: a group of signs and symptoms that occur together and characterize a particular 
abnormality, such as a disease, psychological disorder, or other abnormal physiological 
condition. A syndrome is not synonymous with disease but merely describes a constellation 
of symptoms that may characterize a disease. 
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executing functions dictated by the brain in muscles and relaying sensory 
information from the skin back to the brain. Finally, the autonomic nervous 
system (ANS) consists of nerve cells overlapping in location between the CNS 
and PNS, and controls subconscious bodily functions such as blood pressure, 
heart rate and digestion. 
 
The brain alone contains close to 100 billion nerve cells [2]. It is responsible 
for motor function, sensory perception, autonomic regulation, memory, 
learning, language, emotions, and thoughts, to name only a few. Hence, the 
brain is central to all bodily functions of the nervous system. Brain anatomy is 
complex and beyond the scope of this thesis, but a very basic knowledge of 
anatomy is provided here to help understand the clinical aspects of ischemic 
stroke.  
 
The brain is divided into three main parts: cerebrum, cerebellum and brainstem 
(figure 1.1). The cerebrum consists of two cerebral hemispheres of folded 
tissue called cortex, each divided into 4 lobes that serve distinct functions. The 
cerebellum has a similar structure to the cerebrum, but is smaller. The 
brainstem is covered by the cerebral hemispheres, and extends inferiorly to 
become the spinal cord. 
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Figure 1.1: Left lateral view of the brain. Each part of the brain identified serves a 
specific function. Adapted and modified from: Morton DA, Foreman KB, Albertine KH. 
The Big Picture: Gross Anatomy, 1
st
 edition: www.accessmedicine.com  
 
Despite the extraordinary power of the brain, it is extremely fragile. Neuronal 
cells of the brain do not readily repair or regenerate after an injury or cell 
death. Therefore, a brain injury is often very serious with permanent sequelae, 
such as paralysis, cognitive changes, coma, and even death. Protection of the 
brain from external insults is provided by the skull, meninges
2
, and head gear 
for certain sports activities. On the other hand, function and survival of 
neuronal cells depends on a good and constant blood supply of oxygen and 
glucose, provided by 15 to 20% of the total cardiac output
3
 at rest and an 
effective networking of cerebral arteries, namely the Circle of Willis.  
 
                                                          
2
 Meninges are layers of connective tissue that surround the brain, underneath the skull.  
3
 Cardiac Output is the amount of blood coming out of the heart per minute (mL/min). 
Cardiac Output = Heart Rate X Stroke Volume. 
7 
 
There are two main arterial supplies to the brain: the internal carotid artery and 
the vertebral artery (Figure 1.2). Two internal carotid arteries supply the 
anterior circulation of the brain, and two vertebral arteries supply the posterior 
circulation of the brain. The internal carotid artery (ICA) branches into the 
anterior cerebral artery (ACA), the middle cerebral artery (MCA), and the 
ophthalmic artery which supplies the retina. The vertebral arteries join to form 
the basilar artery, which further divides into two posterior cerebral arteries 
(PCA). Hence, three major pairs of arteries supply the cerebral hemispheres: 
ACA, MCA, and PCA. The anterior and posterior circulations are connected 
through communicating arteries of the Circle of Willis. Anatomy of these 
vessels is shown on figures 1.2 and 1.7. 
 
 
Figure 1.2: A. Lateral and B. coronal views of extracranial and intracranial
4
 arteries.  
A: The common carotid artery bifurcates into the external and internal carotid artery. 
The external carotid supplies blood to the face. The internal carotid supplies the anterior 
part of the brain. The vertebral artery arises from the subclavian artery, and supplies the 
posterior part of the brain. B: The anterior and posterior circulations are linked through 
the posterior communicating artery (Post. Comm.), forming the Circle of Willis 
                                                          
4
 Extracranial: outside of the bony skull; Intracranial = inside the bony skull. The brain is 
intracranial. 
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(highlighted in dark red). This architecture provides collateral circulation of blood in 
case of obstruction in one of the major intracranial arteries. The pink arrow 
demonstrates the direction of blood flow arising from the heart. ACA = Anterior cerebral 
artery; Ant. Comm.= Anterior communicating artery; MCA = Middle cerebral artery; 
PCA = Posterior cerebral artery; ICA = Internal carotid artery; ECA = External carotid 
artery; CCA = Common carotid artery; SCA = Superior cerebellar artery; AICA = 
Anterior Inferior cerebellar artery; PICA = Posterior inferior cerebellar artery; a.= 
artery. Figure 1.2A adapted and modified from Longo DL, Fauci AS, Kasper DL, Hauser 
SL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine, 18th edition: 
www.accessmedicine.com. Figure 1.2B adapted and modified from: Andreoli TE, 
Carpenter CCJ, Griggs RC, Loscalzo J.  Cecil Essentials of Internal Medicine, 6
th
 edition: 
consulted on CD-ROM.  
 
Each main intracranial artery supplies specific areas of the brain (figures 1.3 
and 1.4). In turn, each area of the brain has a different role in the nervous 
system (figures 1.1 and 1.4). Therefore, from the specific symptoms and signs 
of stroke that a patient has, a physician can localize the area of the brain that is 
deprived of oxygen before examining imaging studies.  
 
 
Figure 1.3: Blood supply to the brain by arterial territory. Adapted and modified from 
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s 
Principles of Internal Medicine, 18
th
 edition: www.accessmedicine.com 
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Figure 1.4: Coronal view of the brain showing the motor homunculus
5
 and blood supply 
areas of the precentral gyrus of the frontal lobe. Image modified and adapted from: 
Waxman SG. Clinical Neuroanatomy, 26
th
 edition: www.accessmedicine.com  
 
1.3.  Pathophysiology  
 
In ischemic stroke, a sudden interruption of blood flow in a blood vessel to the 
brain occurs, inhibiting neurons downstream from receiving oxygen and 
glucose (figure 1.5). The inadequate blood flow to the brain is termed cerebral 
ischemia, and results in cellular hypoxia
6
, depletion of adenosine triphosphate 
(ATP) molecules (i.e. loss of energy), and loss of normal cellular functions. 
Neuronal cells undergo a number of biochemical changes and can no longer 
maintain ionic gradients. Consequently, water passively shifts into cells, and 
they swell (cytotoxic edema). If blood flow is not immediately restored within 
                                                          
5
 Motor homunculus: map of brain areas that control muscle movement. On figure 1-4, the 
map shows which brain part controls muscle movement of the limbs, hand, face, tongue. 
6
 Hypoxia: low oxygen levels. 
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a few minutes, cerebral ischemia evolves into cerebral infarction
7
. It only 
requires 4 to 10 minutes [3] of complete oxygen deprivation to cause cerebral 
infarction. The popular expression physicians say, “time is brain”, reflects how 
important it is to act very quickly to prevent as much neuronal cell death as 
possible.  
 
 
Figure 1.5: Ischemic brain tissue downstream of arterial occlusion. Adapted from: 
www.neurologiaroma.it 
 
An ischemic stroke implies that cerebral infarction has occurred. Patients 
suffering a stroke have variable recovery afterwards. A transient ischemic 
attack (TIA) is clinically similar to an ischemic stroke, but the neurologic 
deficit lasts less than 24 hours, and there is full recovery of symptoms with no 
evidence of cerebral infarction on imaging studies. The mechanisms 
underlying an ischemic stroke are the same as those for TIA. However, in TIA, 
                                                          
7
 Infarction: cellular death.  
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the vascular obstruction does not last long enough to cause infarction, probably 
because the thrombus or embolus is small enough to spontaneously dissolve 
and allow timely reperfusion. Although harmless, a TIA is an important 
warning sign: it precedes 15% of all strokes [4], and it considerably increases 
the risk of developing a stroke within the next 90 days (9 to 20% risk), 
especially in the first 2 days (3 to 10% risk) [5-7]. Unfortunately, half of all 
patients who experience a TIA do not report it to their healthcare provider [8]. 
 
In hemorrhagic stroke, there is bleeding in the brain tissue. The focal area 
where bleeding is occurring produces a toxic effect on neuronal cells, 
vasospasm
8
 of blood vessels, and may produce a mass effect
9
 compressing 
surrounding vessels and brain tissue. Moreover, a breakdown of the vascular 
barrier can cause fluid to leak interstitially in the brain (vasogenic edema), 
which in turn can also cause a mass effect. These events can compromise 
blood flow, leading to ischemia and infarction, or cause brain herniation, 
leading to massive cellular death and loss of vital bodily functions. 
 
1.4.  Etiology10  
 
Cerebral ischemia may occur in a specific vascular territory as a result of a 
thrombotic or embolic occlusion of a major vessel, or it may occur globally 
because of decreased systemic blood pressure. Causes of focal and global 
cerebral ischemia are enumerated in Table I-I.   
 
                                                          
8
 Vasospasm: contraction of muscular layer of blood vessels, causing decrease in lumen 
diameter. Also called constriction. 
9
 Mass effect: compression of surrounding brain tissue due to the presence of a mass, such as 
a collection of blood, swelling, or a tumour. A mass effect requires imminent treatment 
because it may cause deadly brain herniation, where the brain tissue is pressed and pushed 
away from its normal position inside the bony skull. 
10
 Etiology: cause underlying the disease. 
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Table I-I: Common Causes of Cerebral Ischemia 
 
 
 
Thrombosis is the formation of a thrombus (blood clot) in the blood stream. 
Hypercoagulability, stasis of blood circulation, and vessel wall injury are 
predisposing factors of thrombosis. Atherosclerotic plaque rupture is an injury 
of the diseased vessel wall. As a response to this injury, a thrombus forms at 
the site of rupture and may occlude the artery in situ or travel distally
11
 to a 
smaller vessel, at which point it is called an embolus. These concepts are 
important for understanding etiology and mechanisms of ischemic stroke 
(figure 1.6). Four common mechanisms are discussed below. 
 
                                                          
11
 Distal: located further from the heart. Antonym = proximal. 
Focal Cerebral Ischemia 
Global Cerebral 
Ischemia 
Disease of the Vascular wall 
Atherosclerotic plaque with occlusive thrombosis in 
situ 
Vasculitis (inflammation of blood vessels) 
Vasospasm (migraine or hemorrhage) 
Mass effect (compression of cerebral vessels) 
Dissection of arterial wall 
Other vascular disease (moyamoya, fibromuscular 
dysplasia) 
 
Embolus 
Cardiac origin (atrial fibrillation, cardiac tumour) 
Artery-to-artery (i.e. embolus from an upstream 
atherosclerotic plaque) 
Venous origin (paradoxical embolus due to cardiac 
defect) 
 
Hyperviscosity of blood 
Inflammatory disease (Lupus) 
Sickle cell disease 
Inherited hypercoagulability 
Medication-induced (e.g. oral contraceptive) 
Hypoperfusion (e.g. 
massive hemorrhage, 
dehydration) 
Cardiac arrest 
Other cause of 
hemodynamic 
compromise (e.g. septic, 
anaphylactic, or  
cardiogenic shock 
states) 
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Figure 1.6: Mechanisms of ischemic stroke. Adapted and modified from [9]. 
 
 
1. Cardioembolic stroke causes up to 20% of all ischemic strokes [3]. A 
thrombus forms in the heart due to cardiac arrhythmia (e.g. atrial fibrillation), a 
structural cardiac defect, or valvular disease. Fragments of thrombi then detach 
and embolize to the brain. Emboli frequently lodge in the major arteries 
(MCA, PCA, ACA). Cardioembolic strokes may affect a single cerebral 
vascular territory or multiple vascular territories. The latter suggests “embolic 
showers” (multiple emboli), which are strongly associated with cardiac 
thromboembolism. 
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2. Large-vessel occlusion is another possible but less common mechanism of 
stroke. It involves total occlusion of the internal carotid artery due to an 
advanced atherosclerotic plaque that ulcerates and forms an obstructive 
thrombus in situ. A border-zone cerebral infarction (“watershed infarction”) 
ensues; this zone is located most distally and between major cerebral vascular 
territories. If collateral arterial circulation has sufficiently developed to bypass 
the severe carotid stenosis, then a total carotid occlusion could be completely 
asymptomatic and not cause any cerebral infarction. 
 
3. Artery-to-artery embolus results from the formation of a thrombus at the 
surface of a ruptured atherosclerotic plaque, and distal embolization of it or of 
a fragment toward the brain. More about atherosclerosis is discussed in chapter 
2. Sites with a predilection for developing atherosclerotic plaque include the 
ICA, carotid bifurcation, and aortic arch (figure 1.7). The proximal ICA and 
bifurcation are the most common sources of artery-to-artery embolus. An 
estimated 20% of all ischemic strokes are caused by carotid atherosclerosis 
alone [10]. Emboli from the ICA may go to any of its major branches. Other 
less common sources of emboli that go to smaller vessels in the brain include 
intracranial atherosclerosis (proximal MCA, ACA, or ophthalmic artery), and 
dissection of the carotid artery (traumatic or spontaneous).  
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Figure 1.7: Anatomy of cerebral arteries and sites of predilection of atheromatous 
plaque. Blue arrows show direction of blood flow. Plaque has a tendency to form in areas 
of flow turbulence, such as bifurcations. Adapted and modified from: Andreoli TE, 
Carpenter CCJ, Griggs RC, Loscalzo J.  Cecil Essentials of Internal Medicine, 6
th
 edition: 
consulted on CD-ROM. 
 
 
4. Small-vessel strokes are small infarctions in the territory of deep 
penetrating arteries of the brain, affecting areas of the basal ganglia (figure 1.3) 
and the brainstem. They are also termed “lacunar strokes”. Microvascular 
obstruction in situ occurs due to microatheroma or lipohyalinotic vessel wall 
thickening associated with hypertensive disease. Approximately 20% of all 
strokes are small-vessel strokes [3].  
 
Causes of spontaneous hemorrhagic stroke include vascular diseases 
(hypertensive, amyloid angiopathy, arteriovenous congenital malformation, 
drug-induced), intracerebral tumours pressing on vessels, and bleeding 
disorders (congenital or induced by blood thinners). 
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1.5.  Epidemiology, Risk Factors, Prognosis, and Cost 
 
In the western world, stroke is the third leading cause of death after heart 
disease and cancer [11], and it is a leading cause of long-term disability [12]. 
Approximately every 40 seconds, a person suffers a stroke [11], and every 4 
minutes, someone dies from stroke in the United States [13]. Each year, 795 
000 people in the USA suffer from a new or recurrent stroke, of which 610 000 
are first attacks, and the remainder are recurrent attacks [11]. In people aged 45 
to 84 years, the age-adjusted stroke incidence rate varies from 2.3 to 6.6 per 
1000 person-years [1]. Stroke incidence increases with age, is higher in blacks 
than in whites, and higher in men than in women. 
 
Risk factors for ischemic stroke are presented in Table I-II. Modifiable implies 
that risk factors can be controlled with lifestyle changes and medications. 
 
Non-modifiable risk factors Modifiable risk factors Other risk factors 
Age 
Race 
Sex 
History of migraines 
Sickle cell disease 
Fibromuscular dysplasia 
Family history of stroke 
Hyperhomocysteinemia 
Hypertension 
Diabetes mellitus 
Smoking 
Physical inactivity 
Hyperlipidemia 
Alcohol or illicit drug abuse 
Oral contraceptive use 
Atrial fibrillation 
Carotid stenosis 
Transient Ischemic 
Attack (TIA) 
Previous ischemic 
stroke 
 
Table I-II. Risk Factors for ischemic stroke 
 
 
Stroke can be deadly or result in a significant loss of autonomy due to 
permanent paralysis, speech or cognitive impairment. Prognosis after an acute 
ischemic stroke is highly variable, because it depends on stroke severity, 
development of complications, and presence of other comorbid diseases. Life-
threatening complications that may occur after an ischemic stroke include 
brain herniation (mass effect), aspiration pneumonia (stroke can cause 
impaired swallowing and choking), acute myocardial infarction, and an 
expanding collection of blood (hematoma) due to hemorrhagic transformation 
of the infarct. The 30-day case fatality rate of ischemic stroke is 8-12%, and 
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that of hemorrhagic stroke is around 40% [14,15]. Among stroke survivors, 15 
to 30% remain permanently disabled [16]. In addition to the burden on the 
patient and family, elevated health care and economical costs ensue. In 2007, 
the direct and indirect cost of stroke was $40.9 billion in the USA [11]. 
 
1.6.  Clinical Presentation 
1.6.1. History 
 
Patients suffering a stroke or TIA present with an abrupt onset neurologic 
deficit or altered consciousness. The time of symptom onset is very important. 
If the onset is within 6 hours of consultation in the emergency room and 
ischemic stroke is confirmed with computed tomography (CT) scan of the 
head, treatment with immediate thrombolysis
12
 is possible. Neurologic deficits 
elicited on medical history include: 
 
 facial or limb weakness (hemiparesis) or paralysis (hemiplegia), usually on 
one side 
 sensory loss in extremities 
 Visual deficit: blindness in one or both eyes, visual field defect, double 
vision 
 Speech disorder: slurred (dysarthria) or incoherent (“word salad”) 
 Language disorder: lack of output (expressive aphasia) or understanding 
(receptive aphasia)  
 Dizziness, loss of balance, loss of coordination 
 Headache, nausea, vomiting 
 Decreased level of consciousness 
 
                                                          
12
 Thrombolysis: dissolution or breaking apart of a thrombus. 
18 
 
Depending on the location of the brain that is ischemic, patients will present a 
specific symptom or a combination of symptoms termed stroke syndromes. 
Symptoms that worsen over time may indicate progressive intracranial edema, 
hemorrhagic transformation, or a stroke-in-evolution (area of ischemia and 
infarction that is increasing in size because of worsening occlusion). Some 
symptoms are suggestive of hemorrhagic stroke, like severe headache, nausea, 
vomiting, neck stiffness, and loss of consciousness, but they are not of 
diagnostic value since they also occur in ischemic stroke. 
 
Risk factors for ischemic stroke and other co-morbidities must be elicited with 
medical history. Hypertension, diabetes mellitus, smoking, elevated cholesterol 
levels, and family history of stroke or heart disease may be present. Also, the 
patient may have recently suffered a similar but transient attack in the past few 
weeks, suggesting TIA as a warning sign for current ischemic stroke. Other 
clues must also be elicited, such as cardiac arrhythmia (palpitations, shortness 
of breath), carotid stenosis, trauma, medication use, and causes of 
hypercoagulability (hormonal therapy). 
 
Many people suffer from “silent” ischemic strokes, in other words, small 
strokes with no apparent symptoms. They are usually discovered incidentally 
on brain imaging, and the patient and family report no history of previous 
stroke or TIA. Etiology of silent ischemic strokes is the same as cerebral 
ischemia discussed above (cardioembolic, artery-to-artery, small vessel 
obstruction). The prevalence of silent ischemic strokes varies from 11% in 
people aged 55-64 years, to 43% in those aged over 85 years [17,18]. Although 
no obvious deficits are observed, minor cognitive and memory deficits 
resulting from silent strokes can be detected with more sensitive 
neurocognitive and psychological testing (for example, the Repeatable Battery 
for the Assessment of Neuropsychology Status [RBANS]). Such minor deficits 
can evolve into dementia and significantly alter quality of life; hence, 
treatment is aimed at preventing both silent and non-silent ischemic strokes. 
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1.6.2. Physical Examination 
 
A thorough physical exam is required to determine if indeed the patient 
suffered a stroke, identify the stroke syndrome, localize and predict the extent 
of the ischemic lesion, establish a baseline neurological status for follow-up of 
clinical evolution, and uncover possible etiologies. 
 
If a patient presents with a significant decrease in level of consciousness like 
stupor or coma, there is a very high risk of severe deterioration and death, and 
urgent intervention is required (e.g. mechanical respiratory assistance, blood 
pressure maintenance). 
 
Vital signs frequently show an elevation of systemic blood pressure; it is a 
normal response to cerebral injury to maintain cerebral perfusion. If there is a 
brainstem or a very large ischemic or hemorrhagic stroke, the patient’s vital 
signs may be unstable and there may be loss of spontaneous breathing 
requiring assisted ventilation. A rapid irregular heart rate is indicative of 
cardiac arrhythmia like atrial fibrillation; in this case, the heart rate must be 
slowed down to maintain adequate perfusion of the body. A fever can be a clue 
of aspiration pneumonia or another infection (e.g. meningitis). 
 
Examination of the head and neck can show signs of trauma like a contusion, 
swelling, and laceration, which can be associated with intracranial hemorrhage 
or arterial dissection. An ocular examination of retinas with fundoscopy is 
required to check for evidence of increased intracranial pressure (ICP) 
(papilledema) or retinal ischemia (“cherry-red spot” appearance of fovea). A 
stiff neck is suspicious for meningitis or hemorrhagic stroke. Auscultation of 
the carotid arteries with a stethoscope may reveal a bruit indicative of 
significant carotid stenosis. 
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On cardiac auscultation, an irregular rhythm may point to arrhythmia, a 
murmur may be a sign of valvular disease, and a gallop
13
 may be heard when 
there is cardiac hypertrophy. Pulmonary edema and swelling of the legs are 
signs of heart failure. All these conditions are associated with the development 
of an intracardiac thrombosis. 
 
Peripheral pulse intensity asymmetry or systolic blood pressure difference 
between two arms may indicate aortic dissection. Weak or absent pedal pulses 
may be indicative of atherosclerotic occlusive peripheral arterial disease, 
which itself is strongly associated with atherosclerosis in other arteries (e.g. 
carotid and coronal arteries). 
 
The neurological examination is essential to diagnose stroke and plan 
management. It is divided into many components: mental status, level of 
consciousness, cranial nerves, motor function, deep tendon reflexes, sensory 
function, cerebellar function, and gait. The neurological examination is 
intricate, but for the purpose of this chapter, a brief description of what 
physicians on a stroke team
14
 use to rapidly assess the patient’s neurological 
status is provided in the Appendix 1, the National Institutes of Health Stroke 
Scale (NIHSS) [19]. The score of the NIHSS helps localize the lesion, 
determine stroke severity, outcome, and appropriate patient management. 
Finally, after the patient’s stroke, a Modified Rankin Scale (Appendix 2) score 
is attributed for purposes of follow-up examinations. 
 
Different stroke syndromes are encountered in ischemic stroke, depending on 
the vascular territory involved. 
 
                                                          
13
 Gallop: an additional heart sound other than the first and second normal heart sounds 
14
 Stroke team: team of physicians responsible for the care of patients presenting with a 
stroke in the emergency room. They are responsible for deciding and administering 
thrombolytic therapy. 
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 Middle cerebral artery occlusion produces contralateral hemiparesis and 
hemisensory loss of the face and upper limb, aphasia, and partial visual 
field loss (figure 1.8). 
 
Figure 1.8: Signs of left middle cerebral artery (MCA) stroke. Right facial and upper 
limb weakness. Adapted and modified from [20]. 
 
 Anterior cerebral artery occlusion produces contralateral hemiparesis 
and hemisensory loss of the lower limb, mutism, incontinence, cognitive 
and personality changes. 
 Ophthalmic or central retinal artery occlusion produces acute 
monocular blindness due to retinal ischemia. Patients may report seeing a 
black curtain moving in the visual field of one eye. If the symptom is 
transient, it is termed amaurosis fugax (“transient monocular blindness”), 
which is equivalent to a TIA. If the symptom is permanent, retinal 
infarction has occurred, much like an ischemic stroke. Amaurosis fugax is 
often an indicator of artery-to-artery embolization, originating either in the 
carotid or ophthalmic artery, as evidenced by the presence of a cholesterol 
embolus in the retinal artery.  
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 Posterior cerebral artery occlusion produces visual field deficits 
(blindness may be partial in one or both eyes), loss of visual recognition 
(persons, objects, shapes), and amnesia. 
 Vertebrobasilar artery occlusion produces dizziness, double vision, 
visual field losses, difficulty swallowing, slurred speech, and 
uncoordinated gait (ataxia). 
 Lacunar strokes typically produce pure motor loss, pure sensory loss, or 
ataxic gait. 
 
1.7.  Differential diagnoses 
 
A physician elaborates a differential diagnosis based on all available clinical 
information. A differential diagnosis is a list of all possible disorders that can 
present in a similar fashion. Before making the final diagnosis, each possible 
disorder should be explored through focused investigations like blood tests and 
imaging; in other words, a workup. This helps narrow down the differential to 
a single diagnosis, after which appropriate treatment can begin. Disorders that 
present similarly to acute ischemic stroke are presented in Table I-III. 
Differential diagnosis of acute ischemic stroke 
Neurological disorders 
Hemorrhagic stroke 
Transient ischemic attack (TIA) 
Seizure (especially post-ictal state) 
Brain tumour (abscess, malignant 
tumour) 
Meningitis 
Benign vertigo 
Neuropathies (Bell’s palsy, spinal cord 
trauma) 
Multiple sclerosis 
Cardiovascular disorders 
Syncope 
Myocardial infarction 
Arrhythmia 
 
 
Metabolic disorders 
Severe infection 
Drugs (illicit or prescription) 
Low serum sodium 
Hypoglycemia 
Table I-III. Differential diagnosis of acute ischemic stroke 
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1.8.  Workup 
 
Once an acute stroke is suspected, the next step is determining if it is ischemic 
or hemorrhagic. Emergent treatment (thrombolysis, surgery) depends on this 
distinction. An immediate computed tomography (CT) of the head without 
contrast injection is required; it is a rapid and very accurate imaging 
examination to differentiate ischemic stroke from hemorrhage. A serum 
glucose level and electrocardiogram (ECG) should also be checked promptly.  
 
On CT scan, hemorrhage appears bright (white), and infarction appears as 
darker (more lucent) than healthy brain parenchyma. Also, subtle early signs of 
infarction include loss of gray-white matter differentiation and effacement of 
cortical sulci (the normal folds in the cortex). If there is no hemorrhage but a 
suspected infarction, a CT scan with contrast injection or CT angiography 
(CTA) of the head and neck vessels is performed to search for occlusion of a 
major artery, localize the area of decreased perfusion, the infarct core and 
ischemic penumbra. CT scan images of the brain are shown in figures 1.9 
through 1.11. 
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Figure 1.9: Normal brain images. A. Axial CT scan of the brain. Adapted from: Moeller 
TB, Reif E. Normal Findings in CT and MRI, 1
st
 edition, page 7. B. Axial T2-weighted 
MRI of the brain. MRI provides a good assessment of brain structures with differences in 
signal intensity. C. CT angiogram of intracerebral arteries with 3-dimensional volume 
rendering (axial and slightly oblique view). Gray matter (large white arrows), white 
matter (curved white arrow), lateral ventricles (black arrowheads), fat (small white 
arrows), and cortical bone (large arrowheads) on different pulse sequences. Structures 
identified are the genu (g) and splenium (s), caudate head (c), putamen (pt), and 
thalamus (T). For B and C, images adapted from: Chen, Pope and Ott. Basic Radiology, 
2
nd
 edition, Chapter 12. 
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Figure 1.10: CT scan of a cerebral infarction in a 56 year old hypertensive and diabetic 
male who presented with left hemiparesis in the emergency department. A and B. Axial 
CT at 2 different levels without contrast injection showing a well-defined hypodense area 
in the right MCA territory (between white arrows) and a mass effect on the surrounding 
brain tissue (compression of right ventricle). The right MCA is brighter than the left 
(large white arrow head on B) and corresponds to an occluding thrombus. C. A 3-D 
volume rendering CT angiogram shows the occlusion in the superior branch of the right 
MCA. D. Axial CT with contrast injection shows decreased filling of blood vessels in the 
right MCA territory (between white arrows) compared to the left (black arrows). Images 
adapted from: Chen, Pope and Ott. Basic Radiology, 2nd edition, Chapter 12. 
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Figure 1.11: Axial CT scan without contrast of a 68 year old hypertensive female who 
was found unresponsive. There is a large bright (hyperdense) area consistent with 
hemorrhage in the right basal ganglia (black arrow), mass effect (small white arrows), 
bleeding into the ventricles (arrowheads), and entrapment of the left ventricle (large 
white arrow). This bleed is probably due to a vascular defect induced by chronic 
hypertension. Thrombolysis is contra-indicated, and immediate neurosurgical 
consultation is required for surgical decompression. Image adapted from: Chen, Pope 
and Ott. Basic Radiology, 2nd edition, Chapter 12. 
 
 
Magnetic Resonance Imaging (MRI) with Diffusion-Weighted Imaging (DWI) 
has a greater sensitivity to detect acute cerebral infarction in the first 6 hours of 
stroke compared to CT scan without contrast. It is also the best modality to see 
the area and extent of infarction. However, MRI is often not the first imaging 
modality used to diagnose acute ischemic stroke. This is because the priority in 
patient management is to rapidly determine if there is hemorrhage and prevent 
delay in therapy. CT scanning acquires images more rapidly than MRI and is 
very sensitive to detect acute hemorrhage. Otherwise, when CT is 
unremarkable but there remains high suspicion of ischemic stroke, MRI with 
DWI is typically indicated. Figures 1.9B and 1.12 show normal and abnormal 
MRI examinations, respectively. 
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Figure 1.12: Axial MR images of the patient with right MCA territory infarction shown 
in Figure 1.10. Images are at the same anatomic level. A. DWI demonstrating restricted 
movement of water in the infarcted area (increased signal intensity between white 
arrows). B. T2-weighted image demonstrating area of hyperintensity and mass effect on 
surrounding structures. C. T1-weighted image with contrast injection showing 
enhancement of vasculature in the territory of infarction, corresponding to slow flow of 
intravascular contrast. Images adapted from: Chen, Pope and Ott. Basic Radiology, 2nd 
edition, Chapter 12. 
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To rule out or rule in other suspected diagnoses and comorbidities, the 
following investigations are ordered as needed: complete blood count (CBC), 
serum electrolytes, urea, creatinine, coagulation studies, troponins and 
creatinine kinase (cardiac enzymes), toxicology screen, and lumbar puncture
15
. 
 
Finally, once acute ischemic stroke is confirmed, a search for the underlying 
etiology is begun with specific investigations. For a suspected cardioembolic 
mechanism, a trans-thoracic or trans-esophageal echocardiography can 
efficiently image the cardiac structure and reveal an intracardiac thrombus. For 
suspected arrhythmia not detected on ECGs, a Holter monitor (24-hour 
continuous monitoring of ECG) is prescribed. For a suspected large artery 
occlusion or artery-to-artery embolus, angiography (CT or MR) from the aortic 
arch to the intracranial vessels or carotid Doppler ultrasound can be used to 
confirm presence of large atherosclerotic plaques and measure carotid stenosis. 
Transcranial Doppler ultrasound through the infratemporal fossa
16
 can be used 
to evaluate the MCA, vertebral artery, intracranial ICA, and presence of 
embolic signals. When still in doubt about the vascular pathology despite other 
imaging methods, conventional angiography is indicated. It is the gold 
standard imaging technique for evaluating vascular disease, degree of stenosis, 
and is performed as part of endovascular interventions. 
 
1.9. Treatment: Primary and Secondary Prevention 
 
Primary prevention of ischemic stroke is recommended for patients who have 
never suffered a stroke. The goal is to decrease the risk of developing an 
ischemic stroke by acting on modifiable risk factors (Table I-II). This involves 
maintaining blood pressure at normal levels, treating atrial fibrillation with 
anticoagulants and antiarrhythmics, appropriate glucose control in diabetics, 
                                                          
15
 Lumbar puncture: sampling of the cerebrospinal fluid to test for hemorrhage or meningitis. 
16
 Infratemporal fossa = bony cavity just medial to the mandible. 
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lowering serum cholesterol levels, and lifestyle modifications like smoking 
cessation, weight loss, healthy diet, and regular exercise. 
 
On the other hand, secondary prevention involves treatment of patients who 
have already suffered a stroke (or TIA), with the goal of decreasing the risk of 
stroke recurrence. Once determination of the underlying cause is found, 
treatment can be targeted to prevent recurrence. For example, patients with 
atrial fibrillation will require anticoagulation with warfarin (Coumadin) or 
dabigatran, and patients with severe carotid stenosis will require recanalization 
with surgery or an endovascular stent. Furthermore, all modifiable risk factors 
for cerebral ischemia must be treated concomitantly. Finally, physical 
rehabilitation is necessary to optimize patient autonomy, improve quality of 
life, and prevent death from stroke-related medical complications (aspiration 
pneumonia, cardiac disease). 
Pharmacological therapies that are commonly used in both primary and 
secondary prevention include cholesterol-lowering agents (HMG-CoA
17
 
reductase inhibitors, known as statins), antihypertensive medications 
(thiazides, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II 
receptor blockers (ARBs), Beta-blockers, Calcium-channel blockers), and 
antiplatelet agents like aspirin, clopidogrel (Plavix) or dipyridamole with 
aspirin (Aggrenox).  
 
1.10. Carotid atherosclerosis 
 
Carotid atherosclerosis is the development of an atherosclerotic plaque in the 
carotid artery, most commonly at the CCA bifurcation and proximal ICA 
regions, and most importantly on the posterior aspect of the vessel wall (figure 
1.13). Risk factors for atherosclerosis are essentially the same as those for 
                                                          
17
 HMG-CoA reductase inhibitor: 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. 
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stroke, including male gender, older age, smoking, hypertension, diabetes 
mellitus, and hyperlipidemia. 
 
 
Figure 1.13: Site of carotid plaque formation. It can cause significant obstruction of 
blood flow or rupture and embolize to a smaller vessel in the brain. Adapted from: 
http://chicago.medicine.uic.edu/departments___programs/departments/neurosurgery/clinica
l_services/neurovascular_surgery/carotid_disease/ 
 
 
Carotid atherosclerotic disease is characterized by the severity of stenosis and 
the presence or absence of associated neurological symptoms (stroke or TIA). 
The degree of stenosis assessed on angiography (CT, MR, or conventional) is 
measured according to the North American Symptomatic Carotid 
Endarterectomy Trial (NASCET) criteria [21], using the diameters of the 
lumen at the point of greatest stenosis and at the normal distal ICA (figure 
1.14). Stenosis is qualified as mild (<30%), low-moderate (30-49%), moderate 
(50-69%), severe (70-99%), near-occlusion (99%), and total occlusion (100%). 
Carotid stenosis can be symptomatic or asymptomatic; symptomatic stenosis 
has a greater risk of future ischemic stroke. 
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Figure 1.14: Two different criteria can be used to measure degree of carotid stenosis on 
angiography: NASCET and European Carotid Surgery Trial (ECST) criteria. Adapted 
and modified from [22]. 
 
Treatment of carotid atherosclerosis includes medical prophylaxis (statins, 
antihypertensives, aspirin), and carotid endarterectomy (CEA) surgery or 
endovascular stent angioplasty (Figure 1.15). Stent angioplasty is usually 
reserved for patients with important comorbidities and elevated risks of 
surgical complications. 
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Figure 1.15: A. Carotid Endarterectomy (CEA) procedure. Adapted and modified from: 
http://stanfordhospital.org/clinicsmedServices/COE/surgicalServices/vascularSurgery/patientEducation/carotid.html  
B. Endovascular carotid angioplasty (stenting) procedure. Adapted and modified from: 
http://www.sfveincenter.com/images/stories/med_images/carotid_stent.jpg
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1.10.1. Treatment Limitations and Current Issues: a need for 
diagnostic tools in asymptomatic patients 
 
Symptomatic extracranial carotid artery occlusive disease is currently managed 
by endarterectomy (or angioplasty). The severity of internal carotid artery 
(ICA) luminal stenosis is used as an indication for carotid endarterectomy 
(CEA), based essentially on the results of the North American Symptomatic 
Carotid Endarterectomy Trial (NASCET) [23,24] and European Carotid 
Surgery Trial [25]. According to NASCET, symptomatic patients with a 
carotid stenosis of less than 50% had an 18% risk of stroke at 5 years under 
medical treatment. This risk climbed to 22% for patients with a carotid stenosis 
of 50 to 69%, and was even higher for patients with a carotid stenosis greater 
than 70%, with a stroke risk of 26% at 2 years. 
 
In asymptomatic patients, however, indications for CEA are still debated. In 
asymptomatic patients with a stenosis of at least 60%, the 5-year risk of stroke 
or death when receiving optimal medical therapy is 11 to 12% [26,27], 
compared to about 6% for those receiving early CEA, which includes a 3% 
perioperative hazard [27]. Recently, results of the ACST-1 trial reported a 10-
year risk of stroke of 17.9% in the medical treatment group, compared to a 
significant lower risk in the CEA group (net risk reduction of 4%) [28]. Within 
the medical treatment group, patients receiving lipid-lowering therapy at study 
onset had a lower risk of stroke at 10 years (14.5% versus 24.9%); however, 
their risk was still significantly higher than for the CEA group [28]. These 
trials demonstrated a small but significant benefit in CEA compared to medical 
treatment alone in asymptomatic patients with significant stenosis, both at 5 
and 10 years. Nevertheless, the setting of these trials is different than that of 
non-trial routine clinical settings, where perioperative risk of CEA is likely to 
be higher than 3%. With the annual rate of stroke varying from 0.6 to 3.8% 
[26-32], the true benefit of CEA in the general population of asymptomatic 
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patients with severe stenosis may be lower than in reported studies. 
Furthermore, degree of carotid stenosis in asymptomatic patients was not 
associated with long-term incidence of stroke [26,28]. Severity of carotid 
stenosis and presence of clinical risk factors are useful but insufficient to 
evaluate the risk of stroke in such patients. Consequently, treatment of 
asymptomatic patients with >60% carotid stenosis still poses a significant 
challenge for clinicians. 
 
Further risk stratification is necessary to better determine the risk of stroke in 
asymptomatic patients with carotid stenosis, and identify a high-risk subgroup 
that would benefit most from CEA. Current research seeks to develop imaging 
modalities capable of differentiating “vulnerable” from stable carotid 
atherosclerotic plaques in asymptomatic patients. Vulnerable atherosclerotic 
plaque, as defined by histopathological criteria [33], is a thrombosis and 
rupture-prone plaque associated with clinical ischemic events. Some features 
of vulnerable plaque have been identified with experimental imaging 
techniques. It is hypothesized that patients presenting imaging criteria of 
plaque vulnerability would benefit from early surgical intervention, whereas 
patients with stable plaque on imaging could be managed medically. In order 
to verify this hypothesis, a validated non-invasive imaging technique for 
plaque characterization is required in order to prospectively study carotid 
plaque progression. 
 
To date, there is no single imaging technique that can reliably identify the 
vulnerable plaque. This is because (1) there is uncertainty as to which plaque 
characteristic is the most predictive of vulnerability, (2) a single imaging 
technique cannot characterize all atherosclerotic plaque features 
(morphological, molecular, and biomechanical), and (3) few imaging 
techniques are currently validated with both histopathology correlation and 
clinical events. In order to recognize the issues at hand with non-invasive 
imaging techniques of carotid plaque, a thorough understanding of 
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atherosclerosis pathology is required. Hence, Chapter 2 discusses 
atherosclerosis, followed by Chapter 3, which describes non-invasive imaging 
modalities of atherosclerosis in carotid plaques. 
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CHAPTER 2 
Atherosclerosis and the Vulnerable Plaque 
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2. Atherosclerosis and the Vulnerable Plaque 
 
2.1.  Overview 
 
Atherosclerosis is a chronic systemic inflammatory disease of large and 
medium-sized arteries. It is characterized by thickening of the arterial wall due 
to an accumulation of lipids and fibrous elements [34], forming lesions called 
atheromas or atherosclerotic plaques. Atherosclerotic plaque formation is 
complex, and the consequences of this disease are dismal, including heart 
disease, aortic disease, cerebrovascular disease, and renal disease. With heart 
and cerebrovascular diseases being the first and third causes of death in the 
Western countries, an estimated 30% of all deaths could be attributed to 
atherosclerosis [13]. To understand this complex disease, knowledge of 
anatomy and physiology is provided, followed by a more in-depth discussion 
of atherosclerosis pathogenesis. 
 
2.2.  Epidemiology 
 
The Framingham Heart Study and the Atherosclerosis Risk in Communities 
Study (ARIC) are prospective studies that identified traditional risk factors for 
coronary heart disease (CHD) caused by atherosclerosis [35,36]. Non-
modifiable risk factors include: increasing age, male gender, and family 
history. Modifiable risk factors include: hyperlipidemia, hypertension, 
cigarette smoking, diabetes mellitus, and an elevated serum C-reactive protein 
(CRP, a marker of systemic inflammation). 
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2.3.  Normal Structure and Function of Arteries 
 
The general architecture of blood vessels is shown on figure 2.1.  Oxygenated 
blood pumped out by the heart is transported by the arterial system. Arteries 
sustain elevated blood pressures; hence they have a thicker wall in comparison 
to veins, which in turn transport deoxygenated blood back to the heart. 
Blood vessels consist of three concentric layers: intima, media, and adventitia 
(figure 2.1B). The intima contains a single layer of endothelial cells and the 
internal elastic lamina; the media consists of multiple layers of smooth muscle 
cells (SMCs) and an external elastic lamina; and the adventitia consists of 
connective tissue, nerve fibers, and vasa vasorum (small arterioles that feed the 
outer layers of the media in large and medium-sized arteries). Large-sized 
arteries (e.g. aorta, common carotid artery, iliac artery) have a media rich in 
elastic fibers, allowing propulsion of blood flow by expansion during systole 
and recoil during diastole. Medium-sized muscular arteries (e.g. coronary, 
renal, and internal carotid arteries) have a media rich in SMCs; these arteries 
can alter the lumen diameter by vasoconstricting and vasodilating (i.e. SMCs 
contract and relax) in physiological responses. Lumen diameter is known to 
greatly affect resistance to flow by Poiseuille’s law18, thus medium-sized 
arteries (sometimes called “resistance arteries”) are responsible for regulating 
systemic arterial resistance. 
 
                                                          
18
 Poiseuille’s law: Resistance = (difference in pressure) / flow = (8*viscosity*length)/ 
π*radius
4 
= 8ηl/ πr
4 
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Figure 2.1: Normal vascular architecture (A) and anatomy (B).  
A. General organization of vascular system. Arrows show the direction of flow. Modified and adapted from Kumar: Robbins&Cotran Pathologic Basis of 
Disease, Professional Edition, 8
th
 ed. (2009). B. Structure of the arterial wall. Modified and adapted from: artery: transverse section of an artery. [Art]. 
Encyclopædia Britannica Online. Retrieved 17 April 2012, from http://www.britannica.com/EBchecked/media/121565/Transverse-section-of-an-artery 
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Endothelial cell function 
Endothelial cells have multiple functions and properties: 
 Maintain a barrier permeable only to selected small molecules; 
 synthesize anticoagulant and prothrombotic molecules (e.g. plasminogen 
activator, tissue factor, von Willebrand’s factor); 
 synthesize collagen and proteoglycans; 
 synthesize vasoconstrictor (endothelin, angiotensin-converting enzyme 
[ACE]) and vasodilator (nitric oxide [NO]) molecules; 
 secrete cytokines (e.g. interleukins) and adhesion molecules (VCAM-1, 
ICAM and selectins); 
 regulate cell growth by secreting growth factors (Platelet-derived growth 
factor [PDGF], Fibroblast growth factor [FGF], macrophage colony-
stimulating factors [M-CSF]) and growth inhibitors (Transforming growth 
factor Beta [TGF-β]); 
 oxidize low-density lipoprotein (LDL). 
The intact endothelium can maintain a non-thrombogenic surface with blood, 
regulate vascular resistance, inflammation, growth of SMCs and other cells. 
Endothelial cells are also tightly connected with intercellular junctions that are 
impermeable to larger molecules. In areas of low shear stress and turbulent 
flow (in vessel curvatures and bifurcations), these junctions can loosen and 
allow passage of macromolecules like LDL. 
The endothelium does not constantly perform all of its functions 
simultaneously; a balance of activities is maintained. Some functions are 
“turned on” or induced by pathological stimuli: this is termed endothelial 
activation [37], and is believed to be involved in the first step of atheroma 
formation. The most common pathological stimuli of endothelial activation are 
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hemodynamic stresses and elevated serum LDL. Once endothelial cells are 
activated, they start expressing adhesion molecules, produce cytokines that 
attract and recruit macrophages, growth factors that stimulate SMC 
hyperplasia, and they synthesize less NO. Endothelial activation can lead to 
endothelial dysfunction, an imbalance of normal regulatory functions. 
 
Smooth muscle cell function 
SMCs are responsible for vessel constriction and dilation. They also function 
to repair blood vessels by proliferating, synthesizing extracellular matrix 
collagen, and secreting growth factors. SMCs migrate and proliferate in 
response growth factors and cytokines secreted by the endothelium.  
 
Physiological response to vascular injury 
When there is a vascular injury that causes either endothelial dysfunction or 
denudation, SMCs are stimulated and intimal thickening of the arterial wall 
occurs, much like healing and formation of a scar in other tissues. A permanent 
slight thickening called neointima results, which itself is not a herald of 
disease. However, if vascular insults are repetitive or persistent, excess vessel 
wall thickening will occur and evolve into a stenotic atherosclerotic lesion. 
 
2.4.  Pathogenesis of Atherosclerosis 
 
The term arteriosclerosis defines arteries that are hardened due to thickening 
and loss of elasticity. Two types of arteriosclerosis exist:  arteriolosclerosis, 
which is a lipohyalinotic thickening of small arteries and arterioles associated 
with hypertension and diabetes; and atherosclerosis, which affects large and 
medium-sized arteries and is discussed in this section. 
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2.4.1. Cellular interactions in atherosclerosis plaque 
progression 
Atherosclerosis is a chronic inflammatory and healing response of the arterial 
wall to endothelial injury. This definition is based on the response-to-injury 
hypothesis [38], which proposes the following sequence of events portrayed in 
figures 2.2: 
1. Endothelial injury and dysfunction 
2. Accumulation of lipoproteins (LDL), followed by oxidation of LDL 
3. Monocyte recruitment, adhesion to endothelium, migration into intima, 
and transformation into macrophages. Activated macrophages engulf 
oxidized LDL, becoming lipid-laden foam cells 
4. Platelet adhesion and release of inflammatory and growth mediators 
(e.g. PDGF) 
5. SMC recruitment, migration to the intima, proliferation, and production 
of extracellular matrix (collagen and proteoglycans) 
6. Extracellular and intracellular (foam cells) lipid accumulation 
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Figure 2.2: Cellular interactions in atherosclerosis plaque progression. SMC, smooth muscle cell; MCP-1, monocyte chemoattractant protein 1; LDL, low-
density lipoprotein; ox-, oxidized; PDGF, platelet-derived growth factor; M-CSF, macrophage colony-stimulating factor; MMP, matrix metalloproteinase. 
Adapted and modified from [39]. 
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Possible causes of endothelial injury include hemodynamic stresses (turbulent 
flow, high blood pressure, low shear stress), elevated serum LDL from a high-
fat diet, inflammatory cytokines in the circulation (for example, from a 
bacterial/viral infection), excess glycosylation of proteins from diabetes, toxins 
from tobacco smoking, and hypoxia. Most plaques form in areas of blood flow 
turbulence, such as bifurcations and curved areas [40]. The turbulence in these 
areas is believed to be associated with differently-shaped endothelial cells that 
have increased permeability to macromolecules like LDL [41].  
LDL diffuses passively through the endothelium into the intima, and is 
removed from the intima with high-density lipoprotein (HDL), a protective 
cholesterol molecule. Accumulation of LDL in the intima will occur if there is 
an imbalance (excess LDL and/or insufficient HDL). Once LDL accumulates, 
LDL oxidation occurs; once enough LDL is oxidized, the endothelium 
activates and expresses adhesion receptors that attract circulation-derived 
monocytes to enter into the intima. Once in the intima, monocytes differentiate 
into macrophages with scavenger receptors and engulf oxidized LDL. 
Eventually, macrophages become lipid-laden and transform into foam cells. 
Endothelial cells, macrophages and platelets produce cytokines and growth 
factors that attract SMCs to the intima and stimulate their proliferation and 
production of extracellular matrix (ECM).  
Extracellular lipid consists of cholesterol and cholesterol esters. It originates 
from circulatory LDL and degenerating cells, accumulates in the plaque and 
eventually forms a lipid-rich necrotic core. Concomitantly, a fibrous cap 
composed of dense collagen forms superficially to the lipid core. 
 
2.4.2. Macroscopic changes in atherosclerosis plaque 
progression 
The modified AHA classification of atherosclerotic plaques reflects the 
sequence of events in the development of atherosclerotic plaque at a more 
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macroscopic level (Table II-I) [42-44]. An atherosclerotic plaque is usually 
eccentric
19
 and its size varies from 0.3 to 1.5 cm in diameter in coronary 
arteries. Although atherosclerosis is a multifocal disease that affects many 
blood vessels, individual atherosclerotic plaques will often be at different 
stages of development.   
Lesion Description 
Type I Intimal xanthoma (or fatty streak)  
Type II Fatty streak with multiple foam cell layers 
Type III  Pre-atheroma with extracellular lipid pools 
Type IV Atheroma with a confluent extracellular lipid core 
Type V Fibroatheroma 
Type VI Complex plaque with possible surface defect and/or haemorrhage 
and/or thrombus 
Type VII Calcified plaque 
Type VIII Fibrotic plaque without lipid core 
Table II-I.  Modified AHA classification of atherosclerotic plaques* 
*Adapted from data published in references [42-44] 
 
Early Type I and II lesions consist of an accumulation of foam cells (“fatty 
streak”); they are not raised, do not impinge on the lumen diameter, and have 
been observed in newborns’ aorta and in children. Although this is the first 
step in atherosclerosis, early lesions are not necessarily destined to become 
advanced plaques. 
 
Type III lesions contain extracellular lipid pools. An extracellular lipid pool is 
a collection of lipid within the ECM. This is distinct from a lipid-rich necrotic 
core, which in addition to lipid, contains debris from dead cells (necrosis), free 
cholesterol crystals, and sometimes thrombus.  
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 When examining the cross-sectional view of an artery and plaque, if the plaque is not 
concentric with the vessel wall and has a disease-free arc, it is eccentric. 
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Type IV and V lesions contain a well-defined lipid-rich necrotic core covered 
by a fibrous cap. By definition they are atheromas. Type V fibroatheroma is a 
more advanced lesion than atheroma because it has additional layers of fibrous 
tissue covering the necrotic core (SMC proliferation and ECM deposition). The 
plaque periphery often shows small proliferating blood vessels 
(neovascularisation) which attempt to supply oxygen to the plaque core. Type 
IV and V plaques are prone to becoming complicated Type VI plaques. 
 
Type VI atherosclerotic lesions result from repeated injury to atheromas, 
inducing an excessive remodeling response and a further increase in plaque 
size. Type VI lesions have one or a combination of the following: a surface 
defect (fibrous cap rupture or erosion), intraplaque hemorrhage, or thrombosis 
at the plaque surface. These complicated Type VI plaques are associated with 
rapid lesion progression, total occlusion, and acute ischemic events; hence they 
are types of vulnerable plaque. 
 
Atheromas or complicated Type VI lesions can become “old” lesions over 
time, either calcified (Type VII), or less frequently, fibrous with minimal lipid 
(Type VIII). Calcification results from cellular death and can be present at all 
stages of atherosclerosis. In early stages, when there is minimal cellular death, 
calcium is sparse or present as microcalcifications. In later stages of 
atherosclerosis, with an enlarging plaque and increased cellular death in the 
necrotic core, there are larger quantities of calcification, often arranged in 
“sheets”[45].  
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2.5.  The Vulnerable Plaque 
 
The term vulnerable plaque (VP) emerged over 20 years ago to describe an 
atherosclerotic plaque that is susceptible to rupture, thrombose, and 
subsequently cause a cardiac ischemic event [46]. Later, a consensus on the 
definition of VP was reached. The term “vulnerable plaque” is applicable to 
prospective studies and describes any thrombosis-prone plaque with high 
probability of undergoing rapid progression, thus becoming a culprit plaque 
[33,47]. Culprit coronary plaque features associated with acute coronary 
syndromes were retrospectively identified in pathology studies: plaque rupture 
was the most frequent feature (65-70%), followed by erosion (25-30%) and 
superficial calcium nodule (2-5%) [44]. Based on these findings, major and 
minor criteria defining VP and different possible types of VP were proposed 
(table II-II and figure 2.3) [33]. The concept of VP is also applied to carotid 
atherosclerotic lesions associated with cerebral ischemic events; these lesions 
were found to have a similar histopathology to that of culprit coronary plaques 
[48], with 90% of culprit carotid plaques being ruptured [49]. 
Table II-II. Criteria Defining Vulnerable Atherosclerotic Plaque. 
Presence of at least one major criterion qualifies a plaque as vulnerable. 
Adapted from data published in reference [33]. 
Major criteria Active inflammation 
Thin cap with large lipid core 
Endothelial denudation with superficial 
platelet aggregation 
Fissured plaque 
Stenosis >90%  
Minor criteria Superficial calcified nodule 
Glistening yellow (seen on angioscopy) 
Intraplaque haemorrhage 
Endothelial dysfunction (measurement of 
flow-dependent coronary artery dilatation 
and other emerging techniques) 
Outward (positive) remodelling 
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Figure 2.3: Different Types of Vulnerable Plaque. Adapted from [33]. 
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A ruptured plaque is defined as “a plaque with a real defect or gap in the 
fibrous cap that had separated its lipid-rich atheromatous core from the flowing 
blood, thereby exposing the thrombogenic core of the plaque” [47]. Therefore, 
a ruptured plaque requires the presence of both a fibrous cap and a lipid core; 
in other words, an atheroma. The mechanism underlying plaque rupture begins 
with formation of a large lipid core that erodes the fibrous cap from below, 
followed by fibrous cap thinning, weakening, and rupture [50]. Other 
mechanisms believed to contribute to plaque rupture are inflammation, 
neovascularisation, intraplaque hemorrhage, and expansive remodelling. 
 
In carotid plaques, a large lipid core is defined as at least 25% cross-sectional 
total plaque area [48], with an average 40% plaque area [51]. Intraplaque 
hemorrhage from fragile neovessels was suggested as a contributor to rapid 
growth of the lipid-rich necrotic core [52]. 
 
In coronary arteries, a thin fibrous cap is defined as <65 μm thick [44]. In 
carotid arteries, pathology from post-CEA symptomatic patients revealed the 
thinnest fibrous cap portion to be at least 80 μm thick [53] and less than 200 
μm, with a representative cap thickness less than 500 μm [54]. Fibrous cap 
thinning is associated with inflammatory changes and ECM degradation within 
the cap: there is a localized increase in macrophages that secrete proteolytic 
enzymes that lead to ECM breakdown (matrix-metalloproteinases [MMPs]) 
[55,56], and a low number of SMCs, possibly due to apoptosis [57], that are 
insufficient to compensate for the loss of ECM support. Fibrous cap thinning 
with a large lipid core leads to a “rupture-prone plaque” (figures 2.3 and 2.4). 
A stable atheroma with a large fibrous cap is shown in figure 2.5 for 
comparison. 
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Figure 2.4: Typical thin fibrous cap atheroma with a large lipid core, neovascularisation, 
intraplaque hemorrhage, and inflammatory macrophages in the shoulder of the cap. This 
plaque is considered a “rupture-prone” vulnerable plaque. 
 
 
 
 
Figure 2.5: A stable plaque with a thick fibrous cap. This plaque is unlikely to rupture. 
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Neovascularization occurs mostly in larger plaques as a response to plaque 
growth. It grows at the periphery and shoulders of the plaque. These 
neovessels are fragile and leaky; they are responsible for intraplaque 
hemorrhage (figure 2.4). When there is intraplaque hemorrhage, macrophages 
are recruited, further inflammation ensues, and the plaque enlarges (55). 
Plaque hemorrhage is distinct from intraplaque hemorrhage because it is 
defined as luminal blood seeping into a ruptured plaque. 
 
Expansive remodeling (or positive or outward remodeling) is the growth of the 
atherosclerotic plaque toward the outer vessel wall. This type of growth 
minimally changes the size of the lumen area because plaque grows toward the 
outer vessel wall (figure 2.6). Although seemingly harmless on arteriography, 
expansive remodeling is associated with high-risk plaques and ruptured 
plaques observed in acute coronary syndromes [44,58,59]. With excessive 
expansive remodeling, there could be a paradoxical increase in lumen area that 
will exacerbate the low shear stress environment, which in turn will lead to a 
perpetuating cycle of increased LDL accumulation, inflammation, outward 
remodeling, and fibrous cap thinning [60]. 
 
Figure 2.6: Expansive (outward) vessel remodeling with minimal change in lumen 
diameter. 
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2.6. Clinical Consequences 
 
The mechanism of an acute clinical event partially depends on the type of 
vessels involved and plaque stability. In general, small arteries occlude 
(microatheroma), medium-sized arteries form VPs that thrombose or embolize, 
and large elastic arteries like the aorta often have plaques with outer vessel 
wall degeneration, leading to aneurysmal dilation, thrombosis, ulceration 
and/or vessel rupture
20
. Acute clinical consequences of atherosclerotic disease 
include myocardial infarction (heart attack), cerebral infarction (stroke), aortic 
aneurysm rupture, acute limb ischemia (peripheral vascular disease), and renal 
failure. Chronic obstruction of blood flow due to a significant stenosis leads to 
chronic oxygen insufficiency of the tissues downstream; this mechanism 
underlies chronic ischemic heart disease (angina and heart failure), ischemic 
encephalopathy (dementia), bowel ischemia, claudication and gangrene of the 
lower limbs. 
 
It is important to note that not all vulnerable plaque thromboses lead to 
ischemic events [61]. This is because there could be formation of collateral 
circulation, or the thrombus formed at the plaque surface could be small, non-
occlusive, and become an organized thrombus that heals with plaque 
progression. Hence, for clinical prospective studies, the frequency of VPs 
detected is expected to be higher than the incidence of ischemic events. 
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 Aortic artery aneurysm rupture is a serious condition because it leads to massive internal 
bleeding and high mortality. Immediate surgical operation is required. 
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2.7.  Prevention 
 
The natural history of atherosclerosis begins in childhood, and development of 
atherosclerotic plaques requires decades. Not all people suffer symptoms or 
consequences from atherosclerosis; some may have small stable plaques that 
never cause disorders. Traditional risk factors for coronary atherosclerotic 
disease are helpful in determining and treating those at high risk, but remain 
poor predictors of first-time stroke or cardiac event [62-65]. 
Epidemiologically, atherosclerosis has a prolonged subclinical (incubation) 
phase; this provides the opportunity to screen for presence of asymptomatic 
(subclinical) disease. The Screening for Heart Attack Prevention and 
Education (SHAPE) Program recommends non-invasive screening of 
asymptomatic patients 45 years of age and older to detect subclinical VP [66]. 
This is also valuable for stroke prevention associated with carotid 
atherosclerosis. If subclinical VP could be reliably identified before the advent 
of stroke, then asymptomatic patients at high risk could benefit from an 
effective prevention treatment strategy, progression of VP could be halted, and 
the incidence of acute ischemic events could decrease (figure 2.7). 
 
To screen for VP, a low-risk, cost-effective validated technique is required. 
Numerous types of experimental non-invasive imaging techniques are 
currently being developed for this purpose, but none has yet been validated for 
widespread clinical use. Discussion of each of these non-invasive imaging 
techniques is presented in the following chapter. 
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Figure 2.7: How primary prevention could be effective in high-risk patients with no warning symptoms. If atherosclerosis is not detected at the subclinical 
phase, and a sudden rupture of a VP develops, for example at 60 years of age, a potentially fatal clinical ischemic event will occur. On the other hand, if 
screening for VP and effective preventative therapy are offered early (during the “blue” subclinical phase), the atheroma will be less likely to evolve into a 
thrombotic plaque, the risk of having a clinical ischemic event at the same age will be lower, and the patient will have a prolonged and better quality of life. 
 

  
 
 
 
 
 
 
 
CHAPTER 3 
Imaging Carotid Atherosclerotic Plaque 
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3. Imaging Carotid Atherosclerotic Plaque  
 
3.1.  Introduction to the manuscript 
 
The manuscript presented in section 3.2 is a slightly longer version of the final 
article that will be submitted to the Canadian Association of Radiologists 
Journal (CARJ). In addition, appropriate formatting of images will be 
performed for submission. The images of section 3.2 are the same as those that 
will be submitted with the final article to the CARJ. Finally, please note that 
the introductory paragraphs of the article, including those describing 
vulnerable plaque and pathophysiology, contain information already detailed in 
Chapters 1 and 2 of the current thesis. These paragraphs have been kept in 
order to maintain the entirety of the article to be submitted. 
 
3.1.1. A brief overview of basic principles of ultrasound, CT, and 
MR imaging 
 
Ultrasound 
 
The principles of diagnostic ultrasound imaging lie within a sequence of 
events, beginning with the production of a high-frequency sound wave 
(typically 5-15 MHz) by transducer elements, transmission and propagation of 
this wave in tissues, reflection of sound wave signals back to the transducer, 
transmission of electrical signals to the scanner for processing, and ending with 
formation of an image. Image formation is based on time to echo arrival (depth 
of reflecting interface), and signal amplitude (brightness). Acoustic impedance 
(z) is responsible for the amplitude of reflected sound waves; it is proportional 
to both tissue density and tissue speed of sound. A tissue such as bone (dense 
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and high speed of sound) has high acoustic impedance compared to muscle or 
water (less dense and slower speed of sound). Consequently, the incident 
ultrasound beam is poorly transmitted through bone and predominantly 
reflected back to the transducer, resulting in a bright, white signal. Tissues 
deep to bone will be shadowed by it (acoustic shadowing) and therefore appear 
black. Water has lower acoustic impedance and reflects minimal signal back to 
the transducer. Hence, when examining carotid plaques, the blood flow in the 
lumen will appear black, muscle and other tissues will appear gray, and 
calcified areas of plaque will appear white. B-mode (“brightness mode”) 
ultrasound scanning provides a two-dimensional image mapping brightness 
and location of reflecting interfaces, allowing assessment of tissue 
morphology. Pulsed wave (PW) Doppler imaging, a technique that evaluates 
blood flow velocity with the Doppler principle, is often combined with B-
mode US; together the technique is called Duplex ultrasound. Color and Power 
Doppler imaging detect direction of blood flow and amplitude of Doppler 
signal, respectively, with colour-coding superimposed on B-mode images. 
These latter two techniques are sensitive to detect blood flow in carotid near-
occlusions and anatomically tortuous vessels. 
 
Contrast agents in US imaging consist of acoustically-active microbubble 
particles. These microbubbles are 2 to 5 μm in diameter, and consist of inert 
non-toxic gas (e.g. sulfur hexafluoride, perfluorocarbon) encapsulated within a 
lipid shell of phospholipids. When under an ultrasound field, microbubbles 
expand and compress rhythmically, producing increased amplitude of the 
reflected signal detected by the transducer, thereby improving image resolution 
[67,68]. 
 
Elastography 
 
Palpation is a common physical exam maneuver to determine tissue rigidity 
and presence of disease; it has been practiced by physicians for millennia. 
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Elastography uses the same principle: it is a measure of the elastic deformation 
of biological tissues and gives us an idea of their rigidity. The physical 
principle is mathematically described by the tensile (elasticity) modulus, 
Young’s modulus, E (Pascal units), which is a measure of tissue rigidity. It is 
equivalent to the stress applied to the tissue (σ, sigma) divided by the 
deformation of tissue (ε, epsilon) (Figure 3.1). In a soft tissue, a defined stress 
σ will produce a deformation ε. In a more rigid tissue, the same stress σ applied 
will produce a smaller ε deformation. Hence each tissue has its signature 
stress-strain curve and rigidity. 
 
Figure 3.1. Scheme explaining relation between stress, strain and elastic modulus in an 
isotropic elastic material. A corresponding stress-strain curve is plotted. Beyond a certain 
compression force (dot “2” on the graph), the material loses its elastic behaviour, i.e. it 
does not return to its original length. 1 = true elastic limit; 2 = elastic limit. 
 
 
Computed Tomography 
 
The word “tomography” signifies “to graph a slice”. Computed tomography 
(CT), also termed computed axial tomography (CAT), refers to an imaging 
technique that uses X-ray images of transverse slices. Images are acquired with 
a spinning X-ray tube and detector positioned opposite to each other in a 
gantry; this provides a series of image slices processed in real time by a 
computer, from which 3D images can be generated (Figure 3.2).  
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Figure 3.2. How a CT machine works. Adapted and modified from: 
http://www.bchsys.org/bchserv/Imaging/CT 
 
Modern CT scanners, called spiral or helical CT, perform continuous image 
acquisition of one cross-sectional image at a time simultaneously with table 
movement through the gantry (the table is where the patient lies). Later, in the 
late 1990’s, CT scanners were improved by adding multiple spinning detectors 
that could produce a greater number of image slices simultaneously, decrease 
image acquisition time, improve spatial resolution, and allow a larger anatomic 
coverage for arterial imaging by CT angiography (CTA) without intervening 
venous contrast enhancement. Such CT scanners are termed multi-detector 
helical CT (MDCT). For both CT and simple X-ray imaging, image 
interpretation is based on examining tissue densities. Dense tissues such as 
bone and calcifications appear bright in images because they absorb more X-
rays; in other words, they are more attenuating. Conversely, less dense 
materials, such as air, will appear black. CT can provide an actual measure of 
tissue density (X-ray absorption or attenuation) per image pixel with 
Hounsefield units (HU). Bone is at least 400 HU, water is 0 HU, and air is 
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approximately -1000 HU. Intravenous injection of iodine-based contrast 
media, which appears bright, helps better depict pathologies by optimizing 
image contrast and visualization of blood vessel lumina. 
 
 
Magnetic Resonance Imaging (MRI) 
 
MRI is based on nuclear magnetic resonance. A few definitions will help 
understand this concept. A magnetic field, B, is a force that is created by a 
rotating electrical charge. For example, the nuclei of atoms rotate around their 
own axes and produce a magnetic field. In the human body, the most prevalent 
atom and the one with the highest rotation frequency per magnetic force (gyro 
magnetic ratio, 42.6 MHz per Tesla) is hydrogen. The hydrogen nucleus 
consists of a single proton that spins (rotates); accordingly, the hydrogen atom 
is often termed “spin”. All spins in the body are randomly aligned in a manner 
that maintains magnetic forces in equilibrium. MR images are produced from 
these spins. MRI uses a large magnet in which the patient is placed. A 
homogeneous magnetic field, B0, is applied inside the magnet. In response, 
spins align in parallel with this magnetic force: a little over half align in the 
same direction as B0 (low-energy state), and the remainder align in the opposite 
direction (high-energy state). This results in a net magnetization in the same 
direction as B0. This net magnetization can be manipulated to obtain images, 
following four main steps: 
 
1. Excitation 
This consists in sending a radiofrequency (RF) pulse by a gradient coil 
at a specific frequency that spins will respond to; in other words, 
resonance of nuclei occurs. Spins absorb energy from the RF pulse; as 
a result, part of the net magnetization is flipped in another direction.  
2. Relaxation 
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Spins attempt to return to their initial low-energy state by releasing the 
energy they absorbed. This released energy is in the form of RF waves. 
Depending on which vectorial direction of emitted energy is examined, 
different types of relaxation occurring simultaneously can be recorded 
(T1 or T2 relaxation). 
3. Acquisition 
RF waves emitted during relaxation are picked up by a radiofrequency 
receive coil. An RF coil can be designed for imaging of specific parts 
of the body, such as a head coil or a dedicated neck coil to examine 
carotid arteries. It can also function as both an emitting and receiving 
RF coil. 
4. Computing and Display 
The RF waves are analyzed and multiple algorithms are applied to 
translate these RF signals into an image displayed on the monitor, 
ready for interpretation. 
 
MRI parameters can be manipulated to optimize visualization of certain 
pathologies based on their respective physico-chemical properties. Multiple 
sequence parameters can be modified, such as flip angle, repetition time, echo 
time, inversion time, field of view, matrix size, resolution, gradient switches 
and signal collecting. Hence, different types of pulse sequences can be created, 
each of which can be tailored to a specific contrast weighting, for example 
(Turbo) Spin Echo sequences (Proton density-, T1- and T2-weighted contrast 
images) and Inversion Recovery sequences (T1-weighted, fluid attenuated, and 
short inversion recovery contrast images). New pulse sequences are 
continuously being developed in research to optimize contrast resolution of 
targeted pathologies. 
 
Interpretation of MRI is based on molecular structure and strength of chemical 
bonds of hydrogen atoms, which affect spin relaxation rapidity and therefore 
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signal intensity. Furthermore, image interpretation also depends on the pulse 
sequence and contrast weighting. For example, on T1-weighted images, water 
appears dark and fat appears bright, whereas on T2-weighted images, water 
appears bright and fat appears dark. Structural anatomy is well-depicted on T1 
images, whereas pathologies producing surrounding edema are well-depicted 
on T2 images (edema consist of water and water is hydrogen-rich). In MRI, 
there are no absolute values of tissue brightness like in CT where brightness is 
representative of density. Rather, MRI interpretation uses relative signal 
intensities of regions of interest (ROIs) that are compared to a reference tissue 
intensity in the same image. The chosen reference tissue often is skeletal 
muscle, such as sternocleidomastoid muscle in neck imaging. Hence, ROIs are 
described as hyperintense, iso-intense, or hypointense to the reference muscle. 
Injection of gadolinium-based contrast agents helps optimize contrast 
resolution and visualize the lumen of blood vessels in a similar manner as CT. 
The main advantages of MRI over CT imaging include its excellent contrast 
resolution in soft tissues, lack of ionizing radiation, better-tolerated contrast 
agents, and possibility to choose any plane of imaging. However, MRI requires 
longer acquisition times and has a lower spatial resolution than CT. Thus, MRI 
is better at imaging soft tissues and CT is better at imaging bony structures. 
 
3.1.2. Role of authors 
 
Maxime Douziech, MD, PhD: original author of this review article. He 
performed literature review and wrote the manuscript. This manuscript was 
submitted for publication in 2008 to Radiographics (refused), and later to 
American Journal of Roentgenology (refused).  
 
Cyrille Naim, MD: performed update of literature review and provided major 
corrections and changes to the manuscript. I will correct and format figures and 
submit this manuscript to the Canadian Association of Radiologists Journal as 
a review article. 
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Gilles Soulez, MD, MSc: senior supervising author. He performed literature 
review and corrections for the manuscript. 
 
 
3.2.  Review article manuscript submitted to CARJ 
 
 
Manuscript title: 
Vulnerable Atherosclerotic Carotid Plaque Evaluation by US, MDCTA and 
MRI: An Overview 
 
Abstract 
Ischemic syndromes associated with carotid atherosclerotic disease are often 
related to plaque rupture. The benefit of endarterectomy for high-grade carotid 
stenosis in symptomatic patients has been established. However, in 
asymptomatic patients, the benefit of endarterectomy remains equivocal. 
Current research seeks to risk stratify asymptomatic patients by characterizing 
vulnerable, rupture-prone atherosclerotic plaque. Plaque composition, 
physiology and biomechanics are studied by non-invasive imaging techniques 
such as magnetic resonance imaging (MRI), computed tomography (CT), 
ultrasound (US), and ultrasound elastography. These techniques are at a 
developmental stage and have yet to be used in clinical practice.  This review 
will describe non-invasive techniques in US, MRI, and CT imaging modalities 
used to characterize atherosclerotic plaque, and will discuss their potential 
clinical applications, benefits and drawbacks. 
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Introduction 
 
Stroke ranks third among all causes of death after cardiac disorders and cancer 
in western countries [11]. Of all strokes, 87% are  ischemic [1], and an 
estimated 20% are caused by carotid atherosclerotic disease [10]. Symptomatic 
extracranial internal carotid artery (ICA) occlusive disease is currently 
managed by carotid endarterectomy (CEA), using severity of ICA luminal 
stenosis as an indication, based essentially on the results of the North 
American Symptomatic Carotid Endarterectomy Trial (NASCET) [21] and 
European Carotid Surgery Trial (ECST) [69,70]. According to NASCET, 
symptomatic patients with carotid stenosis of less than 50% had an 18% risk of 
stroke at 5 years under medical treatment. This risk climbed to 22% for 50 to 
69% stenosis, and 26% for 70 to 99% stenosis at 2 years [21].  
 
In asymptomatic patients, however, indications for carotid endarterectomy 
(CEA) remain controversial. The annual risk of stroke or stroke-related death 
in asymptomatic patients with >60% stenosis is approximately 2% (11-12% at 
5 years and 17.9% at 10 years) [26-28]. In addition, stenosis severity is a poor 
predictor of fatal or non-fatal stroke in asymptomatic patients [26,28]. Medical 
treatment for atherosclerotic disease has improved over the past 20 years, 
especially with lipid-lowering therapy. In Halliday et al.’s study, a subgroup 
analysis of the medical therapy patient group revealed that patients who were 
already on lipid-lowering therapy at study onset had a lower risk of stroke at 
10 years in comparison to those who did not receive such therapy before study 
onset (14.5% versus 24.9%) [28]. However, when comparing each medical 
therapy group with the surgical therapy group, CEA still offered significant 
benefits at 5 and 10 years [28]. Hence, choosing the most appropriate treatment 
to prevent stroke in asymptomatic patients continues to pose a significant 
challenge for physicians. Given that a large proportion of asymptomatic carotid 
stenoses do not have warning signs before the advent of a stroke [31], and that 
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stenosis severity and clinical risk factors are still insufficient to decide on 
optimal management, further risk stratification of asymptomatic patients is 
required. Coronary artery literature [33] and more recently carotid 
atherosclerosis studies [48,54] suggest examining pathology of atherosclerosis 
non-invasively to help determine which patients would benefit from early 
intervention. For instance, an imaging screening test could be performed to 
characterize carotid plaque when evaluating an asymptomatic patient with a 
carotid stenosis. Consequently, patients with a vulnerable plaque prone to 
causing an ischemic stroke could be managed with early CEA, and those with 
stable-appearing plaques could be managed medically.  
 
Plaque imaging is becoming increasingly used in clinical studies and trials; 
therefore, radiologists involved in the management of cerebrovascular diseases 
need to be aware of the pathophysiology of atherosclerotic carotid disease and 
the development of non-invasive imaging techniques that can characterize 
atherosclerotic plaques. This review will provide a basic understanding of 
atherosclerosis pathology, the concept of vulnerable plaque, and will describe 
non-invasive imaging techniques in US, MRI, and CT imaging modalities used 
to characterize atherosclerotic plaque. The potential clinical applications, 
benefits and drawbacks of each technique will be discussed; this will offer 
readers a better outlook on technical developments to come. 
 
The Vulnerable Atherosclerotic Plaque 
 
The term vulnerable plaque (VP) emerged over 20 years ago to describe an 
atherosclerotic plaque that is susceptible to rupture, thrombose, and 
subsequently cause a cardiac ischemic event [46]. Culprit coronary plaques 
that cause acute coronary syndromes were retrospectively identified in 
pathology studies [44]. The features of these culprit lesions were plaque 
rupture (65-70%), plaque erosion (25-30%), and superficial calcium nodule (2-
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5%) [44]. Based on these findings, different possible VPs and major and minor 
criteria defining VP were proposed (Table III-I and Figure 3.2.1) [33]. Briefly, 
a VP either has a ruptured fibrous cap, a large lipid core with a thin fibrous 
cap, or intraplaque hemorrhage. The concept of VP is also applied to carotid 
atherosclerotic lesions associated with cerebral ischemic events; these lesions 
were found to have a similar histopathology to culprit coronary plaques [48]. 
 
Table III-I. Criteria Defining Vulnerable Atherosclerotic Plaque*  
Major criteria  
Active inflammation 
Thin cap with large lipid core 
Endothelial denudation with superficial platelet aggregation 
Fissured plaque 
Stenosis >90%  
Minor criteria  
Superficial calcified nodule 
Glistening yellow (seen on angioscopy) 
Intraplaque haemorrhage 
Endothelial dysfunction (measurement of flow-dependent coronary 
artery dilatation and other emerging techniques) 
Outward (positive) remodelling 
*Presence of at least one major criterion qualifies a plaque as vulnerable 
Adapted from data published in reference [33] 
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Figure 3.2.1. Different Types of Vulnerable Plaque 
(A) Rupture-prone plaque with a large lipid core, a thin fibrous cap and macrophages. (B) Ruptured plaque with a sub-occlusive thrombus and ruptured cap. 
(C) Erosion-prone smooth muscle cell-rich plaque with a proteoglycan matrix. (D) Eroded plaque with a sub-occlusive thrombus. (E) Intra-plaque 
haemorrhage from the vasa vasorum. (F) Calcified nodule protruding into the vessel lumen. (G) Chronic critically stenotic plaque with extensive calcification 
and an old thrombus.  Adapted from Naghavi et al with permission [33]. 
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Pathophysiology of atherosclerosis 
 
Endothelial activation and leukocyte recruitment 
Atherosclerosis is a chronic systemic inflammatory disease of large and 
medium-sized arteries. It is characterized by thickening of the arterial wall due 
to an accumulation of lipids and fibrous elements [34]. The formation of 
atherosclerosis lesions is complex, involving processes such as shear stress, 
endothelial dysfunction, inflammation, neovascularisation, and thrombosis. 
The modified AHA classification of atherosclerotic lesions summarizes the 
natural history of atherosclerosis (Table III-II) [42-44].  
 
Table III-II.  Modified AHA classification 
Lesion Description 
Type I Initial lesion with foam cells (intimal xanthoma or fatty streak) 
Type II Fatty streak with multiple foam cell layers 
Type III Pre-atheroma with extracellular lipid pools 
Type IV Atheroma with a confluent extracellular lipid core 
Type V Fibroatheroma 
Type VI Complex plaque with possible surface defect and/or 
haemorrhage and/or thrombus 
Type VII Calcified plaque 
Type VIII Fibrotic plaque without lipid core 
Adapted from data published in references [42-44] 
 
Under physiological conditions, the endothelium functions as a selective 
barrier between blood and tissues, inhibits adhesion of leukocytes to the 
endothelium [55], and is involved in thrombosis and inflammation. In areas of 
low shear stress and flow turbulence (curved and bifurcating arteries), the 
endothelium is more permeable to large molecules like low-density lipoprotein 
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(LDL). Atheromas preferably form in those areas, and their growth is enhanced 
with elevated serum LDL levels [41].  
 
Endothelial dysfunction triggers oxidation of LDL in the intima and stimulates 
the overlying endothelium to produce chemotactic factors (interleukins), 
express adhesion molecules at its surface (vascular cell and intercellular 
adhesion molecule-1 [VCAM-1 and ICAM-1], selectins) and secrete growth 
factors (macrophage colony-stimulating factor [M-CSF]). Monocytes and T-
lymphocytes from the circulation bind to VCAM-1 surface adhesion molecules 
[55] and enter the arterial wall by diapedesis. Monocyte-derived macrophages 
phagocytose oxidized LDL and become foam cells [34]. Foam cells 
accumulate in layers to form a clinically-silent intimal xanthoma (“fatty 
streak”). Macrophages also release cytokines and growth factors that induce 
smooth muscle cell (SMC) migration, proliferation, and production of 
extracellular matrix (ECM). 
 
Atheroma formation 
Confluence of extracellular lipid pools, degenerating foam cells and necrosis of 
other cells result in formation of a lipid-rich necrotic core. SMCs attempt to 
“heal” the atherosclerotic lesion by proliferating and producing ECM (collagen 
and proteoglycans), which covers the lipid core and forms the fibrous cap. 
With plaque progression, angiogenesis originating from the vasa vasorum 
takes place to supply oxygen to the growing plaque.  
 
Vulnerable Plaque: From Asymptomatic Atheroma to Culprit 
Plaque 
Plaque vulnerability is associated with unstable plaque morphology, 
mechanical instability, and inflammation. As endothelial dysfunction 
continues, the atheroma grows: the lipid core increases in size, neovessels leak 
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(leading to intraplaque hemorrhage), and macrophages within the fibrous cap 
secrete matrix-degrading enzymes (matrix metalloproteinases [MMP]). 
Eventually, the plaque becomes structurally fragile: the fibrous cap thins and 
ruptures, the thrombogenic lipid core is exposed, and thrombosis at the plaque 
surface occurs. A thin fibrous cap is defined as less than 65 μm in coronary 
arteries [44] and less than 200 μm in carotid arteries [54]. In carotid plaques, a 
large lipid core is defined as an average and minimal plaque area of 40% and 
25%, respectively [48,51]. 
 
The definition of VP is based on the assumption of plaque features that precede 
those of culprit plaques. There is no single imaging modality that can 
characterize all relevant plaque features (morphological, molecular and 
biomechanical); hence, the best imaging technique to identify the VP is yet to 
be established.  
 
US, MDCTA and MRI features of plaque vulnerability 
 
Currently, carotid atherosclerosis burden is assessed by measuring luminal 
stenosis with duplex ultrasound, CTA, MRA, or X-ray angiography, but this 
measure remains insufficient to risk-stratify asymptomatic patients. Multiple 
imaging techniques have been developed to characterize plaque composition 
and identify the key features of vulnerable atherosclerotic plaque. Some 
techniques (B-mode US, MRI, MDCTA) have been studied to greater extent, 
whereas others, like targeted contrast agents and non-invasive US 
elastography, are under investigation.  
 
Ultrasound 
Ultrasound (US) is a well-known method of atherosclerotic carotid disease 
evaluation; it is clinically used to assess the presence of plaque, the degree of 
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carotid stenosis with blood flow velocity profiles, and the carotid intima-media 
thickness. Ultrasound is reliable, reproducible, and often the only diagnostic 
imaging modality used for the assessment of carotid arteries before CEA [71]. 
It is also a low-cost, low-risk, and an accessible imaging modality that is well-
tolerated by patients. The following section will focus on the US evaluation of 
carotid plaque vulnerability using morphology, echo texture and surface 
details. 
 
Two-Dimensional B-mode US imaging 
Carotid plaque echogenicity has been correlated with plaque composition 
[72,73]. Hyperechoic plaques are considered to contain fibrous or calcified 
tissue, whereas echolucent plaques are considered to contain soft plaque 
materials such as lipid or hemorrhage. Stable asymptomatic carotid plaques 
tend to be homogeneous and echogenic because of their calcium and/or fibrous 
content. They have a uniform internal architecture and smooth surface contour 
(Figure 3.2.2a). Unstable symptomatic plaques are associated with an irregular 
surface and tend to be heterogeneous and echo-lucent [72,74,75] (Figures 
3.2.2b, 3.2.3 and 3.2.4).  
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Figure 3.2.2. Doppler ultrasound of carotid arteries of a 46-year-old woman with 
hypercholesterolemia and transient cerebral ischemia of the right middle cerebral 
territory. (a) Significant stenosis of the left internal carotid artery from an echogenic 
homogeneous plaque that narrows the vessel lumen. (b) 80% right internal carotid artery 
stenosis (in diameter reduction, according to criteria from [76]). The stenotic plaque is 
echolucent (soft plaque) likely because of its high lipid content, haemorrhage and low 
calcium content. 
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Figure 3.2.3. Doppler ultrasound of the left carotid artery of a 75-year-old asymptomatic 
man. (a) Sagittal reconstruction of the carotid artery lumen on MDCTA of the left ICA 
with a small calcified nodule (an inset of this image zoomed in on the lesion will be 
provided for article submission). (b) Doppler ultrasound longitudinal image of the region 
of interest (red rectangle in a) showing 70% stenosis. The plaque meets criteria of 
vulnerability with plaque heterogeneity and a calcified nodule protruding into the vessel 
lumen. (c) Axial image centered on the calcified nodule. (d) A schematic representation of 
this plaque showing a calcified nodule protruding into the vessel lumen. Image (d) 
adapted and modified from [33] with permission. 
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Figure 3.2.4. Doppler ultrasound of the carotid artery of an 82-year-old male with 
amaurosis fugax and transient left MCA territory ischemia. (a) Ultrasound image 
showing 75% left internal carotid artery stenosis with ruptured plaque and a non-
occlusive clot. (b) Enlargement of the region of interest (red rectangle in a) where 
heterogeneous plaque can be seen. The echo-lucent zone may reflect hemorrhage or a 
lipid core. (c) Axial Doppler image centered on the plaque where stenosis is maximal, 
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showing plaque heterogeneity. (d) Schematic representation of plaque with a non-
occlusive clot and ruptured cap may reflect the plaque features seen on ultrasound in this 
case. This patient has undergone CEA demonstrating a ruptured and thrombotic 
atheroma intraoperatively. (e) Doppler spectral analysis. Maximal systolic velocity is 295 
cm/s. Image (d) adapted and modified from [33] with permission.  
 
 
Irregular plaque surface or ulcerations could be detected on US with utilisation 
of color Doppler or gray-scale flow imaging demonstrating eddy flow within 
the plaque [77]. Gronholdt et al. reported that echolucent plaques were 
associated with increased risk of stroke in symptomatic patients with 
significant stenosis (relative risk (RR) of 4.2 at 4 years) [78]. Other studies 
reached similar conclusions [79-81], but the Asymptomatic Carotid Stenosis 
Trial (ACST) revealed no association between ipsilateral stroke and 
echogenicity [27]. These conflicting results could be explained by limited 
reproducibility of B-mode ultrasound [82] associated with operator-dependent 
technique and subjective characterization of plaque echogenicity. A more 
reproducible way of objectively measuring echogenicity is gray-scale median 
scores. Gray-scale median (GSM) scores measure plaque echogenicity by 
assessing overall plaque brightness from the frequency distribution (histogram) 
of gray-level pixels within the plaque. The technique for comparing plaque 
echogenicity involves standardization of B-mode images and adjustment with 
the signals from blood (GSM = 0) and adventitia (GSM = 190) [74,78]. 
Correlations between subjectively echolucent plaques and low GSM score 
have been found, with an association between them and symptomatic plaques 
[74,83,84]. Moreover, a significant inverse relationship between GSM scores 
and the percentage of necrotic core areas was found [83]. There are many 
limitations B-mode ultrasound. First, GSM measures can be affected by 
settings like time-gain compensation and log compression. Ideally, tissue 
echogenicity should be analysed by an appropriate processing of the raw radio-
frequency (RF) data, such as Integrated Backscatter (IBS) [85] or Pixel 
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Distribution Analysis (PDA). Second, GSM does not take into account plaque 
heterogeneity. Echo-texture analysis, a computer-aided system that can 
characterize both echogenicity and heterogeneity, can detect focal hypoechoic 
areas [86,87]. However, calcifications impair echo-texture analysis. Finally, 
2D imaging limits visualization of areas of interest. 
 
Three-Dimensional B-mode US Imaging 
Three-dimensional ultrasound of carotid arteries has been developed and 
validated to measure plaque volume and vessel wall volume (VWV) changes 
over time [88-90]. This technique uses a conventional transducer that produces 
two-dimensional images in the composite imaging (SonoCT) mode [89,91]. 
Composite imaging (SonoCT) is an ultrasound mode that acquires several 
images based on transmitted ultrasound waves, resulting in a single composite 
image. This mode helps reduce speckle artefact and sharpens tissue 
boundaries. The probe, attached to a mechanical motorized mover, is displaced 
along the neck at a constant speed of 3 mm/s while two-dimensional image 
frames are acquired at regularly-spaced intervals. Image reconstruction and 
multiplanar reformatting provide 3D images that can be segmented manually 
or automatically, one cross-sectional slice at a time. To determine plaque 
volume, each slice area is computed, summed with all other slice areas, and 
multiplied by inter-slice distance [89,91]. A semi-automated segmentation 
algorithm was developed and validated to measure VWV, and considerably 
reduced operator time [92]. The effect of pharmacological agents on plaque 
volume assessed by three-dimensional ultrasound (3D US) was demonstrated 
over short periods of time (3 to 6 months) with cilostazol (antiplatelet agent) 
[93] and atorvastatin [89,94]. Even with small sample sizes of less than 40 
patients, these medications showed a significant decrease in plaque volume in 
comparison to placebo groups, making 3D US plaque volume assessment more 
effective than intima-media thickness in detecting size differences over time. 
Finally, 3D US was more effective than 2D US in detecting plaque ulcers [95], 
and can quantify and follow-up 1 mm ulcerations [91]. More studies with 3D 
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US are warranted to validate its ability to assess plaque composition, surface 
morphology, and vulnerable plaque before use in large clinical studies. 
 
 
Contrast-enhanced US 
Microbubble contrast agents are strictly intravascular: they help better outline 
lumen contours and can penetrate microvasculature. Kono et al. found that 
contrast-enhanced US (CEUS) imaging depicted unsuspected wall 
irregularities and ulceration [96], but this is not yet validated with histology. 
Visualization of neovascularisation within plaque has also been achieved 
(Figure 3.2.5). Significant correlations were found between the degree of intra-
plaque contrast-enhancement on US and amount of angiogenesis on 
histopathology [97-99]. Increased US contrast-enhancement in the plaque also 
correlated significantly with symptomatic carotid plaques [100,101], 
cardiovascular disease, events and risk factors [102], and echolucent plaques 
[103]. 
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Figure 3.2.5. Carotid artery contrast-enhanced ultrasound. Hyperechoic foci within the 
plaque represent neovessels. Sonovue® is an aqueous suspension of stabilized sulfur 
hexafluoride (SF6) microbubbles (precontrast image currently unavailable for pre and 
post-contrast comparison). Courtesy of Christian Greis, Bracco Diagnostics. The color 
image is a schematic representation of vulnerable plaque with a normal cap and 
neovessels. Schematic inset adapted and modified from [33] with permission. 
 
 
Molecular imaging can also be achieved with CEUS by designing 
microbubbles with monoclonal antibodies in their lipid shell. Antibodies 
targeted to VCAM-1, ICAM-1, selectins, and CD81 expressed by endothelial 
cells provided an in vivo assessment of endothelial dysfunction in animals and 
humans [104-106] and plaque proteolysis [107]. Shalhoub and al. 
demonstrated the use of late-phase CEUS and microbubbles targeted to CD31 
(angiogenesis marker) and CD68 (macrophage inflammation marker) and 
significant correlations with immunohistological staining [108]. More studies 
on CEUS molecular imaging are required to determine if the detected 
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endothelial dysfunction or neovascularisation can predict cerebral ischemic 
events. 
 
Drawbacks of CEUS include rare and minor side effects such as headache and 
injection site bruising and pain [109]. There is also a theoretical risk of 
potentiating plaque instability, since a small number of microbubbles 
destroyed during US scanning can potentially damage neovessels and lead to 
intraplaque hemorrhage [110]. 
 
 
Non-Invasive Vascular Elastography by Ultrasound  
Elastography is a map of local deformations of a biological tissue in response 
to a mechanical stress. Elastography techniques function in three steps: 
application of a stress (force) on the tissue; measure of tissue displacement 
(strain) in response to the applied stress; and estimation of tissue elasticity 
(rigidity). For the same applied stress, rigid tissues will have smaller 
displacements than supple tissues. The applied force could either be external 
(compression or dynamic vibration) or internal (natural arterial pulsation or 
shear wave propagation resulting from an acoustic radiation force). There are 
two types of elastography: static (or quasi-static) and dynamic. Static 
elastography consists in measuring the strain gradient between two different 
levels of stress application [111]. It cannot provide an estimation of the tissue 
elasticity because the absolute stress force is unknown; instead it displays a 
map of tissue strain called “elastogram”. In contrast, dynamic elastography 
estimates tissue elasticity (Young’s tensile modulus) by measuring both strain 
and the absolute force applied to the tissue. 
 
Ultrasound non-invasive vascular elastography (NIVE) is a quasi-static 
elastography technique that measures the elastic deformation of the arterial 
wall. When compressed and relaxed by the natural pulsation of the artery, the 
displacement between pairs of pre- and post-compression radiofrequency (RF) 
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lines is estimated and a strain profile can be determined by computing the 
gradient of the displacement field. The time-varying images obtained are called 
elastograms [112]. Currently, researchers studying plaque deformations 
hypothesize that deformations can potentially distinguish symptomatic from 
asymptomatic plaques and lipid-rich from calcium-rich plaques. A feasibility 
study showed that maximal strain concentration was located close to the vessel 
lumen and at the interface between hard and soft materials [113] (Figure 3.2.6).  
 
Figure 3.2.6. (a) CT scanner of carotid bifurcation showing a stenosis on the left side 
surrounded by calcifications. (b) B-mode image of the same plaque from reconstructed 
raw radiofrequency (RF) signals, used for vascular elastography. (c) Strain profile of 
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segmented areas in (b). Rigid structures, such as calcifications, have stable cumulative 
strain values whereas soft plaque areas have increasing cumulative strain values. (d) For 
the same B-mode image, strain values can be displayed by colour code (elastogram). 
Dark zones represent calcifications with low strain values. (e) In a similar manner, shear 
stress (mechanical behaviour at the interface of 2 different structures) can be displayed 
by color code and help locate areas of high mechanical stress (white and dark areas).  
T=fibrous tissue; CA=calcification; L=lumen. Adapted from [113] with permission. 
 
The presence of inhomogeneous strain distribution of deformation may 
hypothetically lead to biomechanical instability and VP. A study by Maurice et 
al. used US NIVE in vivo to determine arterial wall strain in healthy carotid 
arteries; higher strains were observed in women and a good inter-observer 
reproducibility was achieved for common carotid artery strains [114]. Another 
study on 16 patients compared 2 strain parameters, relative lateral shift and 
accumulated axial strain, with US-identified calcified and non-calcified plaque 
areas; there was a greater variability and higher strain values in non-calcified 
echolucent areas [115]. Vascular cognitive decline was significantly associated 
with a greater maximum accumulated strain, but with a sample size of 10 
patients and analysis of a single cardiac cycle per patient [116]. Currently, 
methodology of US NIVE differs among authors, such as the choice of ROI 
and strain parameter, leading to difficulty in comparing results among studies. 
Recent work on US NIVE technical optimisation has been done, including an 
improved implementation of the Lagrangian Speckle Model Estimator (LSME) 
algorithm [117], a semi-automatic plaque segmentation algorithm [118], and 
the elimination of signal artefacts associated with respiratory motion and noise 
using power spectrum sampling [119]. More studies are needed to validate US 
NIVE, notably appropriate visualization and choice of ROIs, as well as 
elucidating associations between axial strain, plaque composition, and clinical 
symptoms. 
 
Few dynamic elastography techniques are used for carotid plaque analysis, 
partly because of their relatively recent technical developments. Acoustic 
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radiation force imaging (ARFI) consists in generation of an acoustic radiation 
force of very short duration (less than 300 μsec) to small volumes of tissue, 
followed by mapping of tissue displacements (< 10 μm) resulting from shear-
wave propagation. Limitations of ARFI include the inability to estimate 
absolute values of displacement and elasticity for comparison among patients 
[120], and low temporal resolution (low frame rate on commercially available 
scanners) which may lead to non-representative strain values in arteries since 
strain varies with the cardiac cycle. Supersonic shear-wave imaging (SSWI) is 
another dynamic elastography technique also using a radiation force, but with a 
much higher temporal resolution than ARFI (5000 image frames per second). 
Instead of measuring tissue displacements, shear wave propagation speed is 
measured; this provides a more accurate estimation of tissue stiffness. There 
are no studies of SSWI in patients with carotid atherosclerotic plaques yet, but 
an in vivo study of the common carotid artery of a healthy subject showed an 
elevation of the shear modulus (stiffness) at the onset of systole in every 
cardiac cycle [121].  
 
 
Multidetector computed tomography angiography (MDCTA) 
 
MDCTA provides an excellent assessment of degree of carotid stenosis, and 
has the potential to characterize carotid plaque morphology in asymptomatic 
patients with significant stenosis. The first studies with single slice helical CT 
showed elevated standard deviations (SD) of plaque component density and 
low sensitivity for detection of ulcers, likely due to excessive volume 
averaging [122].  With the advent of multi-slice helical CT, improved 
resolution resulted in better accuracy of plaque composition assessment 
(Figure 3.2.7).  
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Figure 3.2.7. Patient with left-sided amaurosis fugax. (a) Sagittal reconstruction of the 
carotid artery lumen on MDCTA. Severe left internal carotid artery stenosis and a small 
ulceration. (b) and (c) Cross-sectional images from the regions of interest (red rectangle 
in a). (b) The plaque likely contains a lipid core with an ulcer because the contrast agent 
in the lumen has an irregular contour. (c) A large lipid core and a calcified nodule are 
found inferiorly to the image in (b). 
 
 
The minimal fibrous cap thickness of plaque can be measured on MDCTA (R
2 
= 0.77, p < 0.001) [123]. It can also detect ulcerations more accurately than US 
echo color Doppler (93% sensitive and 98% specific; κ = 0.855) [123,124]. 
DeWeert et al. demonstrated that MDCTA could quantify calcifications and 
fibrous tissue with good histological correlation (R
2
 > 0.73, p < 0.001), but 
could not quantify lipid core except in mildly calcified plaques [125]. Later, 
the same authors used cut-off attenuation values to identify calcium (>130 
HU), fibrous tissue (60-130 HU), and lipid or hemorrhage (<60 HU), and 
found a good inter-observer variability in plaque and component volume 
measurements (interclass correlation coefficient (ICC), 0.76 to 0.99; 
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coefficients of variation <50%) [126]. A classification of plaque into 3 
categories (i.e. fatty (<50 HU), mixed (50-119 HU), and calcified (>120 HU)) 
showed good interobserver agreements [127] and sensitivities of 85%, 89%, 
and 100% respectively [128]. An automated classification computer algorithm 
based on a calculated Hounsfield attenuation threshold for each carotid plaque 
histological component has been reported (Table III-III) [123]. This 
classification was useful to characterize carotid plaque according to the AHA 
classification system adapted for CT images (Table III-IV). The authors 
concluded that MDCTA can accurately evaluate plaque composition compared 
to histopathology, but could not differentiate lipid cores from hemorrhage 
except for large plaques that are mainly fatty or hemorrhagic [123]. A study of 
31 patients demonstrated that MDCTA with plaque density analysis could 
detect hemorrhage with 100% sensitivity and 64.7% specificity, but only in  
plaques that have a median density below 31 HU [129,130]. 
 
 
 
 
 
Table III-III. Hounsfield values (HU) for each plaque component as 
determined by in-vivo MDCTA studies (mean ± SD) 
Study 
Lipid 
core 
Fibrous 
tissue 
Intra-plaque 
hemorrhage 
(IPH) 
Calcium 
Chosen cut-
offs (HU) 
deWeert et 
al. 
[125,126] 
25±19 88±18 n/d 657±416 >130: calcium 
60-130: fibrous 
<60: lipid or IPH 
Wintermark 
et al. [123] 
32.6±20 
95%CI 
(-7, 72) 
46±19 
95%CI 
(6, 86) 
97±22 
95%CI 
(53, 141) 
256±30 
95%CI 
(216, 297) 
<39.5: lipid 
39.5-72: fibrous 
72-177: IPH 
>177: calcium 
Ajduk et al. 
[129] 
median: 59 
(range, 6-150) 
median: 22 
(range, 17-
31) 
n/d >31: no IPH  
<31: IPH  
n/d = not determined; CI = confidence interval 
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Table III-IV.  Modified AHA classification for MDCTA [123] and MRI [131] 
Lesion MDCTA description 
Type I-II Thin plaque with no calcification 
Type III Plaque with small lipid cores and no calcification 
Type IV-V Plaque with a large lipid core, covered by a fibrous cap, possible 
small calcifications 
Type VI Ulcerations and/or wide haemorrhage and/or thrombosis 
Type VII Plaque with a lipid core or fibrotic tissue, with large calcifications 
Type VIII Plaque with fibrous tissue, no lipid core, possible calcifications 
Lesion High-resolution MRI description 
Type I-II Near-normal wall thickness, no calcification 
Type III Diffuse intimal thickening or small eccentric plaque with no 
calcification 
Type IV-V Plaque with a lipid or necrotic core, surrounded by fibrous tissue 
with possible calcification 
Type VI Complex plaque with possible surface defect, haemorrhage or 
thrombus 
Type VII Calcified plaque 
Type VIII Fibrotic plaque without lipid core and with possible small 
calcifications 
 
 
The major advantages of MDCTA lie in its availability, rapidity, relatively 
low-cost, ability to measure absolute tissue density, and identify and quantify 
calcifications with great accuracy. The role of MDCTA in plaque component 
characterization shows promise, but still lacks specificity in identifying lipid 
core and intraplaque hemorrhage, especially in calcified plaques. Beam-
hardening artefacts associated with calcification alter Hounsfield values and 
contribute to inaccurate plaque characterization. Although calcified carotid 
plaques detected by MDCTA are significantly associated with asymptomatic 
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patients [132], calcification is not an absolute marker of plaque stability. 
MDCTA is yet to be sufficiently accurate for risk stratification of 
asymptomatic patients with calcified plaques. Other drawbacks of MDCTA 
include exposure to ionizing radiation and nephrotoxic iodine-based contrast 
agents. 
 
Following contrast injection in MDCTA, the lumen of blood vessels and 
neovessels arising from the vasa vasorum are enhanced. Thus, carotid plaque 
enhancement has been explored in multiple studies. The association between 
circumferential plaque enhancement and neovascularisation density on 
histopathology was recently validated [133]. A retrospective study found that 
carotid wall circumference enhancement on MDCTA was more frequent in 
symptomatic or fatty plaques compared to calcified carotid plaques (OR 3.625, 
p=0.01) [134,135]. However, due to differences in methodology, results from 
other studies are discrepant. For instance, asymptomatic and fibrous plaques 
had greater plaque enhancement on delayed-phase images [136], and plaque 
characterization was significantly different in post-contrast compared to pre-
contrast MDCTA, leading to fatty plaques being misclassified as mixed 
plaques [137]. 
 
Macrophage-Designed Nanoparticle Contrast Agents 
Plaque evaluation with conventional contrast relies on multiple factors, such as 
blood flow and time delay of CT image acquisition. They affect intensity of 
luminal enhancement, which in turn, influences measures of carotid plaque 
size [138] and density [139], resulting in a large variability of density 
measures. To overcome this important limitation, researchers have developed 
N1177, an iodinated nanoparticle contrast agent selectively phagocytosed by 
macrophages [140]. In rabbits, 2 hours after intravenous N1177 administration, 
the contrast agent made it possible to visualize macrophage-rich atherosclerotic 
plaque by increasing plaque density. The same authors later found that the 
intensity of enhancement of N1177 correlated significantly with increased 
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glucose uptake on positron-emission tomography (PET)
21
 and macrophage 
density on histology [141]. Another team found that N1177 nanoparticles were 
only present in macrophage-rich areas of ruptured plaques, but not in those of 
non-ruptured plaques, suggesting specificity for identifying ruptured 
atherosclerotic plaques [142]. This technique has not yet been experimented in 
humans because optimal dosage of N1177 has not been determined; also the 
required pre- and post-injection image acquisition protocol doubles the 
radiation dose compared to MDCTA with conventional contrast agents. 
 
 
High-Resolution Magnetic Resonance Imaging (MRI) 
 
Since the first characterization of atherosclerosis with MRI in 1995 [143], 
high-resolution MRI of carotid plaques has evolved considerably. Studies with 
histological validation determined that multi-contrast high-resolution MRI can 
characterize carotid plaque morphology [144,145], identify and measure 
plaque components like lipid-rich necrotic core, fibrous cap thickness and 
calcifications [146-148], and measure plaque progression and regression with a 
very good accuracy.  
 
MRI can distinguish intermediate from advanced atherosclerotic lesions as 
defined by the modified version of the AHA criteria for MRI (Table III-IV) 
[131,149] and vulnerable plaque definition by Naghavi et al. [33]. Important 
possible predictive features of plaque vulnerability by MRI include thin or 
ruptured fibrous cap, and intraplaque hemorrhage. The fibrous cap appearance 
on 3D TOF bright-blood images highly agrees with histological findings [145]. 
Multi-contrast MRI (T1, T2, PD and 3D TOF) had 81% sensitivity and 90% 
                                                          
21
 FDG-PET is an imaging technique that detects areas with high metabolism of glucose; those 
areas are associated with high metabolic activity and/or inflammation. This technique only 
studies molecular process of hypermetabolism (nonspecific), not plaque morphology. FDG-
PET was not discussed as it was deemed beyond the scope of this thesis and review article. 
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specificity for identifying a thin or ruptured cap [150]. Fibrous cap thickness 
on T1W imaging both pre- and post-gadolinium injection also has a good 
correlation with histology [148]. A retrospective study showed that ruptured 
fibrous cap by MRI was associated with recent history of stroke or TIA [151], 
and a prospective study found an increased risk of development of symptoms 
in patients with a previously detected ruptured fibrous cap by MR [152].  
 
Intraplaque hemorrhage (IPH) is accurately identified by MRI as a 
hyperintense signal on T1W turbo field echo images with 93% sensitivity and 
96% specificity [153], and on T1W 3D gradient echo images (MR direct 
thrombus imaging) with 84% sensitivity and specificity [154]. Different stages 
of IPH could be identified with a high sensitivity but moderate specificity 
(Table III-V) [155]. Retrospective [156,157] and prospective [158,159] studies 
demonstrated a strong association between IPH and recent or recurrent cerebral 
ischemic symptoms. IPH detected in asymptomatic patients was associated 
with significant plaque progression over 18 months [160]. Moreover, a 
retrospective study found that Type VI plaque was significantly more frequent 
in patients with ipsilateral TIA or ischemic stroke [161] and a cross-sectional 
study found that preoperative vulnerable plaque morphology was more 
frequent in symptomatic than asymptomatic patients [162]. The MRI signal 
intensity criteria for identifying plaque components are listed in Table III-V. 
High-resolution MRI of carotid plaques is presented in Figures 3.2.8 and 3.2.9. 
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Table III-V. Relative Signal Intensity of Plaque Components on MRI* 
Plaque components 
MRI weighting 
3D TOF T1W T1W post-
contrast 
T2W Proton 
density 
Lipid-rich necrotic core +/- +/- to + +/- - +/- to + 
Fibrous tissue:  
 Dense matrix +/- +/- +/- to + +/- +/- 
 Loose matrix +/- +/- +/- to + + + 
Fibrous cap:  
 Intact thick hypointense dark 
band 
+/- 
smooth 
+/- to + + +/- 
 Intact thin absent dark band not visible not visible not visible not visible 
 Ruptured hyperintense 
signal at plaque-
lumen interface 
irregular plaque 
surface 
irregular 
plaque surface 
irregular 
plaque surface 
irregular 
plaque surface 
Intraplaque hemorrhage: 
 
 Fresh (<1 week) + + + +/- to - +/- to - 
 Recent (1-6 weeks) + + + + + 
 Old (>6 weeks) - - - - - 
Calcification - - - - - 
+, hyperintense; +/-, isointense; -, hypointense; 3D TOF, 3-dimensional time-of-flight. 
*Based on data from [131,144,147,151,155,163] 
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Figure 3.2.8. Cross-sectional high-resolution MRI of an asymptomatic patient’s right 
internal carotid artery plaque. This patient has a 50% stenosis. (a) T1-weighted image 
showing a thick fibrous cap and large lipid core, easier to depict on the corresponding 
post-gadolinium injection T1-weighted image in (d). (b) A drop in relative signal intensity 
on this T2-weighted image (compared to other sequences) characterizes the presence of a 
lipid-rich necrotic core. (c) Proton density image shows an isointense core. (d) After 
gadolinium injection, plaque enhancement is observed in the postero-medial aspect of the 
plaque, suggesting neovascularisation or inflammation. 
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Figure 3.2.9. High-resolution cross-sectional MRI of the right carotid bifurcation of an 
asymptomatic patient. (a) On T1-weighted acquisition of right internal carotid artery 
stenosis, the plaque appears to be heterogeneous. The external carotid artery lumen is 
observed (white arrow), and both vessel walls consist of heterogeneous signals reflecting 
fibro-calcific tissue. (b) and (c) T2-weighted and Proton Density images show a 
hyperintense area not clearly apparent on T1 pre and post contrast images. This 
hyperintense area likely represents loose matrix fibrous tissue. (d) There is no significant 
plaque enhancement after gadolinium injection, suggesting that there is no 
neovascularisation or inflammation. 
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MRI Technique and Reproducibility 
Pulse sequences for carotid plaque include black-blood and bright-blood 
imaging. Black-blood is a technique that suppresses the signal from flowing 
blood, using double or quadruple inversion recovery sequences (e.g. T1, T2, 
and proton density). Therefore, the lumen appears black, and the vessel wall 
and plaque components can be more accurately delineated. Bright-blood is a 
technique used for MR angiography (the lumen appears hyperintense); it uses 
gradient-recalled echo sequences (e.g. 3D Time-of-Flight (TOF)). This type of 
sequence is useful to improve visualization of superficial plaque calcifications, 
the fibrous cap, and surface hemorrhages. Thus, the current standard for 
carotid plaque imaging and interpretation requires multiple contrast image 
sequences: T1, T2, proton density, 3D TOF, and post-contrast (gadolinium) 
T1-weighted sequences. Post-gadolinium T1-weighted acquisition is an 
additional sequence that shortens T1 and improves contrast resolution and 
signal-to-noise ratio. It results in better delineation of the fibrous cap and lipid 
core, and increased intensity of fibrous tissue and neovascularisation [163,164] 
All MR sequences are fat-suppressed and cardiac-triggered to minimize motion 
artefacts. Total scanning time can be up to 40 minutes. 
 
To visualize atherosclerotic plaque components and identify vulnerable 
plaques, high spatial resolution (voxel size 0.5 X 0.5 mm in-plane and 2 to 3 
mm thick) with excellent contrast between plaque components is essential. 
Hence, a dedicated phased-array surface coil with at least 2 elements on each 
side of the neck is required to optimize signal-to-noise ratio (SNR). A greater 
number of elements within the coil improved SNR and contrast-to-noise ratio 
(CNR)
22
 in a study comparing 8-channel to 4-channel phased array coils at 3T 
[165]. Recent studies on carotid plaque imaging using 3T showed a significant 
improvement over 1.5T in SNR and CNR [166], stronger inter- and intra-
                                                          
22
SNR and CNR are ways of measuring MR image quality.  
SNR = signal intensity of ROI / standard deviation of noise 
CNR = (signal intensity of ROI #1 – signal intensity of ROI #2) / standard deviation of noise 
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observer reproducibility for measuring vessel wall contours (Pearson 
correlation coefficient > 0.9) [167,168], and better repeat scan reliability to 
quantify plaque components and vessel wall thickness (ICC > 0.87 vs. > 0.38) 
[169,170]. The measurement of fibrous cap thickness, however, is suboptimal, 
as the resolution of MRI is usually above 300 μm while the size of thin fibrous 
caps is less than 200 μm. 
 
Studies on inter-reader reproducibility for plaque morphology are lacking; one 
study found moderate inter-reader reproducibility for plaque component 
discrimination at 1.5T [171], and another found good inter-reader 
reproducibility for fibrous cap measurement of 60 patients at 1.5T (ICC = 
0.71) [172]. 
 
Inflammation, Neovascularisation and Contrast-enhanced MRI 
It has been shown that the degree of plaque enhancement post-gadolinium 
injection correlates with neovascularisation and the degree of macrophage 
infiltration (i.e., inflammation) [163,164,173]. Also, a retrospective study 
found that carotid plaque inflammation detected by contrast-enhanced MRI 
was a sign of multisite plaque activation and increased coronary ischemic 
events [174].  
 
Molecular MRI 
Contrast agents can be used with MRI to target specific molecules such as cell 
surface receptors [175,176]. Nanoparticles, such as ultra-small 
superparamagnetic iron oxide (USPIO), have been shown to be phagocytosed 
by macrophages in carotid plaques of recently symptomatic TIA patients [177] 
and to identify plaque inflammation [178]. Howarth et al. found that 
symptomatic patients had greater areas of signal drop from phagocytosed 
USPIO [179], and the same author group also demonstrated a significant 
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decrease in USPIO-identified inflammation with aggressive lipid-lowering 
therapy over 3 months [180]. Other contrast agents were targeted to lipid core 
of plaques in a rabbit model by an unknown mechanism [181]. Recently, the 
contrast agent P947 was found to detect matrix metalloproteinases, 
angiotensin-converting enzyme, and aminopeptidase N activity in vulnerable 
plaques ex-vivo and in a rabbit model in vivo [182]. More developments on 
plaque molecular imaging with these contrast agents are expected for the 
future. 
 
Clinical and future perspectives 
Multicontrast high-resolution MRI of carotid plaque has shown significant 
promise to detect vulnerable plaque, which is why it is currently used in 
numerous clinical studies. Compared to other imaging techniques, it has good 
sensitivity and specificity to identify plaque components and excellent contrast 
within the small atherosclerotic plaque. However, there are significant 
drawbacks that prevent high-resolution MRI from being easily introduced into 
clinical practice. It is an expensive examination with frequent contra-
indications, limited availability and lengthy examination duration, thus not 
suitable for screening purposes. It is also susceptible to poor image quality, 
reaching at times over 30% of patient examinations, mainly due to motion 
artefacts [183].  
 
The current area of research focuses on clinical and technical aspects of MRI: 
prospective studies to measure plaque progression [183-185]; detection of the 
vulnerable plaque and assessment of its predictive value [186,187]; 
determining which clinical factors are associated with vulnerable plaque 
features [188-190]; increasing the use of 3T magnetic field and document its 
reproducibility; and technical optimization to improve image quality and 
shorten total examination time. So far, technical improvements have resulted in 
shorter scanning times: 3T magnetic field with a single excitation instead of 
97 
 
two for black-blood sequences [166]; parallel imaging techniques [191]; and 
local excitation black-blood imaging [192]. Better blood flow suppression was 
proposed to improve image quality [193], and a newly developed T1W 
sequence, rapid acquisition gradient echo (RAGE), had a better diagnostic 
capability than fast-spin echo sequence to detect IPH [194]. With ongoing 
development of these technical improvements and clinical studies, 
multicontrast high-resolution MRI may become the imaging technique of 
choice to characterize vulnerable carotid plaque morphology. 
 
Conclusion 
 
To date, the best non-invasive imaging modality to study the natural history of 
atherosclerosis for stroke prevention is yet to come. By describing how 
ultrasound (US), multidetector computed tomographic angiography (MDCTA) 
and magnetic resonance imaging (MRI) are used to characterize atherosclerotic 
carotid disease, this review has helped determine the best avenues to explore 
for non-invasive carotid plaque imaging. . Newer developments such as 
ultrasound elastography, targeted contrast agents in ultrasound, CT and MRI, 
and optimization of MRI techniques are emerging; study of plaque evolution is 
the next step.  
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4. Characterization of Carotid Plaques with 
Ultrasound NIVE: Feasibility and Correlation with 
High-Resolution MRI 
4.1.  Introduction to manuscript 
 
This preamble introduces study rationale. The goal of this master’s thesis 
research project was to develop and validate the ultrasound non-invasive 
vascular elastography (US NIVE) technique for vulnerable plaque (VP) 
detection in patients with significant carotid stenosis. In order to do so, a 
correlation study between plaque strain values and plaque volume composition 
was undertaken. Plaque composition was determined by a reference standard, 
multicontrast high-resolution MRI of carotid plaque. Furthermore, an 
association between plaque strain and clinical symptoms was sought. Hence, 
patients were grouped as symptomatic or asymptomatic and their strain 
profiles were compared. 
 
Validation of US NIVE could provide valuable information on the 
biomechanical aspects of atherosclerotic plaque progression and vulnerable 
plaques. Ultimately, asymptomatic patients with carotid stenosis could be risk-
stratified into low-risk and high-risk groups, and targeted therapy could be 
efficiently instituted. 
 
 
The choice of MRI to validate US NIVE was judicious. When validating a new 
technique such as US NIVE, a gold standard or reference standard technique is 
required. US NIVE is a technique that measures plaque axial strain non-
invasively. The gold standard for measuring plaque axial strain is intravascular 
ultrasound elastography (IVUS); it consists of a catheter inserted directly into 
the arterial system (e.g. through the femoral artery) with a transducer element 
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at its tip and algorithms to calculate tissue axial displacements and produce an 
elastogram. IVUS of carotid arteries is invasive and carries an elevated risk of 
stroke for patients who have carotid atherosclerotic plaque. This technique was 
only validated in coronary arteries. Otherwise, there is no non-invasive gold 
standard technique that can accurately measure axial strain in vivo in carotid 
arteries.  
 
An alternative reference standard was sought to help validate US NIVE. 
Atherosclerotic plaque can be described by its biomechanical properties, 
morphology, composition, and molecular processes. Since our working 
hypothesis is the presence of an association between plaque stiffness and 
plaque composition (“soft” vs. “hard” plaque components), the gold standard 
technique must characterize plaque composition. This can be achieved by 
histopathology after surgical excision (CEA) of the plaque “en bloc”, followed 
by laboratory preparation techniques (i.e. slicing, staining) and analysis under 
the microscope by a pathologist. This implies a standardization of surgical and 
pathological techniques, along with a thorough cooperation between the 
clinician, the surgeon, the pathologist, the hospital’s laboratory, and all 
research personnel. It demands significant costs, time constraints, and 
resources. In addition, validation with histopathology requires that all included 
patients have a CEA, which is not the case in this study. Thus the patient 
population would have been limited to symptomatic patients with severe 
stenosis who already benefit from endarterectomy. It is more relevant to 
evaluate this technology in a broader population including asymptomatic 
patients who actually will be the future target population of vulnerable plaque 
detection. Thus, high-resolution multicontrast MRI was found to be the most 
appropriate reference standard since it was extensively validated with histology 
in the past.  
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ABSTRACT 
 
TITLE: 
Characterization of Carotid Plaques with Ultrasound Non-Invasive Vascular 
Elastography (NIVE): Feasibility and Correlation with High-Resolution 
Magnetic Resonance Imaging 
 
ABSTRACT: 
OBJECTIVES: Evaluate the ability of ultrasound Non-Invasive Vascular 
Elastography (NIVE) strain analysis to characterize carotid plaque composition 
and vulnerability as determined by high resolution MRI. 
METHODS: Thirty-one subjects with 50% or greater carotid stenosis 
underwent NIVE and high-resolution MRI of internal carotid arteries. Time-
varying strain images (elastograms) of segmented plaques were generated from 
ultrasonic raw radiofrequency sequences. On MRI, corresponding plaques and 
components were segmented and quantified. Associations between strain 
parameters, plaque composition and symptomatology were estimated with 
curve-fitting regressions and Mann-Whitney tests. 
RESULTS: Mean stenosis and age were 72.7% and 69.3 years. Of 31 plaques, 
9 were symptomatic, 17 contained lipid and 7 were vulnerable on MRI. Strains 
were significantly lower in plaques containing a lipid core compared to those 
without lipid, with 77% to 100% sensitivity and 57% to 79% specificity (p < 
0.032). A statistically significant quadratic fit was found between strain and 
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lipid content (p < 0.03). Strains did not discriminate symptomatic patients or 
vulnerable plaques. 
CONCLUSIONS: Ultrasound NIVE is feasible in patients with significant 
carotid stenosis and can detect the presence of a lipid core with high sensitivity 
and moderate specificity. Further studies of plaque progression with NIVE are 
required to identify vulnerable plaques.  
 
KEY WORDS (from Medical Subject Headings):    
Carotid Artery Plaque; Atherosclerotic Plaque; Elastography; Ultrasound; 
Magnetic Resonance Imaging (MRI). 
 
KEY POINTS: 
 Ultrasound NIVE is feasible in patients with significant carotid stenosis  
 Ultrasound NIVE detects a lipid core with high sensitivity and 
moderate specificity 
 Further plaque progression studies with NIVE are required to identify 
vulnerable plaques 
 
ABBREVIATIONS AND ACRONYMS: 
Ultrasound Non-Invasive Vascular Elastography (Ultrasound NIVE); 
Ultrasound (US); high-resolution Magnetic Resonance Imaging (high-
resolution MRI); Radiofrequency (RF); Lagrangian Speckle Model Estimator 
(LSME); Mean Strain at Peak Systolic Compression (MSPSC); Mean Strain 
Amplitude (MSA); Maximal Strain Rate (MaxSR); Minimal Strain Rates 
(MinSR); Intraplaque Hemorrhage (IPH); lipid percentage of total plaque 
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volume (%Lipid volume) and calcium percentage of total plaque volume 
(%Calcium volume); Standard Deviation (SD); Intravascular Ultrasound 
Elastography (IVUS). 
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INTRODUCTION 
 
It is estimated that up to 20% of strokes are caused by carotid atherosclerosis 
[10] (1). Severity of carotid stenosis is a strong predictor of recurrent 
atheroembolic strokes in symptomatic patients with a significant stenosis [195] 
(2), but it is not a reliable predictor of stroke incidence in asymptomatic 
patients [28] (3). Hence, appropriate management of asymptomatic patients 
remains controversial, warranting further risk stratification.  
 
According to the coronary artery literature, risk stratification should involve 
identification of the vulnerable plaque, that is, an atherosclerotic plaque at 
elevated risk of causing an ischemic event [33] (4). Pathology of culprit 
coronary plaques has been shown to be similar to that of symptomatic carotid 
plaques [48] (5). Thus, research in stroke prevention emphasizes the 
identification of vulnerable plaques in carotid arteries with a variety of imaging 
techniques that characterize plaque composition, morphology, molecular 
processes, or biomechanical properties. For instance, CT and PET-CT were 
proposed to evaluate plaque composition and inflammation, respectively 
[125,196] (6, 7). B-mode echo-texture [86] (8) and plaque volume 
measurement by ultrasound [89] (9) were also tested to evaluate plaque 
vulnerability and evolution with statin therapy. Ultimately, multicontrast high-
resolution MRI was found to be the most accurate non-invasive imaging 
technique to identify and quantify plaque components compared to histology 
[148,153] (10, 11). In addition, MRI-detected intra-plaque hemorrhage and 
fibrous cap disruption were associated with plaque vulnerability [152,157] (12, 
13). Despite its high sensitivity and specificity for plaque morphology 
[144,147,148,153] (10, 11, 14, 15), elevated costs and time requirements 
render implementation of MRI difficult for patient screening and follow-up. As 
a result, an affordable non-invasive imaging technique to characterize carotid 
plaque composition and its progression is yet to be determined.  
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To date, no single carotid plaque imaging feature is recognized as a reliable 
independent predictor of future ischemic events. Furthermore, there is no 
established technique analyzing plaque biomechanics non-invasively. Non-
Invasive Vascular Elastography (NIVE) by ultrasound is a novel ultrasonic 
technique that characterizes plaque biomechanics by mapping carotid plaque 
strains [113] (16). It is low-cost, implementable on clinical ultrasound 
scanners, and could potentially accompany routine carotid imaging 
examinations. A previous study assessed the feasibility of NIVE to analyze the 
strain of carotid walls in healthy subjects [114] (17). The next step is to 
evaluate the ability of NIVE strain analysis to characterize atherosclerotic 
plaques in patients with a carotid stenosis. We hypothesized that lipid-rich and 
vulnerable plaques have different strains (deformations) than calcified and 
non-vulnerable plaques. Hence, we aimed to evaluate the ability of ultrasound 
NIVE strain analysis to characterize carotid plaque composition and 
vulnerability, using high resolution MRI as a reference standard. As a 
secondary endpoint, we aimed to determine the feasibility of NIVE to 
discriminate symptomatic from asymptomatic patients. 
 
METHODS 
 
This prospective study was compliant with the Health Insurance Portability 
and Accountability Act and approved by the institutional review board. All 
subjects gave their written informed consent. Subjects were recruited from the 
vascular and interventional radiology, vascular surgery, neurology, and 
vascular medicine clinics. Between January 2006 and December 2010, 44 non-
consecutive patients referred to the radiology department for suspected 
significant carotid stenosis were enrolled. Indications for imaging carotid 
arteries were based on local standards of care. Men and women aged 40 to 85 
years were eligible if they had a symptomatic or asymptomatic carotid artery 
stenosis of at least 50% diameter reduction documented on a previous 
angiography study if available [CT angiography (n=23), MR angiography 
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(n=4), digital subtraction angiography (n=1)] combined with duplex Doppler 
ultrasound, or based solely on duplex Doppler ultrasound (n=16). For 
angiography studies, stenosis was evaluated according to the NASCET criteria 
[21] (18). One carotid artery per patient was selected for analysis (“index 
side”): the symptomatic side, and for asymptomatic patients, the most severely 
stenotic side. Subjects were excluded if they had any contraindication to 
ultrasound, MRI or gadolinium injection; incomplete MRI or ultrasound 
elastography examination; endarterectomy within the last 10 years; carotid 
stenting; total occlusion; or severe calcification that impeded proper ultrasound 
imaging. 
 
At enrolment, a medical history and clinical examination were performed for 
all subjects. Baseline modified Rankin scale scores were recorded, and subjects 
were classified as symptomatic if they had a stroke or transient ischemic attack 
(TIA) attributed to their index carotid artery plaque in the previous three 
months. If there was any doubt on the relationship between the occurrence of 
neurologic symptoms and the index carotid, the patient was referred for an 
independent assessment by a neurologist. Serum fasting lipid profile and C-
reactive protein were sampled. A color and pulsed Doppler ultrasound 
examination was performed using standardized criteria [76] (19) to confirm 
degree of stenosis, followed by an ultrasound acquisition for elastography and 
a high-resolution MRI of the index carotid artery. All imaging examinations 
were performed within the first month of participation. 
 
Asymptomatic subjects were followed annually in order to determine if their 
index carotid plaque had become symptomatic or occluded, in the form of a 
stroke, a TIA, or a newly documented asymptomatic total artery occlusion. In 
that case, subjects were classified in the “symptomatic” group for analysis. 
Follow-up consisted of completion of a dedicated questionnaire with telephone 
interviews and medical and imaging file reviews. 
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Ultrasound Elastography Protocol 
 
Ultrasound Non-Invasive Vascular Elastography (NIVE) estimates the local 
deformation of a plaque induced by its natural cardiac pulsation, as explained 
schematically in Figure 4.1. 
 
 
Figure 4.1. Schematic depiction of ultrasound NIVE. Blood pressure from the systolic 
carotid pulse induces a compression (axial stress denoted by large red arrows) and a 
deformation (axial strain denoted by ∆L/L X 100) of the atherosclerotic plaque. This is a 
simplified depiction, because axial strain is calculated for each individual window (1.54 X 
2.99 mm), after which mean axial strain for the entire segmented plaque is calculated. 
 
A single operator performed all ultrasonic raw radiofrequency (RF) data 
sequence acquisitions, with an ES500RP system (Ultrasonix, Vancouver, 
Canada) equipped with a L14-5/38 linear array transducer (20 MHz sampling 
frequency; 20-25 frames per second; 38.5 x 149.6 μm pixel size). B-mode 
images from reconstructed RF data were acquired longitudinally, centered on 
the plaque at the level of the carotid bulb, and in a time-varying sequence over 
approximately 10 seconds. Brachial blood pressure and heart rate were 
measured before, during, and after ultrasound acquisitions. 
 
ΔL 
ΔL 
L 
L 
Near plaque portion 
Deep plaque portion 
Pre-compression 
(end-diastole) 
Post-compression 
(systolic pulse) 
Lumen 
Ultrasound 
transducer 
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The implemented NIVE algorithm software consisted of two major steps to 
obtain an elastogram from consecutive RF images. First, manual segmentation 
of the plaque on the first image frame was followed by automatic adaptation of 
the initialized region through the time-varying sequence [118] (20). The 
segmentation was performed by a technician and reviewed by a radiologist, 
both blinded to MRI. Second, the Lagrangian Speckle Model Estimator 
(LSME) algorithm [112] (21) was applied to compute axial strain of the time-
varying sequence of the segmented plaque. This algorithm calculates speckle 
vector translations and morphological changes between consecutive image 
frames, thus providing values of relative axial strain over time. Hence, for each 
pair of image frames, an elastogram (color map of axial strain) was obtained, 
and strain parameters were computed from the average axial strain of the 
whole plaque (i.e., both near and far plaque portions illustrated in Figure 4.1). 
Time-varying strain curves were filtered to eliminate respiratory and motion 
artefacts [119] (22), and 2 to 5 consecutive cardiac cycles were chosen for 
analysis. A thorough biomechanical description of axial strain was obtained 
with four different strain parameters as outcome variables of NIVE: Mean 
Strain at Peak Systolic Compression (MSPSC), Mean Strain Amplitude 
(MSA), and Maximal and Minimal Strain Rates (MaxSR, MinSR). Figure 4.2 
explains each parameter in detail.  
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Figure 4.2. Elastogram and strain curves of the left carotid plaque of a 70 year old man 
who presented with left-sided amaurosis fugax. (a) A two-dimensional longitudinal view 
B-mode image reconstructed from raw RF data showing the segmented plaque (red 
contour) on the anterior vascular wall of the internal carotid artery (ICA), and the same 
image with a superimposed elastogram (color map) representing cumulated axial strain 
at maximal systolic compression. The colors range from -20% (dark blue) to +20% (dark 
red), denoting areas of dilation and compression respectively. (b) A graph of 
instantaneous mean axial strain is obtained from the strain difference between two 
consecutive image frames, thus representing the variation of mean axial strain over time. 
Peak systolic compression is denoted by red circles. Mean Strain at Peak Systolic 
Compression (MSPSC) is the average of these peak values over the number of cardiac 
cycles. Dotted vertical lines represent end-diastole, estimated from B-mode videos and M-
mode images. (c) Strain Rate is the slope of the instantaneous strain in (b). Maximum 
Strain Rate (MaxSR) is the mean of the greatest strain rate occurring at end-diastole 
(green circles). Minimum Strain Rate (MinSR) is the mean of the lowest strain rate, 
occurring at the onset of diastole (purple circles). In other words, MaxSR represents 
greatest tissue compression over time, and MinSR represents greatest tissue dilation over 
time, which explains why MinSR is a negative value. (d) A graph of cumulated mean 
axial strains is derived from (b). Double-sided blue arrows represent strain amplitude for 
each cardiac cycle. Mean Strain Amplitude (MSA) is the average of these three 
amplitudes. The peak of the third cardiac cycle corresponds to the elastogram in (a). 
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MR Imaging Protocol 
 
Using a 1.5-Tesla MRI unit (Siemens, Avanto, Erlangen, Germany) and a 
dedicated 4-element radiofrequency surface coil, axial images of the index 
carotid artery were obtained from 10 mm below to 3 cm above the bifurcation. 
First, a 3D Time-of-Flight sequence was performed [repetition time 
(msec)/echo time (msec), 24/7.15; flip angle (FA), 25°; section thickness, 1 
mm; field of view, 12 cm; resolution, 0.6 X 1 mm; number of signals averaged, 
3]. Using the same field of view and positioning, as well as ECG-gating, fat-
suppression, and 0.6 X 0.5 X 3 mm voxel size with 1 mm intersection gap, 
four black-blood double-inversion recovery turbo spin echo sequences were 
acquired with the following parameters: T2-weighted [repetition time 
(msec)/echo time (msec), 2 R-R intervals/78; number of signals averaged, 3]; 
proton density weighted [2 R-R intervals/11; 2]; and pre- and post-contrast T1-
weighted [600-700/6.8; 2] sequences. Two adjacent slices containing the major 
portion of the plaque were selected for post-contrast imaging. Gadolinium-
BOPTA (MultiHance, Bracco Diagnostics, Vaughan, ON, Canada) was 
injected at a rate of 2 ml/sec (0.1 mmol/kg), after which image acquisition was 
performed every minute for 10 minutes. Total imaging time was typically less 
than 45 minutes. 
 
MR Image Review 
 
Plaque image analysis and segmentation were performed by one junior reader 
(6 months training) and reviewed by a senior reader (20 year experience in MR 
vascular imaging). Both were blinded to plaque strain values and elastograms. 
All image sequences were used for interpretation and segmentation, including 
the post-contrast image sequence of the major plaque portion, which 
complemented plaque characterization. The post-contrast image sequence 
chosen for analysis was acquired at least 5 minutes after injection onset and 
displayed the best image quality and maximum enhancement. At each image 
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slice level, vessel contours and components were manually traced using a 
segmentation software (QPlaque MR 1.0.16, Medis, Netherlands) that allows 
simultaneous tracing on all sequences and provides volume and area 
measurements. Plaque components were identified using previously published 
criteria [131,144,155,164] (14, 23-25), and included: lipid core, calcifications, 
intra-plaque hemorrhage, loose matrix, fibrous cap, and 
inflammation/neovasculature. Inflammation/neovasculature was defined as a 
region of enhancement on the post-contrast injection sequence [163,173,197] 
(26-28). Fibrous tissue was not segmented; it was defined as the remainder of 
the plaque between inner and outer vessel wall contours, and only included 
fibrous cap and loose matrix segmented areas for volumetric analyses. A 
segmented plaque is illustrated as an example in Figure 4.3. 
 
The carotid plaque was deemed vulnerable on MRI if it had one of the 
following features: thin fibrous cap with a large lipid core (≥25% surface area), 
ruptured fibrous cap, or intraplaque hemorrhage (Figure 4.3). The main 
outcome variables for high-resolution MRI were lipid and calcium proportions, 
in percentage of total plaque volume (“%Lipid volume” and “%Calcium 
volume”). 
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Figure 4.3. High-resolution MRI of the left internal carotid artery plaque of a 65 year old 
man who presented with a left hemispheric stroke (axial view). This is a vulnerable-
appearing lipid-rich hemorrhagic plaque. The external and internal carotid arteries are 
indicated with a white and black arrow, respectively. The segmentation using the 
QPlaque software is shown superimposed on the T1-weighted image (framed inset at the 
center). The green and red contours designate the outer and inner vascular wall contours 
of the internal carotid artery. Yellow represents lipid, pink represents hemorrhage, and 
purple represents inflammation. T1W = T1-weighted; T2W = T2-weighted; PDW = 
Proton Density-weighted; T1WC+ = T1-weighted post-contrast injection. 
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RESULTS 
 
Forty-four subjects were recruited. Thirty-one met inclusion criteria for 
analysis as the flowchart demonstrates (Figure 4.4). No adverse events 
occurred. Population baseline clinical, MRI and ultrasound characteristics are 
presented in Tables IV-I and IV-II. During a mean follow-up of 69.9 weeks 
(SD 82.4; range 0-253.6), one of the 23 asymptomatic subjects developed an 
asymptomatic total artery occlusion. 
 
Figure 4.4. Flowchart of subject recruitment. 
 
  
Referred to radiology for carotid 
artery stenosis imaging and signed 
informed consent for participation 
(n=44) 
32 asymptomatic 
12 symptomatic 
Included for analysis (n=31) 
22 non-vulnerable plaques 
9 vulnerable plaques 
Color Doppler US and US-NIVE 
(n=43) 
Excluded (n=1) 
Ultrasound contra-indication because of 
unstable symptomatic plaque 
Excluded (n=1) 
Contra-indication to MR 
High-resolution MRI (n=42) 
Excluded (n=7) 
4 MR technical issues (incomplete MRI) 
3 stenoses <50% estimated at baseline 
Refused (n=4) 
Discomfort or panic during MR exam Included for analysis (n=31) 
Asymptomatic at 
study onset (n=23) 
Symptomatic at 
study onset (n=8) 
Still Asymptomatic on 
May 31st 2011 (n=12) 
Censored (n=10) 
CEA for asymptomatic 
stenosis (n=7) 
Loss to follow-up (n=2) 
Refusal (n=1) 
Target Outcome:     
Total occlusion (n=1)  
at 6 months follow-up 
Follow-up 
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Table IV-I. Population Clinical Characteristics 
 
Total 
n = 31 
Symptomatic 
n=9 
Asymptomatic 
n=22 
P-value 
Clinical Characteristics     
Male (number) *  22 (71%) 8 (88.9%) 14 (63.6%) 0.160 
Age (y) ‡ 69.3 ± 7.8 69.3 ± 9.0 69.3 ± 7.5 0.793 
Mean percent diameter stenosis (%)‡ 72.7 ± 12.2 74.4 ± 12.4 72.1 ± 12.4 0.544 
Left index carotid artery * 13 (41.9%) 6 (66.7%) 7 (31.8%) 0.074 
Clinical history 
Symptomatic 9 (29%)   N/A 
Amaurosis fugax 3   N/A 
TIA 1   N/A 
Completed stroke 3   N/A 
Retinal infarct 1   N/A 
Asymptomatic carotid occlusion 1   N/A 
Body Mass Index (kg/m
2
) † 26.6 ± 4.5 28.2 ± 6.0 26.0 ± 3.8 0.246 
Peripheral vascular disease * 22 (71%) 2 (22.2%) 20 (90.9%) 0.0001
¥
 
Ischemic heart disease * 12 (38.7%) 3 (33.3%) 9 (40.9%) 0.694 
Diabetes Mellitus * 15 (48.4%) 5 (55.6%) 10 (45.5%) 0.609 
Dyslipidemia * 27 (87.1%) 7 (77.8%) 20 (90.9%) 0.322 
Hypertension * 27 (87.1%) 6 (66.7%) 21 (95.5%) 0.030
¥
 
Smoking history * 25 (80.7%) 7 (77.8%) 18 (81.8%) 0.965 
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Table IV-I. Population Clinical Characteristics (cont’d) 
 
Total 
n = 31 
Symptomatic 
n=9 
Asymptomatic 
n=22 
P-value 
Rankin scale
a
 *    0 23 (74.2%) 5 (55.6%) 18 (81.8%) 
0.039
¥
  1 4 (12.9%) 3 (33.3%) 1 (4.5%) 
 2 3 (9.7%) 0 (0.0%) 3 (13.6%) 
 3 1 (3.2%) 1 (11.1%) 0 (0.0%) 
Aspirin
§ 
* 26 (83.9%) 8 (88.9%) 18 (81.8%) 0.627 
Antiplatelet
§ 
* 10 (32.3%) 6 (66.7%) 7 (31.8%) 0.935 
Anticoagulant
§ 
* 2 (6.5%) 1 (11.1%) 1 (4.5%) 0.499 
Statin
§ 
* 27 (87.1%) 8 (88.9%) 19 (86.4%) 0.849 
Blood biochemistry ‡     
Total cholesterol (C) (mmol/L)  3.85 ± 0.82 3.87 ± 1.11 3.84 ± 0.71 0.826 
LDL-C (mmol/L) 2.00 ± 0.70 2.11 ± 1.04 1.97 ± 0.54 0.807 
C-Reactive Protein (mg/L) 4.01 ± 3.20 3.02 ± 1.72 4.30 ± 3.51 0.670 
Mean sBP (mm Hg) † 132.3 ± 16.3 120.2 ± 12.2 137.1 ± 15.4 0.007
¥
 
Mean dBP (mm Hg) † 67.3 ± 10.0 66.9 ± 10.3 69.3 ± 10.1 0.553 
Mean heart rate (beats per minute) † 69.7 ± 14.8 73.6 ± 18.1 69.8 ± 13.5 0.530 
N/A: not applicable; sBP: systolic blood pressure; dBP: diastolic blood pressure 
* Pearson Chi-squared test 
† Independent sample student T-test  
‡ Mann-Whitney test 
a
 Rankin scale at participation onset (includes residual symptoms from any previous stroke) 
§ 
Consistent use of medications for at least 3 months prior to participation 
¥
 Statistically significant  
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Table IV-II. Population MRI and Ultrasound Characteristics 
 Total 
n = 31 
Symptomatic 
n=9 
Asymptomatic 
n=22 
P-value 
MRI characteristics     
Vulnerable by MR * 7 (22.6%) 4 (44.4%) 3 (13.6%) 0.063 
Presence of: 
Lipid ** 17 (54.8%) 7 (77.8%) 10 (45.5%) 0.132 
Calcium ** 27 (87.1%) 8 (88.9%) 19 (86.4%) 1.000 
Fibrous cap * 
Thick intact 24 (77.4%) 5 (55.6%) 19 (86.4%) 
0.019
¥
 Thin Intact 2 (6.5%) 0 (0%) 2 (9.1%) 
Ruptured 5 (16.1%) 4 (44.4%) 1 (4.5%) 
Intra-plaque hemorrhage ** 2 (6.5%) 2 (22.2%) 0 (0%) 0.077 
Contrast enhancement * 19 (61.3%) 6 (66.7%) 13 (59.1%) 0.694 
Modified AHA criteria * [23] [131]  
Type IV-V, fibroatheroma 10 (32.3%) 3 (33.3%) 7 (31.8%) 
0.019
¥
 
Type VI, complicated 5 (16.1%) 4 (44.4%) 1 (4.5%) 
Type VII, calcified 9 (29.0%) 0 (0.0%) 9 (40.9%) 
Type VIII, fibrous 7 (22.6%) 2 (22.2%) 5 (22.7%) 
Plaque volume, mm
3 
† 1529.2 ± 676.5 1598.5 ± 792.3 1500.9 ± 641.7 0.722 
Max segmental wall thickness, mm‡ 5.6 ± 2.0 6.1 ± 3.1 5.3 ± 1.4 0.896 
Mean fibrous cap thickness, mm †
 
1.4 ± 0.5 1.5 ± 0.5 1.3 ± 0.6 0.516 
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Table IV-II. Population MRI and Ultrasound Characteristics (cont’d) 
 Total 
n = 31 
Symptomatic 
n=9 
Asymptomatic 
n=22 
P-value 
Mean % volumes  
Lipid ‡ 4.8 ± 9.3 9.4 ± 11.3 3.0 ± 7.9 0.022
¥
 
Calcium †
 
5.1 ± 4.6 2.2 ± 2.5 6.3 ± 4.8 0.005
¥ 
Contrast enhancement ‡ 2.2 ± 2.9 3.0 ± 4.1 1.8 ± 2.3 0.638 
Loose matrix ‡ 1.3 ± 2.4 0.8 ± 1.4 1.5 ± 2.7 0.668 
Fibrous tissue (loose matrix 
included) ‡ 87.8 ± 9.4 85.2 ± 12.7 88.9 ± 7.7 0.828 
Intra-plaque hemorrhage ‡ 0.05 ± 0.2 0.2 ± 0.3 0.0 ± 0.0 0.025
¥ 
Ultrasound characteristics    
Degree of calcification * 
0 = absent 7 (22.6%) 4 (44.4%) 3 (13.6%) 
0.176 1 = slight 5 (16.1%) 2 (22.2%) 3 (13.6%) 
2 = moderate 9 (29.0%) 2 (22.2%) 7 (31.8%) 
3 = severe 10 (32.3%) 1 (11.1%) 9 (40.9%) 
Plaque echogenicity * 
1 = hypoechoic 8 (25.8%) 3 (33.3%) 5 (22.7%) 
0.0004
¥
 2 = isoechoic 2 (6.5%) 2 (22.2%) 0 (0.0%) 
3 = hyperechoic 16 (51.6%) 0 (0.0%) 16 (72.7%) 
4 = heterogeneous 5 (16.1%) 4 (44.4%) 1 (4.5%) 
* Pearson Chi-squared test 
** Fisher’s exact test (bilateral) 
† Independent sample student T-test  
‡ Mann-Whitney test 
¥
 Statistically significant 
128 
 
 
For three NIVE parameters, absolute strain values were significantly lower in 
atherosclerotic plaques containing a lipid core compared to those devoid of 
lipid (Table IV-III). Figure 4.5 shows the Receiver Operating Characteristic 
(ROC) curve for the three significant NIVE parameters. Depending on chosen 
cut-off strain values to determine the presence or absence of a lipid core, 
sensitivities and specificities ranged from 77% to 100% and 57% to 79%, 
respectively. For indication of preventative medical therapy and regular 
follow-up, a greater sensitivity is required. Thus, for MSPSC, MaxSR and 
MinSR, maximum sensitivities of 88.2%, 94.1% and 100%, respectively, with 
corresponding specificities of 57.1%, were obtained for strain value thresholds 
of 0.254%, 1.834%  s-1, and -2.380%  s-1, respectively. On the other hand, 
for indication of surgical therapy, a greater specificity is preferred. Maximum 
specificities of 71.4%, 78.6%, and 78.6%, with corresponding sensitivities of 
76.5%, 76.5%, and 94.1%, respectively, were obtained for strain value 
thresholds of 0.212%, 1.440%  s-1, and -2.099%  s-1. 
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Table IV-III. Bivariate Associations between Strain Parameters and Clinical Factors 
Strain parameters 
Strain values, Mean ± SD 
                        Median 
P-value‡ 
 
Total 
n = 31 
Lipid Present 
n = 17 
Lipid Absent 
n = 14  
MSPSC (%) 
0.205 ± 0.120 
0.193 
0.163 ± 0.076 
0.140 
0.257 ± 0.144 
0.259 0.032* 
MSA (%) 
1.248 ± 0.775 
1.060 
1.101 ± 0.677 
0.806 
1.428 ± 0.871 
1.396 0.131 
MaxSR (% s-1) 
1.587 ± 1.004 
1.407 
1.110 ± 0.446 
0.997 
2.166 ± 1.193 
2.020 0.003* 
MinSR (% s-1) 
-1.841 ± 1.199 
-1.650 
-1.234 ± 0.585 
-1.139 
-2.578 ± 1.354 
-2.408 0.001* 
 
Calcium Present 
n = 27 
Calcium Absent 
n = 4  
MSPSC (%) 
0.213 ± 0.124 
0.205 
0.154 ± 0.086 
0.166 0.346 
MSA (%) 
1.290 ± 0.804 
1.060 
0.971 ± 0.542 
1.053 0.480 
MaxSR (% s-1) 
1.643 ± 1.042 
1.407 
1.212 ± 0.669 
1.276 0.480 
MinSR (% s-1) 
-1.925 ± 1.241 
-1.815 
-1.275 ± 0.746 
-1.349 0.263 
 
Symptomatic 
n = 9 
Asymptomatic 
n = 22 
 
MSPSC (%) 
0.193 ± 0.103 
0.163 
0.210 ± 0.128 
0.206 0.761 
MSA (%) 
1.083 ± 0.613 
0.963 
1.316 ± 0.836 
1.180 0.459 
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Table IV-III. Bivariate Associations… (cont’d) 
MaxSR (% s-1) 
1.624 ± 1.425 
1.162 
1.572 ± 0.816 
1.488 0.514 
MinSR (% s-1) 
-1.815 ± 1.453 
-1.278 
-1.852 ± 1.118 
-1.886 0.602 
 Vulnerable 
on MRI 
n = 7 
Non-Vulnerable 
on MRI 
n = 24  
MSPSC (%) 
0.169 ± 0.098 
0.128 
0.216 ± 0.125 
0.212 0.238 
MSA (%) 
0.921 ± 0.396 
0.806 
1.344 ± 0.837 
1.337 0.219 
MaxSR (% s-1) 
1.593 ± 1.615 
0.902 
1.585 ± 0.796 
1.488 0.345 
MinSR (% s-1) 
-1.639 ± 1.663 
-0.849 
-1.900 ± 1.067 
-1.950 0.131 
 
Male 
n =22 
Female 
n = 9  
MSPSC (%) 
0.204 ± 0.131 
0.155 
0.207 ± 0.093 
0.221 0.602 
MSA (%) 
1.320 ± 0.856 
1.083 
1.074 ± 0.531 
0.938 0.663 
MaxSR (% s-1) 
1.545 ± 1.088 
1.233 
1.690 ± 0.810 
1.736 0.384 
MinSR (% s-1) 
-1.792 ± 1.311 
-1.418 
-1.961 ± 0.927 
-2.214 0.258 
MSA = Mean Strain Amplitude; MSPSC = Mean Strain at Peak Systolic Compression; MaxSR = Maximal 
Strain Rate; MinSR = Minimal Strain Rate; sBP = systolic blood pressure; dBP = diastolic blood pressure. 
‡ Mann-Whitney test 
* Statistically significant 
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Figure 4.5.  ROC curves for NIVE strain parameters to detect the presence of a lipid 
core. 
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NIVE strain parameters did not show a significant difference between 
symptomatic and asymptomatic groups, vulnerable and non-vulnerable plaques 
on MRI, genders, or presence and absence of calcium, inflammation, loose 
matrix, hemorrhage or ulceration (Figure 4.6, Table IV-III). There were no 
significant associations between strain parameters and modified Rankin scale 
score, degree of stenosis, age, heart rate, and mean diastolic and systolic blood 
pressures, except for a single strain parameter, MSA, correlating negatively 
with heart rate (Spearman correlation coefficient (rs) = -0.385, p = 0.036). 
 
Figure 4.6. Distribution of axial strain parameters by presence of symptoms. MSPSC = 
Mean Strain at Peak Systolic Compression; MSA = Mean Strain Amplitude; MaxSR and 
MinSR = Maximal and Minimal Strain Rates. 
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There was a significant correlation between the %Lipid volume and each of the 
4 NIVE parameters (Figure 4.7a). Curve-fitting analyses revealed a statistically 
significant quadratic fit, estimated with the addition of the quadratic term 
(%Lipid volume)
2
 (Table IV-IV). On scatter plots, higher strains were 
observed with little to no lipid content, followed by an initial decrease in strain 
values until approximately 12% Lipid volume, after which strain values 
increased slightly with lipid content (the opposite was observed for MinSR) 
(Figure 4.7a). Only age and heart rate were found to have a confounding effect 
on these associations. Nevertheless, these associations were maintained at 
significance levels when controlling those two variables in multivariate 
analyses (Table IV-IV). An inverse correlation between %Calcium volume and 
%Lipid volume was found (rs = - 0.624, p = 0.00009), but %Calcium volume 
did not significantly change the nature or strength of the association between 
%Lipid volume and each strain parameter. 
 
There were borderline positive linear associations between %Calcium volume 
and two strain parameters, MSA and MinSR (Figure 4.7b); however these 
associations lost significance when controlling for confounding variables 
(Table IV-IV). Finally, there were no significant correlations between 
percentage volumes of other plaque components and strain parameters. 
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Figure 4.7: 
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Figure 4.7. Scatter plots with curve fitting functions of the natural logarithm of strain 
parameters with (a) % Lipid volume and (b) % Calcium volume (bivariate analyses). 
Note that only for the MinSR parameter, 2 outliers were removed to normalize the 
distribution. For all other parameters, a natural logarithm was applied for 
normalization. MSPSC = Mean Strain at Peak Systolic Compression; MSA = Mean 
Strain Amplitude; MaxSR and MinSR = Maximal and Minimal Strain Rates.  
Note: red stars = symptomatic group, blue circles = asymptomatic group 
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 Table IV-IV. Multivariate Analyses for Each Strain Parameter 
Multivariate model 
Estimate 
(linear or quadratic coefficient) 
p-value 
Joint p-value 
(F-test) 
95% CI 
Ln(MSPSC) *   
%Lipid volume -10.98 0.008¥ 
0.0211¥ 
-18.78 ; -3.18 
(%Lipid volume)2 30.48 0.016¥ 6.27 ; 54.68 
Ln(MSA) **   
%Lipid volume -11.33 0.0031¥ 
0.0105¥ 
-18.46 ; -4.21 
(%Lipid volume)2 32.29 0.0056¥ 10.36 ; 54.23 
Ln(MaxSR) **   
%Lipid volume -11.67 0.0021¥ 
0.0078¥ 
-18.68 ; -4.50 
(%Lipid volume)2 34.04 0.0032¥ 12.59 ; 55.62 
MinSR *†   
%Lipid volume 16.98 0.0031¥ 
0.0068¥ 
6.34 ; 27.67 
(%Lipid volume)2 -45.53 0.0089¥ -78.66 ; -12.59 
Ln(MSA) **     
%Calcium volume 3.62 0.0877 N/A -0.58 ; 7.78 
MinSR *†     
%Calcium volume -6.25 0.0584 N/A -12.71 ; 0.25 
Ln( )= natural logarithmic of ( ) ; MSPSC = Mean Strain at Peak Systolic Compression; MSA = Mean Strain Amplitude; 
MaxSR = Maximal Strain Rate; MinSR = Minimal Strain Rate; %Lipid volume = percent of lipid contained in total 
plaque volume; (%Lipid volume)
2
 = %Lipid volume X %Lipid volume (quadratic term); %Calcium volume = percent of 
calcium contained in total plaque volume;  CI = confidence interval. 
*Controlled for age 
**Controlled for both age and heart rate 
†
 Removal of 2 outlier negative values to obtain a normal distribution; these outliers are kept in Figure 4.7 scatter plots 
¥ 
Statistically significant 
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DISCUSSION 
 
This study demonstrated the clinical feasibility of NIVE to characterize plaque 
composition by strain analysis in patients with 50% or greater carotid stenosis. 
The NIVE algorithm used in our study is based on the Lagrangian Speckle 
Model Estimator that estimates the deformation of plaque components induced 
by the cardiac pulsation [112] (21). It does not require external compression or 
creation of a radiation force. Acoustic radiation force impulse imaging was 
tested in phantoms, ex-vivo and in-vivo in carotid arteries but without clinical 
validation [198] (29).  
 
In this patient population, NIVE strain parameters (MSPSC, Max and MinSR) 
could detect the presence of a lipid core with sensitivities of up to 100% and 
corresponding specificities of up to 79%. The ability of non-invasively 
detecting a lipid core with NIVE in patients with 50% or greater stenosis can 
be valuable to detect plaque vulnerability and monitor the efficacy of medical 
treatment on plaque stabilization. Such a tool could also be helpful to help 
determine which asymptomatic patients would most benefit from medical 
versus surgical treatment.  
 
We observed significantly lower strain values in carotid plaques that contained 
a lipid core. This contradicts findings from previous authors who observed 
higher strain values in early fatty plaques compared to non-fatty plaques using 
Intravascular Ultrasound Elastography (IVUS) in iliac and femoral arteries of 
pigs [199] (30). In this last study, the types of atherosclerotic plaques were 
different than those of the present patient population: all fatty plaques were 
less than 30% stenotic, and all plaques were homogeneous and devoid of 
calcium. Conversely, the present study included mostly heterogeneous plaques 
with some degree of calcification, and at least 50% diameter reduction. Given 
that strain parameters were spatially averaged on the whole segmented plaque, 
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we interpret our findings with a “damper” hypothesis, whereby a lipid core 
embedded in a large stenotic plaque behaves as a damper reducing deformation 
of the whole plaque.  
 
We observed a non-linear “U”-shaped association between axial strain indices 
and plaque lipid content (Figure 4.7a). This quadratic fit is explained by the 
above finding where plaques containing lipid had smaller strains than those 
devoid of lipid. As the lipid core further increased in size above a threshold of 
approximately 12% lipid volume, there was a slight and steady increase in 
strain, but with values that remained lower than strains of plaques devoid of 
lipid (Figures 4.7a). The latter part of the association relies on a very small 
number of subjects, but concurs with the observation of others [199] (30) that 
increasing lipid content will increase strain. Therefore, although NIVE can 
currently detect plaques that contain a lipid core, further technical optimisation 
and analysis may provide NIVE with the ability to determine which fatty 
plaque would become vulnerable. The assessment of Young’s modulograms 
with a priori information relying on elastography strain maps is an avenue 
deserving attention for such an objective [200,201] (31, 32). 
 
We observed a significant tendency for MSA to increase and MinSR to 
decrease with calcium content, despite wide variability (Figure 4.7b). In 
contrast, previous authors reported lower strain values in calcified areas on in 
vivo ultrasound elastograms [115] (33). In a previous study on a few in vivo 
cases, we found that the effect of a rigid calcium annulus could cause a high 
mechanical stress on other plaque components and induce high strain values 
around it [113] (16). Since we are averaging strain parameters within the whole 
plaque, this “hammer effect” may explain the large variability and slight rise in 
strain associated with calcium content. Detection of areas with elevated strain 
or high strain spatial variation may be valuable to identify areas of potential 
plaque rupture and elevated shear stress. Areas suspected of having these 
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features included the shoulders of a plaque or areas adjacent to superficial 
calcium nodules [33] (4). 
 
Strain parameters did not discriminate symptomatic subjects or vulnerable 
plaque according to MRI criteria. This can partially be explained by the spatial 
averaging of strain parameters as discussed above. In addition, we did not 
study more sensitive surrogate endpoints of vulnerability such as subclinical 
ischemic lesions on follow-up brain MRI or advanced neuropsychological 
testing [116] (34), thus limiting the evaluation of vulnerability to hard clinical 
endpoints, which usually require a larger sample size to find meaningful 
differences. Finally, in contrast to the study by Maurice et al [114] (17) on 
normal subjects demonstrating higher strain values in women, we did not find 
gender differences. This may be attributed to our sample population, with a 
male predominance and advanced atherosclerotic disease.  
 
Baseline clinical characteristics were similar among symptomatic and 
asymptomatic subjects, except for a higher prevalence of peripheral vascular 
disease, hypertension, and higher mean systolic blood pressure in 
asymptomatic subjects. This can be explained by the selection process of 
asymptomatic patients (mainly recruited from vascular surgery and 
interventional radiology clinics), and by the strong association between 
peripheral vascular disease and hypertension [202] (35). 
 
Other imaging results from the present study are consistent with previous 
studies. Symptomatic patients had a higher prevalence of plaque vulnerability 
features by MRI [157] (12), higher lipid and lower calcium plaque content 
[152,203] (13,36) by MRI, and lower plaque echogenicity [80] (37) by 
ultrasound compared to asymptomatic patients.  
 
Our study adds to earlier findings by providing a non-invasive technique, 
measurements averaged over more than one cardiac cycle, and four distinct 
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strain parameters that showed consistent associations with lipid content. The 
strain parameters MSPSC and MSA used in this study were similar to those 
used in other studies, both in computation methodology and strain magnitude 
[113-115,199,204] (16, 17, 30, 33, 38). Finally, our study is the first to provide 
non-invasive strain analysis in vivo in patients with significant carotid stenosis 
due to atherosclerotic disease, with high-resolution multicontrast MRI as a 
reference standard for plaque composition. 
 
The present ultrasound NIVE technique has limitations in the characterization 
of atherosclerotic plaques. First, as described above, given that most 
atherosclerotic plaques are heterogeneous structures made of lipid and calcium, 
areas with high and low deformations are pooled together to compute mean 
strain. This evens out strain parameter values and consequently decreases the 
ability of NIVE to discriminate plaques based on mechanical behavior. 
Second, most of the plaque consists of fibrous tissue. With a two-dimensional 
longitudinal acquisition, a limited B-mode image quality obtained from 
reconstructed RF signals, and no real time visualization of elastograms, we 
could not target specific regions of interest within the plaque during image 
acquisition and segmentation. This last drawback could be alleviated with 
further developments to obtain real-time imaging; it is comparable to 
performing color Doppler scanning without image feedback for probe 
positioning over the region of interest. 
 
The present study provides a comprehensive evaluation of the current 
ultrasound NIVE technique and a better understanding of carotid plaque 
biomechanical behaviour in relation to plaque content. In addition, it 
demonstrates the need for technical optimisation of strain analysis in order to 
identify the lipid core, discriminate other plaque components, and ultimately 
detect vulnerability. Further studies with exploration of real-time imaging to 
visualize and target plaque components, echo-texture analysis based on raw RF 
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signals, and shear strain mapping could be valuable to improve plaque 
characterization and detect vulnerability. 
 
In conclusion, ultrasound NIVE determines time-varying atherosclerotic 
plaque strains. This technique is feasible and can detect the presence of a lipid 
core in subjects with 50% or greater carotid stenosis with high sensitivity and 
moderate specificity. Larger patient populations and further technical 
optimization of ultrasound NIVE with plaque subcomponent analysis are 
required to better characterize the biomechanical behaviour of carotid 
atherosclerotic plaques. 
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4.3.  Further discussion and future perspectives 
 
This postscript provides further discussion on methodology, results, and 
prospects of ultrasound non-invasive vascular elastography (US NIVE). 
 
4.3.1. Study Methodology 
 
The methodology of this study can be divided into three main components: 
clinical, MRI, and US NIVE. 
 
The clinical methodology is focused on determining which patient is 
symptomatic and which is asymptomatic. This touches upon an important 
distinction between clinical and surrogate endpoints. Clinical endpoints are 
based on signs and symptoms that a patient presents with, whereas surrogate 
endpoints are based on pathological or indirect evidence of disease that does 
not necessarily cause apparent signs or symptoms (e.g. presence of an 
ulcerated plaque on an imaging study of an asymptomatic patient). Hence, as 
previously discussed in Chapter 2, not all vulnerable plaques are symptomatic. 
A vulnerable plaque may rupture and send a microembolus to the brain; the 
patient could have absolutely no new symptoms or complaints despite a small 
infarcted area in the brain. Moreover, a vulnerable plaque may rupture and 
occlude the internal carotid artery without causing clinical symptoms if the 
patient has an effective collateral circulation. It follows that classifying patients 
into symptomatic and asymptomatic for the purpose of detecting the vulnerable 
plaque must be done carefully and also consider silent manifestations of plaque 
vulnerability.  
 
Cerebral ischemia due to a vulnerable carotid plaque occurs only in the 
anterior cerebral circulation. Lacunar infarcts in the basal ganglia region imply 
small penetrating artery disease; they are not caused by carotid plaque. A 
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patient who presents with stroke symptoms could have any type of stroke; the 
type of stroke must be defined before assuming it is caused by an ipsilateral 
carotid plaque. 
 
In the present study, careful investigation as to the cause of stroke or TIA was 
performed for every patient by consulting medical records and the patient’s 
physician if needed. Imaging studies were verified to confirm cerebral 
infarction (CT or MRI of the brain), cardiac thrombus (echocardiography), and 
large-vessel atherosclerotic disease (US color pulsed Doppler, CTA, MRA, or 
conventional angiography). The location of stroke and atherosclerotic plaque 
were well noted. Thus, symptomatic patients were classified as such when 
symptomatic from their ipsilateral carotid plaque. Asymptomatic patients were 
followed to determine if their carotid plaque was indeed vulnerable, either by 
developing future cerebral ischemic events from their carotid plaque or a total 
carotid occlusion from rapid plaque progression. If one of these situations 
occurred, the asymptomatic patient was classified as “symptomatic” regardless 
of presence or absence of clinical symptoms. Despite annual follow-up of 
asymptomatic patients with telephone interviews, dedicated questionnaires 
(Appendix 3) and thorough review of medical records and imaging 
examinations, valuable information could have been lost. Asymptomatic 
patients did not systematically have annual brain or carotid artery imaging; 
prescription of imaging studies was at the discretion of their physician, based 
on clinical indications. Therefore, some asymptomatic patients with 
microembolic strokes from their carotid artery or asymptomatic total carotid 
occlusion could have been missed. 
 
The MRI protocol of the present study was based on an extensive literature 
review validating MRI against histopathology. In order to appropriately 
identify all major plaque components (lipid rich necrotic core, fibrous cap, 
intraplaque hemorrhage, loose and dense fibrous matrix, 
neovascularisation/inflammation, and calcifications), black-blood T1, T2, 
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proton density weighting, and T1 post-gadolinium contrast injection images 
are required, along with bright-blood 3D-TOF. Image slices for each of these 
pulse sequences had to be exactly at the same distances from the bifurcation 
and have the exact same plane for appropriate analysis. The detailed MRI 
protocol is based on protocols from validation studies and is described in the 
manuscript. High-resolution MRI of carotid plaque is a technically demanding 
examination that requires cooperation among investigators, radiology 
technicians, and frequent quality control of standardized technique, especially 
in our setting where the study was on-going for years with a small sample of 
recruited patients and changing staff. When data analysis began in 2010, there 
was already over 3 years of patient recruitment. During those 3 years, MRI 
acquisition methods differed slightly across patients and scanner operators. 
According to the study protocol, ten 3 mm-thick slices had to be acquired per 
image sequence, and these 10 slices had to concord in location and plane 
across all sequences. In reality, a few MRI studies had, for example, 12 slices 
in the T2 sequence, and 11 slices in T1 and proton density sequences, with an 
overlap of only 9 slices (Figure 4.8). In these patients, this partial overlap of 
image slices prevented full coverage of the plaque by all MR sequences. There 
are rational explanations for this: some plaques were too extensive to be 
covered by 10 slices, and some patients moved a few millimeters up or down 
in between sequence acquisitions. In such cases, the following was performed: 
1. Image registration for proper positioning of slices 
2. For quantitative analysis such as plaque volume, if plaque coverage 
was incomplete on the T1-weighted acquisition, available slices on 
other sequences (proton density or T2-weighted) were used. For 
instance, in Figure 4.8, a total of 14 slices would be used to quantify 
plaque volume and vessel wall areas. 
3. For plaque morphology and AHA classification, interpretation was 
based on the overlapping slices, since they included the bulk of the 
plaque and all image sequences were available for proper plaque 
component identification. 
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Figure 4.8. Common issue of slice acquisition overlap between image sequences.  
 
Another common problem that occurred was a missing sequence, especially 
3D TOF, which was not acquired in all patients for variable reasons (time 
constraints, unintentional oversight). Also, some sequences had poor image 
quality due to motion artefacts and could not be used for analysis. Based on a 
previous image quality assessment protocol [144], we required the following 
for MRI analysis to be valid: 
1. At least 2 image sequences (among T1, T2, proton density, T1 post 
contrast, and 3D TOF) had to have an image quality of at least grade 2. 
2. Image quality rating depends on overall SNR. Rating is from 1 (poor) 
to 5 (excellent): 
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Grade 1: low SNR limits use, arterial wall and vessel margins are 
unidentifiable 
Grade 2: marginal SNR, arterial wall is visible, but the substructure, 
lumen, and outer boundaries are indistinct 
Grade 3: marginal SNR, wall structures are identifiable, but lumen and 
outer boundaries are partially obscured 
Grade 4: high SNR with minimal artefacts, vessel wall, lumen, and 
adventitial boundary are clearly defined 
Grade 5: high SNR without artefacts, wall architecture depicted in 
detail, lumen and adventitial boundary are clearly defined. 
 
Measurements of plaque burden and components were obtained with a semi-
automatic segmentation software, QPlaque MR (Medis medical imaging 
systems, Leiden, Netherlands), dedicated to segmenting carotid plaque images 
in the transverse plane. Thus, image interpretation and segmentation was 
facilitated with image registration (placing all 5 image sequences at the 
corresponding spatial coordinates in all three x, y, and z dimensions), ability to 
adjust window-level, and zooming to pixel level for precise segmentation. 
Segmentation could be performed on any sequence because it appeared 
simultaneously on all other sequences, allowing for direct comparison and 
precise spatial registration. The main limitation of the QPlaqueMR software 
was the lack of an option to measure SNR, CNR, and relative signal intensity 
(rSI) compared to sternocleidomastoid muscle. Therefore, image interpretation 
was based on a subjective evaluation of rSI’s.  
 
The US NIVE methodology was complex and evolved considerably with 
techniques to decrease artefactual RF signals. First, a semi-automatic 
segmentation algorithm [118] provided improvements over manual 
segmentation: segmentation time decreased considerably and segmentation 
contours became less subjected to bias due to “copy-pasting” segmentation 
masks over multiple image frames and manual modifications per frame. 
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Second, a method to minimize noise and filter strain curves was proposed and 
applied [119]. The goals were to resolve issues of reproducibility of 
identification of peak strain values in noisy strain curves and to decrease noise 
related to respiratory motion and heart rate. The technique consisted of 
frequency spectrum analysis of initial raw strain curves, followed by 
elimination of frequencies below 0.3 Hz (representing a respiratory rate below 
approximately 20 per minute) and harmonic frequencies above 1.5 times the 
patient’s heart rate. Thus, only frequencies in between, including the 
fundamental frequency corresponding to the heart rate, were sampled for 
analysis. After sampling, a reverse transformation back into time-varying strain 
curves was performed with the selected frequencies, resulting in smoother less 
noisy filtered strain curves. Associations of MRI plaque measurements with 
peak strain values from filtered strain curves were similar to those with peak 
strain values from raw noisy curves. Thus, this technique of filtering strain 
curves was adopted for analysis of all patients in the present study. Cardiac-
gating with electrocardiography (ECG) during US NIVE acquisition would 
have been a good alternative to eliminate noise related to pulse rate, but the 
machine used in this study, SonixRP, did not include this option.  
 
Another issue arose pertaining to computation of strain parameters of carotid 
plaques. Since two-dimensional B-mode US imaging was performed, the 
longitudinal views of carotid arteries often demonstrated both a near plaque 
portion (i.e. on the anterior carotid wall) and a far plaque portion (i.e. on the 
posterior carotid wall). Strain parameters of near plaque portions did not differ 
significantly from those of far plaque portions; hence, a weighted average 
strain value was computed based on plaque portion area. The following 
equation describes computation of the weighted average for total plaque strain: 
STOT = SN * (AN / ATOT) + SF * (AF / ATOT) 
Where STOT = Total plaque Strain; SN = Strain of Near plaque portion; SF = 
Strain of Far plaque portion; AN = Near plaque Area; AF = Far plaque Area; 
and ATOT = Total plaque Area. 
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4.3.2. Quadratic Correlation 
 
The quadratic correlation found in this study relies on only 31 subjects, of 
which approximately 5 subjects with greater lipid volumes make it a U-shaped 
association. Although the discussion section in the above manuscript provides 
a rational explanation for this type of association, the conclusions drawn from 
it must be taken with a grain of salt. First, the sample population was too small 
to provide a sufficient power for this analysis. Second, high-resolution MRI 
has important limitations involving image quality, reproducibility of 
interpretation and measures, and specificity for precise segmentation of each 
individual component. Furthermore, our study used a 1.5T magnet; a 3.0T 
magnet may have provided a more robust quantification of plaque components. 
Quantification of plaque components on histological samples of carotid 
plaques would have been ideal; however, given the size and prospective nature 
of this study, in addition to a majority of asymptomatic patients not undergoing 
carotid endarterectomy, histological analysis could not be performed. 
 
4.3.3. Clinical Correlations 
 
In this study, clinical correlations depended on a slightly heterogeneous 
follow-up of subjects enrolled in this study. Symptomatic patients were more 
readily identified as such, since their clinical presentation and subsequent brain 
and cardiovascular imaging provided relatively concrete evidence of their 
carotid plaque vulnerability. Asymptomatic patients, on the other hand, were 
recruited through the Picture Archiving and Communication System (PACS) 
of the CHUM (Centre Hospitalier de l’Université de Montréal). Patients who 
had any type of carotid imaging that showed a 50% or greater carotid stenosis 
were contacted and asked if they were interested in participating. A portion of 
these patients were followed by a neurologist for remote symptoms, whereas 
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others were not because they never had any history of neurological symptoms. 
All asymptomatic patients were followed by the principle investigator (myself) 
by telephone to determine if patients developed neurological symptoms. 
Patients did not have serial brain imaging or serial neurological exams; hence 
the follow-up of this study was subject to information bias. Ideally, this study 
would have involved a neurological consultation and regular follow-ups in an 
equal manner for all asymptomatic patients (for example, with a single 
neurologist or a few that are trained to follow the same study protocol and 
indications for brain imaging). These measures could have decreased loss to 
follow-up and provided more accurate clinical information than telephone 
interviews and chart reviews. However, given the small sample population, it 
is unclear whether a more robust follow-up would have significantly changed 
results. 
 
4.3.4. US Elastography Technical Optimization 
 
The US elastography technique used in this study is still in its developmental 
stages. First, the frame-rate of imaging acquisition was only occasionally 
known; this could have contributed to the variability of strains observed from 
one subject’s plaque to the next, although the use of cumulative strain values 
(such as for MSA) should have minimized this variability. Second, correction 
for artefacts (respiratory and motion artefacts, angle correction) was gradually 
implemented with power spectrum analysis and an algorithm for angle 
correction. At the time of publishing results, we found that only power 
spectrum analysis correcting for respiratory and motion artefacts caused a 
significant change in strain results; angle correction did not. Furthermore, the 
method of angle correction was not yet established for significantly stenotic 
carotid arteries. Hence we only “filtered” strain curves to eliminate motion 
artefacts from heart rate and respiration; this was performed uniformly across 
all 31 plaques, without any angle correction. Third, only axial strain was 
computed by the LSME algorithm, not lateral strain, because lateral resolution 
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of the ultrasound beam was twice as low as axial resolution (see Figure 4.1). 
Thus, whereas some plaques experienced more lateral strain than others, our 
data could not elucidate this information. Fourth, although two physicians 
performed US elastography acquisitions for each patient, only acquisitions 
performed by a single observer were analyzed and no study of interobserver 
reproducibility was performed. Fifth, B-mode images from reconstructed raw 
RF data were of poor quality; comparison with clinical B-mode US images had 
to be performed to appropriately localize and segment all plaques in a 
subjective manner. Individual plaque components and regions of interest could 
not be readily identified during imaging acquisition or during segmentation. It 
followed that we could not perform subsegmental analysis of individual plaque 
components to analyze their individual strains. Currently, however, an 
algorithm is being developed in our lab (LBUM) to help identify plaque 
subcomponents based on statistical distributions of signal echogenicity. In 
addition to modulography, this may contribute to detecting vulnerable plaque 
areas. Still, the most efficient manner of identifying subcomponents would be 
interactively during US NIVE acquisition; that is, with improved image quality 
on real-time imaging. 
 
 
4.3.5. Final Conclusion 
 
Ultrasound Non-Invasive Vascular Elastography is a novel technique that 
deserves attention in vascular medicine. Although it is at its developmental 
stages, technical optimization can be readily implemented, and US NIVE could 
be easily incorporated as an adjunct to routine carotid Doppler ultrasound 
examinations to help determine which plaques are vulnerable to biomechanical 
rupture. The results of the present pilot study on large carotid plaques 
presented in this thesis open an important door for this avenue. 
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Appendix 2: Modified Rankin Scale 
 
Modified RANKIN scale: 
 
0   Asymptomatic 
1   Non-disabling symptoms which do not interfere with lifestyle.  
2     Minor disability-symptoms which lead to some restriction in lifestyle 
but do not interfere with the patients capacity to look after themselves.  
3   Moderate disability-symptoms which significantly interfere with lifestyle 
or prevent totally independent existence, but able to walk without 
assistance.  
4  Moderately severe disability-symptoms which clearly prevent 
independent existence. Unable to walk without assistance but does not 
need constant attention day and night.  
5    Severely disabled-totally dependent requiring constant attention day and 
night. 
 
Is any disability rated above caused by medical condition/s other than stroke  
 
Yes  No  
 
If yes, give details ______________________________________________________ 
 
 
 
French translation of Modified RANKIN scale: 
 
0    Asymptomatique 
1    Symptômes non-invalidantes qui n’interfèrent pas avec le style de vie 
du patient 
2    Symptômes invalidantes mineurs qui limitent le patient mais 
n’interfèrent pas dans la capacité du patient de s’occuper de lui-même 
3    Symptômes invalidantes modérés qui limitent significativement le style 
de vie du patient ou qui empêchent une indépendance totale mais le patient est 
capable de marcher sans aide. 
4    Symptômes invalidantes modérément sévères qui empêchent 
l’indépendance totale même si le patient n’a pas besoin d’une attention 
continue jour et nuit. Le patient est incapable de marcher sans aide.  
5    Handicap sévère - dépendance continue jour et nuit. 
6    Décès 
 
Est-ce que l’échelle d’évaluation est due à une condition autre que l’AVC?       
Oui          Non  
Si oui, préciser ___________________________________________________ 
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Appendix 3: Follow-up Questionnaires and Forms 
 
ÉLASTOGRAPHIE VASCULAIRE NON-INTRUSIVE : ÉTUDE 
D’EFFICACITÉ ET ANALYSE PRÉLIMINAIRE DE LA 
VULNÉRABILITÉ DE LA PLAQUE CAROTIDIENNE (NIVE II) 
 
QUESTIONNAIRE ET FORMULAIRE STANDARDISÉ DE SUIVI AUX 
PATIENTS ASYMPTOMATIQUES  (i.e. CLINIQUEMENT NON-
VULNÉRABLES) CHAQUE 6 MOIS APRES L’ÉLASTOGRAPHIE 
ULTRASONORE 
  
Instructions (à faire à chaque 6 mois):  
Étape 1 : Compléter le tableau A de la fiche d’identification du patient classifié 
initialement « non-vulnérable » (voir annexe) 
Étape 2 : Étudier le dossier hospitalier du patient pour compléter le 
formulaire/questionnaire ci-dessous 
Étape 3 : Entrevue téléphonique avec le patient pour compléter ce même 
questionnaire 
Étape 4 : Compléter le tableau B de suivi de la fiche d’identification du patient 
initialement « non-vulnérable » (voir annexe) 
Étape 5 : Entrée de données à partir des tableaux A et B 
 
 
DÉBUT DU FORMULAIRE ET QUESTIONNAIRE : 
 
Date de l’examen du dossier : _________________________________ 
 
Date de l’entrevue avec le patient : _____________________________ 
 
1. Avez-vous eu une endartérectomie carotidienne? OUI [   ]                   NON 
[   ] 
 Si NON, pourquoi? 
i. [   ] Annulée car 
___________________________________________ 
__________________________________________________
_______ 
ii. [   ] Prévue pour 
le__________________________________________ 
__________________________________________________
________ 
iii. [   ] Pas 
d’indication______________________________________
__ 
__________________________________________________
________ 
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2. Selon la réponse en 2., demander l’une ou l’autre de ces questions :  
a. « Avez-vous eu un ACV ou une ICT entre l’échographie (nommer la 
date de l’élasto) et votre chirurgie? »           OUI [   ]                   NON 
[   ]             
ou 
b.  « Avez-vous eu un ACV ou une ICT après l’échographie (nommer la 
date de l’élasto)?»        OUI [   ]                   NON [   ] 
 Si NON, passer à la question 5. 
 Si OUI, passer à la question 4. 
3. Avez-vous consulté dans un hôpital pour cet(s) événement(s)?         OUI [   
]               NON [   ] 
 Si NON, passer à la question 5. 
 Si OUI, répondre aux questions suivantes : 
a) Combien 
d’événements?_______________________________________
_ 
b) Quelle(s) 
date(s)?_____________________________________________ 
c) Dans quel(s) 
hôpital(aux)?______________________________________ 
d) Le diagnostic exact? (ACV ou ICT ou thrombose 
asymptomatique ou ACV asymptomatique de novo selon 
imagerie) 
e) Examens Radiologiques : 
 
EXAMEN DATE DIAGNOSTIC 
ECHO/DOPPLER cou   
ANGIOGRAPHIE    
CT-ANGIO   
MR-ANGIO (pas celui 
de l’étude) 
  
CT CERVEAU   
IRM CERVEAU   
Échographie 
cardiaque 
  
 
f) La cause de l’événement (encercler): 
 [   ] Embolie d’origine cardiaque (FA, valvulopathie, insuff 
♥, …) 
 [   ] Thrombo-embolie (carotide interne, siphon carotidien, 
artères vertébrales, tronc basilaire, origine de l’a. sylvienne 
(=MCA)) 
 [   ] Thrombose localisée à la carotide (non-embolique) 
 [   ] Infarctus lacunaire (diagnostic d’exclusion) 
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 [   ] Autre (dissection, inflammatoire, infectieux, post-
radiothérapie, hématologique, néo solide, 
hypercoagulabilité, iatrogénique médicamenteux, 
vasospastique sur drogue, métabolique,…) 
________________________________________________
_________ 
 [   ] Inconnue (vérifier les facteurs de risque suivants) 
 
HTA [   ] Tabac [   ] Hypercholestérolémie [   ] Diabète [   ] 
ROH [   ] (>3 
verres/jour) 
Migraine [   ] Contraception orale [   ] Obésité/sédentarité [   ] 
 
g) les symptômes précis? (cocher dans le tableau suivant) 
(symptômes doivent être : apparition soudaine+déficit 
focalisé+rapidement maximal+durée au moins 1 minute ± 
amélioration progressive) 
 En gris : symptômes non reliés à l’artère carotidienne 
interne  
 Noter côté (gauche ou droit) du symptôme, pas de la 
localisation 
 Noter côté gauche ou droit lorsqu’applicable, sinon 
préciser autre localisation ou information si cela peut 
aider au diagnostic eg. Convulsion généralisée vs. focale 
 
 
 
 
Symptôme/déficit (encercler le 
symptôme) 
Gauche 
[√ ] 
Droite 
[√ ] 
Durée 
(minutes) 
Évolution 
(permanent 
ou 
temporaire) 
Convulsion 
(cause peut être ischémie aigue ou chronique 
cérébrale, hémorragie cérébrale) 
   
Changement soudain de l’état 
mental 
 Confusion, delirium 
 Stupeur ou coma 
o (causé par infarctus de 
l’hémisphère ou infarctus du tronc 
cérébral ou hémorragie 
cérébrale) 
   
Hémiparésie/faiblesse soudaine 
 Faciale 
 Dysphagie 
 Membre supérieur 
 Membre inférieur 
 dérobement des jambes 
    
Perte hémisensorielle soudaine 
 Ouïe 
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 Visuelle « voile noir » 
(probablement hémianopie) 
 Visuelle monoculaire 
(amaurose fugace) 
 Diplopie soudaine 
 Membre supérieur 
 Membre inferieur 
Paresthésies (douleurs en chocs, 
fourmillements au niveau du corps) 
Aphasie soudaine 
 Incohérence verbale 
 Incapable de vocaliser 
 Difficulté de compréhension 
   
Dysarthrie  
(“slurred speech” i.e. difficulté 
d’articulation) 
   
Ataxie (maladresse (=clumsiness), 
difficulté de coordination, de marche, 
de contrôle des mouvements) 
 Du tronc 
 Des membres 
    
Vertige, trouble de l’équilibre, 
céphalée postérieure 
 Lipothymie/tête légère, tinnitus 
(ACV peu probable) 
 Associé à dysarthrie, diplopie, 
ataxie (ACV du tronc) 
    
Syndrome de Gertsmann (acalculie, 
agraphie, agnosie doigts et perte 
discrimination gauche/droite) 
    
Syndrome d’Anton-Babinski 
(« Contralateral Neglect 
Syndrome ») : négligence du trouble, 
de l’hémicorps, de l’hémichamp visuel 
(néglige souvent le côté gauche) 
    
Céphalée sévère, dlr nuque, perte de 
conscience, vomissement (ces 
symptômes suggèrent hémorragie 
intracérébrale) 
   
Autres symptômes pertinents 
 
 
 
 
 
    
 
 
h) En résumé : 
 
(cochez et indiquer le territoire + côté du territoire G ou D, 
p.ex. : ACV Sylvien gauche causé par embolie cardiaque selon 
dossier hospitalier): 
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 [   ] Selon le dossier HND, le nouveau territoire 
intracrânien ischémique est : 
_____________________________________________
_____________________________________________
__________________ 
Et la  cause est : 
_____________________________________________
_________ 
 
 [   ] Le patient connaît le nouveau territoire intracrânien 
ischémique, c’est : 
_____________________________________________
_____________________________________________
__________________ 
Et la cause est : 
_____________________________________________
_________ 
 
 [   ] Selon les symptômes du tableau g) rapportés par 
le patient, le médecin complétant ce questionnaire peut 
présumer que le nouveau territoire intracrânien 
ischémique est : 
_____________________________________________
_____________________________________________
__________________ 
Et la cause est : 
_____________________________________________
_____________________________________________
__________________ 
 
 
4. « Auriez-vous eu des symptômes parmi les suivants depuis votre 
échographie avec nous le (nommer la date de l’élasto)? » (symptômes 
doivent être : apparition soudaine+déficit focalisé+rapidement 
maximal+durée au moins 1 minute ± amélioration progressive)  
 Veuillez passer au tableau de la question 4.g) (compléter si il y a lieu) 
 
a) Si vous avez eu des symptômes, combien de fois sont-ils 
survenus depuis l’échographie? _______________________ 
 Quelle(s) date(s)? 
_____________________________________________
_______ 
 
 Selon les symptômes du tableau g) rapportés par le 
patient, le médecin complétant ce questionnaire peut 
présumer que le nouveau territoire intracrânien 
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ischémique est : 
_____________________________________________
_____________________________________________
__________________ 
Et la cause est : 
_____________________________________________
_____________________________________________
__________________ 
 
 
b) Si le patient n’a eu aucun des symptômes ci-haut, donc le 
patient est toujours asymptomatique et dans le groupe clinique 
« non-vulnérable », procéder comme ceci: 
 
o Patient n’est pas prévu pour une endartérectomie : 
Répéter ce questionnaire dans 6 mois 
 
o Patient a eu l’endartérectomie pour la carotide 
étudiée : 
Passer à la question 5 et cesser le suivi pour l’artère 
carotidienne opérée après la fin du questionnaire 
 
o Patient attend une endartérectomie :  
Répéter ce questionnaire peu après la chirurgie si prévue à 
une certaine date ou dans 6 mois (prendre la date la plus 
proche) 
 
 
5. Avez-vous eu une complication durant et immédiatement après votre 
endartérectomie carotidienne? 
 OUI [   ]   NON [   ] 
 Si OUI, nommer les complications avec dates: 
______________________________________________________
______________________________________________________
______________________________________________________
___________________________ 
 Date de l’endartérectomie _________________ 
 Quelle carotide opérée (D ou G)? _________    
 Avez-vous eu ACV ou ICT comme complication immédiate de la 
chirurgie? OUI [   ]                   NON [   ] 
i. Si OUI, quelle date? __________  
ii. Quel territoire ischémique intracrânien (D ou G)? 
________________________________________________
________________________________________________
__________________ 
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FICHE D’IDENTIFICATION DU PATIENT INITIALEMENT 
CLASSÉ CLINIQUEMENT NON-VULNÉRABLE 
 
TABLEAUX A ET B 
 
 
 
Tableau A : Informations au moment de l’inclusion (jour d’élasto 
ou IRM) du patient initialement non-vulnérable 
CAROTIDE étudiée par 
NIVE 
GAUCHE [   ] DROITE [   ] 
CAROTIDE étudiée par 
IRM 
GAUCHE [   ] DROITE [   ] 
ÉTUDE dans 
lesquelles éligible 
(NIVE I, II, et/ou 
BRACCO ou exclu) 
Si une carotide exclue, 
indiquer raison et barrer la 
colonne 
  
Groupe d’âge 
(entourer) 
 
40-49 
50-59 
60-69 
70-85 
40-49 
50-59 
60-69 
70-85 
% sténose (indiquer 
par quel examen) 
  
Date d’acquisition 
élastographie (si patient 
uniquement dans BRACCO, 
date de l’IRM) 
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Tableau B : Informations du suivi du patient initialement non-
vulnérable 
 
Date d’obtention de l’information: __________________  
 
√ 
Événement Date(s) Territoire 
cerveau 
affecté 
Cause : carotide 
gauche ou droite 
ou autre cause 
 ACV ou ICT 
symptomatique 
   
 Date de 
l’examen 
diagnostic 
Territoire 
cerveau 
affecté 
IRM ou 
CT 
Cause 
 ACV ou ICT 
silencieux 
    
 Date de 
l’examen 
diagnostic 
Carotide 
gauche ou 
droite? 
CTA, MRA ou 
Echo-Doppler 
 Thrombose 
carotidienne 
asymptomatique 
   
 Date de 
procédure 
Carotide 
gauche ou 
droite? 
ACV ou ICT 
immédiat? 
 Endartérectomie 
(ou stent) 
   
Conclusion : [   ] Patient cliniquement 
non-vulnérable 
[   ] Patient 
cliniquement 
vulnérable 
Suivi : [   ] n’est plus nécessaire [   ] À prévoir le 
__________ 
 
